The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) [structure] wherein ring A is an optionally substituted aromatic group, one of X 1 and X 2 is a carbon atom, and the other is a nitrogen atom, X 3 is a nitrogen atom, or CR 2 , X 4 is a nitrogen atom, or CR 3 , X 5 is a sulfur atom, or —CH═CH—, Z 1 is an oxygen atom, —C(R 6 )(R 7 )—, —NH—, —C(R 6 )(R 7 )—NH—, —NH—C(R 6 )(R 7 )—, —C(R 6 )(R 7 )—O—, —O—C(R 6 )(R 7 )—, or a single bond, one of Z 2 and Z 3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

Description

737 parts

›TECHNICAL FIELD

The present invention relates to a bicyclic or tricyclic heterocyclic compound. More particularly, the present invention relates to a novel bicyclic or tricyclic heterocyclic compound having a Kynurenine Aminotransferase-II (hereinafter sometimes to be also indicated as KAT-II) inhibitory action, and useful as a medicament for cognitive impairment, neurodegenerative disease, or schizophrenia, and use thereof.

›BACKGROUND ART

N-methyl-D-aspartic acid receptor (hereinafter sometimes to be also indicated as NMDAR) and nicotinic acetylcholine receptor (hereinafter sometimes to be also indicated as nAChR) are known to be involved in some cognitive function processes. It is shown from animal studies that activation of NMDAR or nAChR improves some mental diseases including schizophrenia, dementia, depression, and stress vulnerability (see non-patent document 1 for NMDAR, non-patent documents 2 and 3 for nAChR).

Kynurenic acid (hereinafter sometimes to be also indicated as KYNA) is an endogenous tryptophan metabolite produced in the brain by kynurenine pathway. Tryptophan is metabolized by indoleamine 2,3-dioxygenase (IDO) and the like to produce kynurenine, and kynurenine is metabolized to produce KYNA. There are 4 kinds of known enzymes that catalyze the reaction to produce KYNA from kynurenine. That is, kynurenine-aminotransferases 1, 2, 3, and 4. Of these, KAT-II plays a key role in the production of KYNA in the brain, and it is known that KYNA concentration significantly decreases in hippocampus in KAT-II knockout mouse, as compared to that in wild-type mouse (see non-patent document 4).

KYNA is known to be an antagonist of NMDAR and nicotinic acetylcholine α7 receptor (hereinafter sometimes to be also indicated as α7nAChR). Therefore, KYNA is considered to be mainly involved in the control of presynaptic activity of GABA neuron, glutamic acid neuron via α7nAChR in the brain, and control of postsynaptic activity of glutamic acid neuron via NMDAR (see non-patent documents 5, 6 and 7).

Therefore, KAT-II inhibitor is expected to be useful for the treatment of central diseases such as schizophrenia, attention deficit/hyperactivity disorder, Alzheimer's disease, major depression and the like through activation of NMDAR and/or nAChR based on a decrease in the KYNA concentration in the brain. As documents describing the relationship between KAT-II and/or KYNA and dementia, depression, or stress vulnerability, the following are reported.

In the studies of mammals, it was confirmed that an increase in the KYNA concentration in the brain causes disorders of cognitive functions such as context learning, working memory and the like, and that an increase in the KYNA concentration may be involved in the cognitive dysfunction such as schizophrenia and the like (see non-patent documents 8-10).

R. Schwarcz et al. show that topical injection of KYNA into the brain of rodents suppresses release of dopamine, acetylcholine or glutamic acid in the site, and a possibility is proposed that attenuation of KYNA production in the brain improves cognitive function of schizophrenia (see non-patent document 11 for dopamine, non-patent document 12 for acetylcholine, non-patent document 13 for glutamic acid).

It has been reported that KYNA concentration in the cerebrospinal fluid of schizophrenia patients and bipolar disorder patients is significantly higher than that of normal volunteers and patients free of mental diseases, and the results support involvement of KYNA in the pathophysiology of schizophrenia and bipolar disorder (see non-patent document 14 for schizophrenia, and non-patent document 15 for bipolar disorder).

It has been reported that administration of a KAT-II inhibitor decreases the KYNA concentration in the brain to dialysates in a dose-dependent manner, and KAT-II inhibitors show activity in anhedonia model [chronic mild stress], which is one kind of depression models, and it has been reported that KAT-II inhibitors may be suitable for cognitive function and negative symptoms of schizophrenia (see non-patent document 16).

BTBR mouse, which is one kind of autism spectrum disorder mice, is reported to show high KYNA concentration in the medial prefrontal cortex, as compared to C57 Bl/6J mouse (see non-patent document 17).

It is known that KYNA concentration is significantly high in the putamen and caudate nucleus of postmortem brain of Alzheimer's disease patients, as compared to the control group free of dementia. It has been reported that inhibition of NMDAR by KYNA possibly causes memory disorder, learning and cognition function of Alzheimer's disease patients (see non-patent document 18).

It has been reported that patients with ischemic cerebrovascular diseases (cerebral infarction) and showing a greater kynurenine/tryptophan ratio show degraded cognitive function, and correlation between inflammatory reactions characterized by an increased IDO activity and cerebrovascular dementia is suggested (see non-patent document 19).

It has been reported that the concentration of kynurenic acid in the frontal cortex of postmortem brain of a subgroup such as HIV encephalopathy (HIV in brain) and the like in the HIV-1 (human immunodeficiency virus 1) infected patients is significantly higher than that of the control group. In addition, it is suggested that a decrease in the kynurenic acid production can be useful for an antidementia drug (see non-patent document 20).

As a compound having a KAT-II inhibitory activity, for example, the following compound has been reported.

R. Schwarcz et al. disclosed that a novel kynurenine derivative having a KAT-II inhibitory activity is effective for the treatment of cognitive impairment related to the aging of the brain and perinatal brain damage (see patent document 1).

M. M. Claffey et al. and A. B. Dounay et al. disclose that the compounds represented by the following formulas are KAT-II inhibitory compounds, and useful for the treatment of schizophrenia and cognitive deficit relating to other neurodegeneration and/or neurological disorder (see patent documents 2-4).

However, a KAT-II inhibitory action of a bicyclic or tricyclic heterocyclic compound like that of the compound of the present invention has not been reported.

Thiadiazolopyrimidone derivatives represented by the following structural formulas and the like have been sold by plural companies (e.g., AKos Consulting & Solutions GmbH, Ambinter, Aurora Fine Chemicals, ChemDiv, Inc.). However, a KAT-II inhibitory action and other pharmacological activities of these compounds have not been disclosed at all.

›DOCUMENT LIST

Patent Documents

patent document 1: WO 1995/004714

patent document 2: WO 2010/146488

patent document 3: WO 2012/073143

patent document 4: WO 2013/186666

Non-Patent Documents

non-patent document 1: R. G. M. Morris et al., “Philosophical transactions of the Royal Society of London” vol. 329, pages 187-204, 1990

non-patent document 2: E. X. Albuquerque et al., “Physiological Reviews” vol. 89, pages 73-120, 2009

non-patent document 3: D. S. McGehee, “Trends in Neurosciences” vol. 25, pages 171-172, 2002

non-patent document 4: M. C. Potter et al., “Neuropsychopharmacology” vol. 35, pages 1734-1742, 2010

non-patent document 5: R. Schwarcz et al., “Nature Reviews Neuroscience” vol. 13, pages 465-477, 2012

non-patent document 6: M. Alkondon et al., “The Journal of Neuroscience” vol. 24, pages 4635-4648, 2004

non-patent document 7: G. Henderson et al., “Journal of Physiology” vol. 430, pages 189-212, 1990

non-patent document 8: A. C. Chess et al., “Behavioural Brain Research” vol. 170, pages 326-332, 2006

non-patent document 9: A. C. Chess et al., “Schizophrenia Bulletin” vol. 33, pages 797-804, 2007

non-patent document 10: A. C. Chess et al., “Behavioural Brain Research” vol. 201, pages 325-331, 2009

non-patent document 11: A. Rassoulpour et al., “Journal of Neurochemistry” vol. 93, pages 762-765, 2005

non-patent document 12: A. Zmarowski et al., “European Journal of Neuroscience” vol. 29, pages 529-538, 2009

non-patent document 13: H.-Q. Wu et al., “Journal of Molecular Neuroscience” vol. 40, pages 204-210, 2010

non-patent document 14: K. R. Linderholm et al., “Schizophrenia Bulletin” vol. 38, pages 426-432, 2012

non-patent document 15: S. K. Olssona et al., “Bipolar Disorders” vol. 14, pages 719-726, 2012

non-patent document 16: B. Campbell et al., “Advancing Drug Discovery for Schizophrenia” The New York Academy of Sciences Mar. 9-11, 2011 (Final program, pages 17-18)

non-patent document 17: S. M. McTighe et al., “PLoS ONE” vol. 8, e62189, 2013

non-patent document 18: H. Baran et al., “Journal of Neural Transmission” vol. 106, pages 165-181, 1999

non-patent document 19: A. B. Gold et al., “Journal of Neuroinflammation” vol. 8, 17, 2011

non-patent document 20: H. Baran et al., “International Journal of Tryptophan Research” vol. 5, pages 49-64, 2012

›SUMMARY OF THE INVENTION

Problems to be Solved by the Invention

An object to be solved by the present invention is provision of a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like.

Means of Solving the Problems

The present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems and found a novel bicyclic or tricyclic heterocyclic compound having a superior KAT-II inhibitory action and completed the present invention.

That is, the present invention relates to a compound represented by the formula (I):

wherein ring A is an optionally substituted aromatic group,

one of X 1 and X 2 is a carbon atom, and the other is a nitrogen atom,

X 3 is a nitrogen atom, or CR 2 ,

X 4 is a nitrogen atom, or CR 3 ,

X 5 is a sulfur atom, or —CH═CH—,

Z 1 is an oxygen atom, —C(R 6 )(R 7 )—, —NH—, —C(R 6 )(R 7 )—NH—, —NH—C(R 6 )(R 7 )—, —C(R 6 )(R 7 )—O—, —O—C(R 6 )(R 7 )—, or a single bond (where the left end shows a bond to ring A, and the right end shows a bond to the adjacent carbonyl),

one of Z 2 and Z 3 is CH and the other is a nitrogen atom, or both are nitrogen atoms,

R 1 is a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted nonaromatic heterocyclic group, or a halogen atom,

R 2 is a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted aryl, an optionally substituted nonaromatic heterocyclic group, optionally substituted heteroaryl, optionally substituted alkoxy, or optionally substituted cycloalkoxy,

or, R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, an optionally substituted ring,

R 3 is a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, or a halogen atom,

R 4 and R 5 are each independently a hydrogen atom, or optionally substituted alkyl,

or, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , an optionally substituted nitrogen-containing non-aromatic heterocycle,

R 6 and R 7 are each independently a hydrogen atom, optionally substituted alkyl, or optionally substituted cycloalkyl,

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, an optionally substituted cycloalkane,

a part represented by the following formula in the aforementioned formula (I):

(A) when X 1 is a carbon atom and X 2 is a nitrogen atom, a group represented by the following formula (i-a):

and

(B) when X 1 is a nitrogen atom and X 2 is a carbon atom, a group represented by the following formula (i-b):

provided (a) when a part represented by the following formula in the aforementioned formula (I):

is a group represented by the formula (ii-a):

(a-1) Z 2 is a nitrogen atom, and Z 3 is CH or a nitrogen atom;

(a-2) Z 2 is CH, and Z 3 is a nitrogen atom, and a part represented by the following formula in the formula (I):

is a group represented by the formula (v-x):

(a-3) Z 2 is CH, and Z 3 is a nitrogen atom, and a part represented by the following formula in the formula (I):

is a group represented by the formula (v-y):

and a part represented by the following formula in the formula (I):

is a group represented by the formula (iii-a), (iii-b), or (iii-c):

wherein R 6x and R 7x are each optionally substituted alkyl or R 6x and R 7x are bonded to each other to form, together with the adjacent carbon atom, an optionally substituted cycloalkane, R 8x is halogenoalkyl, or a fluorine atom, and

(b) when a part represented by the following formula in the aforementioned formula (I):

is a group represented by the formula (ii-b):

(b-1) Z 2 is a nitrogen atom, and Z 3 is CH or a nitrogen atom; or

(b-2) Z 2 is CH, and Z 3 is a nitrogen atom,

R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , an optionally substituted nitrogen-containing non-aromatic heterocycle, and a part represented by the following formula in the formula (I):

is a group represented by the formula (iii-d):

or a pharmacologically acceptable salt thereof.

The present invention also relates to a method for the treatment or prophylaxis of various diseases (e.g., schizophrenia) involving KAT-II, which comprises administering an effective amount of a compound represented by the aforementioned formula (I) (hereinafter to be also indicated as compound (I)), or a pharmacologically acceptable salt to a patient.

The present invention also relates to a pharmaceutical composition comprising the aforementioned compound (I) or a pharmacologically acceptable salt thereof as an active ingredient, and use of the aforementioned compound (I) or a pharmacologically acceptable salt thereof for the production of the pharmaceutical composition.

Effect of the Invention

Since a compound represented by the formula (I) or a pharmacologically acceptable salt thereof affords a superior KAT-II inhibitory action, a pharmaceutical composition containing same as an active ingredient is useful for the prophylaxis or treatment of various diseases (e.g., schizophrenia) involving KAT-II.

›DESCRIPTION OF EMBODIMENTS · 1 of 25

The definition of each term used in the present specification is as follows.

The term “alkyl” means a linear or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms (C 1 -C 6 ), and specific examples include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, and various branched chain isomers thereof.

The term “alkenyl” means a linear or branched chain unsaturated hydrocarbon group having 1 or 2 carbon-carbon double bonds and 2 to 6 carbon atoms (C 2 -C 6 ), and specific examples include, vinyl, propenyl, isopropenyl, butenyl, pentenyl, hexenyl, and various branched chain isomers thereof.

The term “alkylidene” means a linear or branched chain divalent hydrocarbon group having 1 to 6 carbon atoms (C 1 -C 6 ), and specific examples include, methylidene, ethylidene, propylidene, butylidene, pentylidene, hexylidene, and various branched chain isomers thereof.

The term “cycloalkyl” means a 3-8-membered (C 3 -C 8 ) monocyclic alicyclic saturated hydrocarbon group, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

The term “cycloalkane” means a 3-8-membered (C 3 -C 8 ) monocyclic alicyclic saturated hydrocarbon, and specific examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, and cyclooctane.

The term “cycloalkenyl” means a 3-8-membered (C 3 -C 8 ) monocyclic alicyclic hydrocarbon group having 1 or 2 carbon-carbon double bonds, and specific examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.

The term “cycloalkene” means 3-8-membered (C 3 -C 8 ) monocyclic alicyclic hydrocarbon having 1 or 2 carbon-carbon double bonds, and specific examples include cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, and cyclooctene.

The term “aryl” means a monocyclic or bicyclic aromatic hydrocarbon group having 6-11 ring-constituting carbon atoms (C 6 -C 11 ), and specific examples include monocyclic aryl such as phenyl and the like; and optionally partly saturated bicyclic aryl having 9-11 ring-constituting carbon atoms (C 9 -C 11 ) such as naphthyl, tetrahydronaphthyl, indenyl, indanyl and the like.

The term “arene” means monocyclic or bicyclic aromatic hydrocarbon having 6-11 ring-constituting carbon atoms (C 6 -C 11 ), and specific examples include monocyclic arene such as benzene and the like; and optionally partly saturated bicyclic arene having 9-11 ring-constituting carbon atoms (C 9 -C 11 ) such as naphthalene, tetrahydronaphthalene, indene, indane and the like.

The term “nonaromatic heterocyclic group” means a 4- to 12-membered monocyclic or bicyclic nonaromatic heterocyclic group containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as azetidinyl, pyrrolidyl, pyrazolidinyl, piperidyl, oxetanyl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, imidazolidinyl, tetrahydropyrazinyl, piperazinyl, morpholinyl and the like; and a 6- to 12-membered bicyclic nonaromatic heterocyclic group containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as azabicyclo[3.1.0]hexyl and the like.

The term “nitrogen-containing nonaromatic heterocyclic group” means the aforementioned nonaromatic heterocyclic group containing at least one nitrogen atom, and specific examples include azetidinyl, pyrrolidyl, pyrazolidinyl, piperidyl, dihydroimidazolyl, imidazolidinyl, tetrahydropyrazinyl, piperazinyl, morpholinyl, and azabicyclo[3.1.0]hexyl.

The term “non-aromatic heterocycle” means a 4- to 12-membered monocyclic or bicyclic non-aromatic heterocycle containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include a 4- to 7-membered monocyclic non-aromatic heterocycle containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as azetidine, pyrrolidine, pyrazolidine, piperidine, oxetane, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, dihydroimidazole, imidazolidine, tetrahydropyrazine, piperazine, morpholine and the like; and a 6-12-membered bicyclic non-aromatic heterocycle containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as azabicyclo[3.1.0]hexane and the like.

The term “nitrogen-containing non-aromatic heterocycle” means the aforementioned non-aromatic heterocycle containing at least one nitrogen atom, and specific examples include azetidine, pyrrolidine, pyrazolidine, piperidine, dihydroimidazole, imidazolidine, tetrahydropyrazine, piperazine, morpholine, and azabicyclo[3.1.0]hexane.

The term “heteroaryl” means a 5- to 11-membered monocyclic or bicyclic aromatic heterocyclic group containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazyl, pyrimidinyl, pyridazinyl and the like; and optionally partly saturated 8- to 11-membered bicyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolanyl, thienopyridyl, thiazolopyridyl, thiazolopyrimidinyl, thiazolopyridazyl, thiadiazolopyridyl, thiadiazolopyrimidinyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, pyridopyrimidinyl, pyrimidopyridazyl, triazolopyridyl and the like.

›DESCRIPTION OF EMBODIMENTS · 2 of 25

The term “nitrogen-containing heteroaryl” means the aforementioned heteroaryl containing at least one nitrogen atom, and specific examples include 5- to 6-membered monocyclic nitrogen-containing heteroaryl such as pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazyl, pyrimidinyl, pyridazinyl and the like; and optionally partly saturated 8- to 11-membered bicyclic nitrogen-containing heteroaryl such as indolinyl, isoindolinyl, thienopyridyl, thiazolopyridyl, thiazolopyrimidinyl, thiazolopyridazyl, thiadiazolopyridyl, thiadiazolopyrimidinyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, pyridopyrimidinyl, pyrimidopyridazyl, triazolopyridyl and the like.

The term “heteroarene” means a 5- to 11-membered monocyclic or bicyclic aromatic heterocycle containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include a 5- to 6-membered monocyclic heteroarene containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine and the like; and an optionally partly saturated 8- to 11-membered bicyclic heteroarene containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as indoline, isoindoline, dihydrobenzofuran, dihydroisobenzofuran, benzodioxolane, thienopyridine, thiazolopyridine, thiazolopyrimidine, thiazolopyridazine, thiadiazolopyridine, thiadiazolopyrimidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, pyridopyrimidine, pyrimidopyridazine, triazolopyridine and the like.

The term “nitrogen-containing heteroarene” means the aforementioned heteroarene containing at least one nitrogen atom, and specific examples include 5- to 6-membered monocyclic nitrogen-containing heteroarene such as pyrrole, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine and the like; and 8- to 11-membered bicyclic nitrogen-containing heteroarene such as indoline, isoindoline, thienopyridine, thiazolopyridine, thiazolopyrimidine, thiazolopyridazine, thiadiazolopyridine, thiadiazolopyrimidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, pyridopyrimidine, pyrimidopyridazine, triazolopyridine and the like.

The term “aromatic group” means a 5- to 11-membered monocyclic or bicyclic aromatic group optionally containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include the aforementioned aryl, heteroaryl, more specifically, monocyclic aryl such as phenyl and the like; optionally partly saturated bicyclic aryl having 9-11 ring-constituting carbon atoms (C 9 -C 11 ) such as naphthyl, tetrahydronaphthyl, indenyl, indanyl and the like; 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazyl, pyrimidinyl, pyridazinyl and the like; and optionally partly saturated 8- to 11-membered bicyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolanyl, thienopyridyl, triazolopyridyl, thiazolopyrimidinyl, thiazolopyridazyl, thiadiazolopyridyl, thiadiazolopyrimidinyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, pyridopyrimidinyl, pyrimidopyridazyl, triazolopyridyl and the like.

The term “aromatic ring” means a 5- to 11-membered monocyclic or bicyclic aromatic ring optionally containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include the aforementioned arene, heteroarene, more specifically, monocyclic arene such as benzene and the like; optionally partly saturated bicyclic arene having 9-11 ring-constituting carbon atoms (C 9 -C 11 ) such as naphthalene, tetrahydronaphthalene, indene, indane and the like; a 5- to 6-membered monocyclic heteroarene containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine and the like; and optionally partly saturated 8- to 11-membered bicyclic heteroarene containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom such as indoline, isoindoline, dihydrobenzofuran, dihydroisobenzofuran, benzodioxolane, thienopyridine, triazolopyridine, thiazolopyrimidine, thiazolopyridazine, thiadiazolopyridine, thiadiazolopyrimidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, pyridopyrimidine, pyrimidopyridazine, triazolopyridine and the like.

The term “ring” means a 5- to 11-membered monocyclic or bicyclic ring optionally containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and specific examples include the aforementioned cycloalkane, arene, non-aromatic heterocycle, and heteroarene.

The term “halogen atom” or “halogeno” means fluorine atom, chlorine atom, bromine atom or iodine atom.

The term “alkoxy” means a group wherein an oxygen atom is bonded to the aforementioned linear or branched chain alkyl having 1 to 6 carbon atoms (C 1 -C 6 ), and specific examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, isobutoxy, pentyloxy, hexyloxy, and various branched chain isomers thereof.

›DESCRIPTION OF EMBODIMENTS · 3 of 25

The term “alkoxyphenyl” means phenyl substituted by 1, 2 or 3 alkoxys mentioned above, and specific examples include methoxyphenyl, and dimethoxyphenyl.

The term “cycloalkoxy” means a group wherein an oxygen atom is bonded to the aforementioned 3-8-membered (C 3 -C 8 ) monocyclic alicyclic saturated hydrocarbon group, and specific examples include cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy.

The term “halogenoalkyl”, “halogenocycloalkyl” and “halogenoalkoxy” mean the aforementioned alkyl, cycloalkyl and alkoxy, each substituted by 1-7 halogen atoms, respectively, and specific examples include trifluoromethyl, chlorocyclopropyl, and trifluoromethoxy, respectively.

The term “alkanoyl” means a group having 2-7 carbon atoms (C 2 -C 7 ) wherein carbonyl is bonded to the aforementioned linear or branched chain alkyl having 1 to 6 carbon atoms (C 1 -C 6 ), and specific examples include acetyl, propanoyl, butyryl, and various branched chain isomers thereof.

The term “aralkyl” means a group wherein the aforementioned linear or branched chain alkyl having 1 to 6 carbon atoms (C 1 -C 6 ) is bonded to the aforementioned monocyclic or bicyclic aromatic hydrocarbon group having 6-11 ring-constituting carbon atoms (C 6 -C 11 ), and specific examples include phenylmethyl.

Each abbreviation used in the present specification means the following unless particularly defined.

Boc: tert-butoxycarbonyl D: deuterium ( 2 H) DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene DME: 1,2-dimethoxyethane DMF: N,N-dimethylformamide EDC hydrochloride: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride HATU: O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate HOBt monohydrate: 1-hydroxybenzotriazole monohydrate HPLC: high performance liquid chromatography mCPBA: methachloroperbenzoic acid THF: tetrahydrofuran TLC: thin layer chromatography Lawesson's reagent: 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide

In the following, each symbol in the formula (I) represented by the aforementioned compound is explained by showing specific examples.

The aromatic group of the “optionally substituted aromatic group” for ring A is as defined above, and specific examples thereof include aryl and heteroaryl. Preferable aryl or heteroaryl includes phenyl, tetrahydronaphthyl, furyl, thienyl, pyrazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazyl, indolinyl, tetrahydroquinolyl, thienopyridyl, dihydrobenzofuranyl, benzodioxolanyl, and triazolopyridyl. Of these, phenyl, thienyl, and benzodioxolanyl are more preferable, and phenyl is particularly preferable.

Z 1 is as defined above, from which an oxygen atom, —C(R 6 )(R 7 )—, —C(R 6 )(R 7 )—NH—, —NH—C(R 6 )(R 7 )—, or —O—C(R 6 )(R 7 )— is preferable.

Z 2 and Z 3 are as defined above. Preferably, one is CH and the other is a nitrogen atom.

When R 1 is “optionally substituted alkyl”, the alkyl moiety of the group is as defined above, and is preferably C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl.

When R 1 is “optionally substituted cycloalkyl”, the cycloalkyl moiety of the group is as defined above, and is preferably C 3 -C 8 cycloalkyl, more preferably C 3 -C 6 cycloalkyl.

When R 1 is “optionally substituted aryl”, the aryl moiety of the group is as defined above, preferably phenyl.

When R 1 is “optionally substituted nonaromatic heterocyclic group”, the nonaromatic heterocyclic group moiety of the group is as defined above, and is preferably a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom. Of these, pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, or morpholinyl is more preferable, and pyrrolidyl, oxetanyl, or tetrahydropyranyl is particularly preferable.

When R 1 is “halogen atom”, the halogen atom is as defined above, and is preferably a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, more preferably a fluorine atom, a chlorine atom, or a bromine atom.

Preferable examples of R 1 include a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, an optionally substituted nonaromatic heterocyclic group, and a halogen atom. Of these, a hydrogen atom, optionally substituted C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, an optionally substituted nonaromatic heterocyclic group which is selected from the group consisting of pyrrolidyl, oxetanyl, and tetrahydropyranyl, a fluorine atom, and a chlorine atom are more preferable.

When R 2 is “optionally substituted alkyl”, the alkyl moiety of the group is as defined above, and is preferably C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl.

When R 2 is “optionally substituted cycloalkyl”, the cycloalkyl moiety of the group is as defined above, and is preferably C 3 -C 8 cycloalkyl, more preferably C 3 -C 6 cycloalkyl.

When R 2 is “optionally substituted aryl”, the aryl moiety of the group is as defined above, preferably phenyl.

When R 2 is “optionally substituted nonaromatic heterocyclic group”, the nonaromatic heterocyclic group moiety of the group is as defined above, and is preferably, a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom. Of these, azetidinyl, pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl are more preferable, and azetidinyl, pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, and morpholinyl are particularly preferable.

When R 2 is “optionally substituted heteroaryl”, the heteroaryl moiety of the group is as defined above, and is preferably a 5- to 6-membered monocyclic aromatic heterocyclic group containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom. Of these, thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl are more preferable, and thienyl, oxadiazolyl, pyridyl, and pyrimidinyl are particularly preferable.

›DESCRIPTION OF EMBODIMENTS · 4 of 25

When R 2 is “optionally substituted alkoxy”, the alkoxy moiety of the group is as defined above, and is preferably C 1 -C 6 alkoxy, more preferably C 1 -C 4 alkoxy.

When R 2 is “optionally substituted cycloalkoxy”, the cycloalkoxy moiety of the group is as defined above, and is preferably C 3 -C 8 cycloalkoxy, more preferably C 3 -C 6 cycloalkoxy.

Preferable examples of R 2 include a hydrogen atom, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted amino, optionally substituted phenyl, an optionally substituted nonaromatic heterocyclic group which is selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl, optionally substituted heteroaryl, which is selected from the group consisting of thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl, optionally substituted C 1 -C 6 alkoxy, and optionally substituted C 3 -C 8 cycloalkoxy. Of these, a hydrogen atom, optionally substituted C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted amino, optionally substituted phenyl, an optionally substituted nonaromatic heterocyclic group which is selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, and morpholinyl, optionally substituted heteroaryl which is selected from the group consisting of thienyl, oxadiazolyl, pyridyl, and pyrimidinyl, and optionally substituted C 1 -C 4 alkoxy are more preferable.

When R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, an “optionally substituted ring”, the ring moiety of the group is as defined above, and is preferably cycloalkene, arene, non-aromatic heterocycle, or heteroarene. Said cycloalkene is as defined above, and monocyclic alicyclic unsaturated hydrocarbon having 1 or 2 carbon-carbon double bonds and 5-8 carbon atoms (C 5 -C 8 ) is preferable, and cyclohexene is more preferable. Said arene is as defined above, and benzene is preferable. Said non-aromatic heterocycle is as defined above, and a 4- to 7-membered non-aromatic heterocycle containing 1 or 2 nitrogen atoms besides carbon atom is preferable, which is more preferably pyrrolidine, piperidine, dihydroimidazole, imidazolidine, tetrahydropyrazine, or piperazine, particularly preferably piperidine, dihydroimidazole, or imidazolidine. Said heteroarene is as defined above, and 5- to 6-membered monocyclic heteroarene containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of sulfur atom and nitrogen atom is preferable, more preferably thiophene or pyridine.

Preferable examples the “optionally substituted ring” formed by R 1 and R 2 bonded to each other and together with the adjacent X 2 and carbon atom include optionally substituted cyclohexene, optionally substituted benzene, an optionally substituted nonaromatic heterocyclic group, which is selected from the group consisting of pyrrolidine, piperidine, dihydroimidazole, imidazolidine, tetrahydropyrazine, and piperazine, optionally substituted heteroaryl selected from the group consisting of thiophene and pyridine, more preferably, optionally substituted benzene, or optionally substituted nonaromatic heterocyclic group which is selected from the group consisting of piperidine, dihydroimidazole, and imidazolidine.

When R 3 is “optionally substituted alkyl”, the alkyl moiety of the group is as defined above, and is preferably C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl.

When R 3 is “optionally substituted cycloalkyl”, the cycloalkyl moiety of the group is as defined above, and is preferably C 3 -C 8 cycloalkyl, more preferably C 3 -C 6 cycloalkyl.

When R 3 is “halogen atom”, the halogen atom is as defined above, and is preferably a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, more preferably a fluorine atom, a chlorine atom, or a bromine atom.

When R 4 or R 5 is “optionally substituted alkyl”, the alkyl moiety of the group is as defined above, and is preferably C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl.

When R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , “optionally substituted nitrogen-containing non-aromatic heterocycle”, the nitrogen-containing non-aromatic heterocycle moiety of the group is as defined above, of which a 4- to 8-membered monocyclic or bicyclic nonaromatic heterocyclic group containing, besides carbon atom, at least one nitrogen atom, and containing 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom is preferable, azetidine, pyrrolidine, pyrazolidine, piperidine, morpholine or azabicyclo[3.1.0]hexane is more preferable, pyrrolidine or piperidine is particularly preferable, and pyrrolidine is most preferable.

When R 6 or R 7 is “optionally substituted alkyl”, the alkyl moiety of the group is as defined above, and is preferably C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl.

When R 6 or R 7 is “optionally substituted cycloalkyl”, the cycloalkyl moiety of the group is as defined above, and is preferably C 3 -C 8 cycloalkyl, more preferably C 3 -C 6 cycloalkyl.

Preferable examples of R 6 and R 7 include a hydrogen atom, optionally substituted C 1 -C 4 alkyl, and optionally substituted C 3 -C 6 cycloalkyl, more preferably, a hydrogen atom, and optionally substituted C 1 -C 4 alkyl.

When R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, “optionally substituted cycloalkane”, the cycloalkane moiety of the group is as defined above, of which C 3 -C 8 cycloalkane is preferable, C 3 -C 6 cycloalkane is more preferable.

When the “ring” or “group” defined by each symbol in the aforementioned formula (I) or a combination of each symbol is “optionally substituted aromatic group”, “optionally substituted alkyl”, “optionally substituted cycloalkyl”, “optionally substituted aryl”, “optionally substituted nonaromatic heterocyclic group”, “optionally substituted amino”, “optionally substituted heteroaryl”, “optionally substituted alkoxy”, “optionally substituted cycloalkoxy”, “optionally substituted ring”, “optionally substituted nitrogen-containing non-aromatic heterocycle” or “optionally substituted cycloalkane”, these “ring” and “group” may be unsubstituted, or have one or more, the same or different substituent(s) at substitutable position(s) of each “ring” or “group”. The aforementioned “ring” or “group” has substituent(s), the number thereof is preferably 1-7, more preferably 1, 2, or 3.

›DESCRIPTION OF EMBODIMENTS · 5 of 25

Examples of the aforementioned substituent of the “ring” or “group” include

(1) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of phenyl optionally substituted by 1, 2 or 3 alkoxys, a halogen atom, hydroxy, amino optionally substituted by 1 or 2 alkyls, and alkoxy (preferably, alkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of phenyl optionally substituted by 1, 2 or 3 alkoxys, a halogen atom, hydroxy, amino optionally substituted by 1 or 2 alkyls, and alkoxy); (2) aryl optionally substituted by 1, 2 or 3 alkoxys (preferably, phenyl optionally substituted by 1, 2 or 3 alkoxys); (3) a nonaromatic heterocyclic group optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy and alkoxycarbonyl (preferably, nonaromatic heterocyclic group which is selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, and morpholinyl and optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy and alkoxycarbonyl); (4) heteroaryl optionally substituted by 1 or 2 oxos (preferably, pyridine, or isoindolinyl optionally substituted by 1 or 2 oxos); (5) cyano; (6) a halogen atom; (7) hydroxy; (8) oxo; (9) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxyalkyl, alkoxycarbonyl and phenylalkoxycarbonyl; (10) alkylsulfonyl; (11) phenylsulfonyl; (12) alkoxy optionally substituted by 1-7 halogen atoms (preferably, alkoxy optionally substituted by 1, 2 or 3 halogen atoms); (13) alkanoyloxy; (14) alkoxycarbonyl; and (15) alkylidene.

The substituent of the aforementioned “ring” or “group” defined by each symbol or a combination of each symbol is more specifically explained below.

Examples of preferable substituent of ring A (optionally substituted aromatic group) include

(1) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of a halogen atom, amino optionally substituted by 1 or 2 alkyls, and alkoxy (preferably alkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of a halogen atom, amino optionally substituted by 1 or 2 alkyls, and alkoxy); (2) cyano; (3) a halogen atom; (4) amino optionally substituted by 1 or 2 alkyls; and (5) alkoxy optionally substituted by 1-7 halogen atoms (preferably alkoxy optionally substituted by 1, 2 or 3 halogen atoms).

Of those mentioned above, more preferable substituent is (1) alkyl, or (2) a halogen atom.

When R 1 is “optionally substituted alkyl”, examples of the preferable substituent of the group include

(1) aryl optionally substituted by 1, 2 or 3 alkoxys (preferably, phenyl optionally substituted by 1, 2 or 3 alkoxys); (2) nonaromatic heterocyclic group optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl and alkoxycarbonyl (preferably, nonaromatic heterocyclic group which is selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, and tetrahydropyranyl and optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl and alkoxycarbonyl); (3) a halogen atom; (4) hydroxy; (5) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl; and (6) alkoxy.

When R 1 is “optionally substituted cycloalkyl”, “optionally substituted aryl”, or “optionally substituted nonaromatic heterocyclic group”, examples of the preferable substituent of the group include

(1) alkyl optionally substituted by 1, 2 or 3 alkoxys; (2) aryl optionally substituted by 1, 2 or 3 alkoxys (preferably, phenyl optionally substituted by 1, 2 or 3 alkoxys); (3) a nonaromatic heterocyclic group optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl and alkoxycarbonyl (preferably, a nonaromatic heterocyclic group which is selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, and tetrahydropyranyl and optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl and alkoxycarbonyl); (4) a halogen atom; (5) hydroxy; (6) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl; and (7) alkoxy.

Of the above-mentioned substituents for R 1 , more preferable substituents include

(1) a nonaromatic heterocyclic group selected from the group consisting of oxetanyl, and tetrahydropyranyl; (2) a halogen atom; (3) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and halogenoalkyl; and (4) alkoxy.

When R 2 is “optionally substituted alkyl” or “optionally substituted alkoxy”, preferable substituents of the group include

(1) aryl optionally substituted by 1, 2 or 3 alkoxys (preferably, phenyl optionally substituted by 1, 2 or 3 alkoxys); (2) nonaromatic heterocyclic group optionally substituted by 1, 2 or 3 alkoxys (preferably, nonaromatic heterocyclic group which is selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl and optionally substituted by 1, 2 or 3 alkoxys, and a nonaromatic heterocyclic group); (3) heteroaryl optionally substituted by 1 or 2 oxos (preferably, pyridine, or isoindolinyl optionally substituted 1 or 2 oxos); (4) cyano; (5) a halogen atom; (6) hydroxy; (7) oxo; (8) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxyalkyl and alkoxycarbonyl; (9) alkylsulfonyl; (10) phenylsulfonyl; (11) alkoxy optionally substituted by 1-7 halogen atoms (preferably, alkoxy optionally substituted by 1, 2 or 3 halogen atoms); (12) alkanoyloxy; and (13) alkylidene.

›DESCRIPTION OF EMBODIMENTS · 6 of 25

Of these, more preferable substituents include

(1) phenyl; (2) a nonaromatic heterocyclic group selected from the group consisting of piperidyl, and morpholinyl; (3) heteroaryl selected from the group consisting of pyridine, and isoindolinyl; (4) cyano; (5) a halogen atom; (6) hydroxy; (7) oxo; (8) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxyalkyl; (9) phenylsulfonyl; and (10) alkoxy.

When R 2 is “optionally substituted cycloalkyl”, “optionally substituted amino”, “optionally substituted aryl”, “optionally substituted nonaromatic heterocyclic group”, “optionally substituted heteroaryl”, or “optionally substituted cycloalkoxy”, examples of the preferable substituent of the group include

(1) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of phenyl optionally substituted by 1, 2 or 3 alkoxys, a halogen atom, hydroxy, amino optionally substituted by 1 or 2 alkyls, and alkoxy (preferably, alkyl phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of phenyl optionally substituted by 1, 2 or 3 alkoxys, a halogen atom, hydroxy, amino optionally substituted by 1 or 2 alkyls, and alkoxy); (2) aryl optionally substituted by 1, 2 or 3 alkoxys (preferably, phenyl optionally substituted by 1, 2 or 3 alkoxys); (3) nonaromatic heterocyclic group optionally substituted by 1, 2 or 3 alkoxys (preferably, nonaromatic heterocyclic group which is selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl and optionally substituted by 1, 2 or 3 alkoxys); (4) heteroaryl optionally substituted by 1 or 2 oxos (preferably, pyridine, or isoindolinyl optionally substituted by 1 or 2 oxos); (5) cyano; (6) a halogen atom; (7) hydroxy; (8) oxo; (9) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxyalkyl and alkoxycarbonyl; (10) alkylsulfonyl; (11) phenylsulfonyl; (12) alkoxy optionally substituted by 1-7 halogen atoms (preferably, alkoxy optionally substituted by 1, 2 or 3 halogen atoms); (13) alkanoyloxy; and (14) alkylidene.

Of these, more preferable substituents when R 2 is “optionally substituted alkyl” or “optionally substituted alkoxy” include

(1) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of a halogen atom, and alkoxy (preferably, alkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of a halogen atom, and alkoxy); (2) phenyl; (3) a nonaromatic heterocyclic group selected from the group consisting of piperidyl, and morpholinyl; (4) heteroaryl selected from the group consisting of pyridine, and isoindolinyl; (5) cyano; (6) a halogen atom; (7) hydroxy; (8) oxo; (9) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxyalkyl; (10) phenylsulfonyl; and (11) alkoxy.

When R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, “optionally substituted ring”, preferable substituent on the ring includes

(1) alkyl optionally substituted by 1-7 halogen atoms (preferably, alkyl optionally substituted by 1, 2 or 3 halogen atoms); and (2) a halogen atom.

When R 3 is “optionally substituted alkyl”, or “optionally substituted cycloalkyl”, preferable substituent of the group includes a halogen atom.

When R 4 and R 5 are each “optionally substituted alkyl”, and when R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , “optionally substituted nitrogen-containing non-aromatic heterocycle”, preferable substituent of the group or on the ring includes, respectively,

(1) a halogen atom; and (2) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl.

Of these, a halogen atom is more preferable.

When R 6 and R 7 are each “optionally substituted alkyl”, or “optionally substituted cycloalkyl”, and when R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, “optionally substituted cycloalkane”, preferable substituent of the group or on the ring includes, respectively, a halogen atom, and alkoxy.

One embodiment of the present invention (hereinafter sometimes to be abbreviated as embodiment A) is a compound wherein a part represented by the following formula in the aforementioned formula (I):

(hereinafter sometimes to be abbreviated as partial structure A) is a group represented by the following formula (iv-a), (iv-b), (iv-c), (iv-d), (iv-e), (iv-f), or (iv-g):

wherein the symbols are as defined above, or a pharmacologically acceptable salt thereof.

Of the compounds of the aforementioned embodiment A, a compound wherein the partial structure A is a group represented by the above-mentioned formula (iv-a), (iv-c), or (iv-d), or a pharmacologically acceptable salt thereof is more preferable, a compound wherein the partial structure A is a group represented by the above-mentioned formula (iv-a), or a pharmacologically acceptable salt thereof is particularly preferable.

When the compound (I) of the present invention including the aforementioned embodiment A is more specifically explained, a compound of the formula (I), wherein

›DESCRIPTION OF EMBODIMENTS · 7 of 25

ring A is a 5- to 11-membered monocyclic or bicyclic aromatic group optionally containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said aromatic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of (1) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of amino optionally substituted by 1 or 2 alkyls, alkoxy, and a halogen atom; (2) cyano; (3) amino optionally substituted by 1 or 2 alkyls; (4) alkoxy optionally substituted by 1-7 halogen atoms; and (5) a halogen atom),

R 1 is (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (c) cycloalkyl optionally substituted by 1, 2 or 3 alkoxyalkyls; (d) a halogen atom; (e) phenyl; or (f) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl),

R 2 is (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of alkylidene, cyano, amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, 5- to 11-membered monocyclic or bicyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by 1 or 2 oxos), and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) cycloalkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, alkanoyloxy, and a halogen atom; (d) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenylalkyl; (e) alkoxy optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (f) cycloalkoxy optionally substituted by alkyl; (g) phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (h) 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); or (i) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy), or, R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, a ring selected from the group consisting of 4- to 7-membered (C 4 -C 7 ) cycloalkene, benzene, a 4- to 7-membered monocyclic non-aromatic heterocycle containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and 5- to 6-membered monocyclic heteroarene containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said ring is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom),

R 3 is (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 halogen atoms; (c) cycloalkyl; or (d) a halogen atom,

R 4 and R 5 are each independently a hydrogen atom, or alkyl,

or, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , 4- to 12-membered monocyclic or bicyclic nitrogen-containing non-aromatic heterocycle containing, besides carbon atom, at least one nitrogen atom and 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nitrogen-containing non-aromatic heterocycle is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of amino optionally substituted by a group selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl, and a halogen atom), and

›DESCRIPTION OF EMBODIMENTS · 8 of 25

R 6 and R 7 are each independently (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkoxy, and a halogen atom; or (c) cycloalkyl,

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, cycloalkane, or a pharmacologically acceptable salt thereof can be mentioned.

Of the embodiments, a more preferable embodiment is a compound wherein

ring A is an aromatic group selected from the group consisting of phenyl, tetrahydronaphthyl, indanyl, furyl, thienyl, pyrazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazyl, indolinyl, tetrahydroquinolyl, thienopyridyl, dihydrobenzofuranyl, benzodioxolanyl, and triazolopyridine (said aromatic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of (1) alkyl optionally substituted by a group selected from the group consisting of amino optionally substituted by 1 or 2 alkyls, and alkoxy; (2) halogenoalkyl; (3) cyano; (4) amino optionally substituted by 1 or 2 alkyls; (5) alkoxy; (6) halogenoalkoxy, and (7) a halogen atom),

R 1 is (a) a hydrogen atom; (b) alkyl optionally substituted by a group selected from the group consisting of amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkoxyphenyl, and a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by a group selected from the group consisting of alkyl, and alkoxycarbonyl); (c) halogenoalkyl; (d) cycloalkyl optionally substituted by alkoxyalkyl; (e) a halogen atom; (f) phenyl; or (g) a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by a group selected from the group consisting of alkyl, and alkoxycarbonyl),

R 2 is (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkylidene, cyano, amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, isoindolinyl optionally substituted by 1 or 2 oxos, and a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) halogenoalkyl optionally substituted by a group selected from the group consisting of amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), alkoxy, phenylsulfonyl, phenyl, and pyridyl; (d) cycloalkyl optionally substituted by a group selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and alkanoyloxy; (e) halogenocycloalkyl; (f) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenylalkyl; (g) alkoxy optionally substituted by amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (h) halogenoalkoxy; (i) cycloalkoxy optionally substituted by alkyl; (j) phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (k) heteroaryl selected from the group consisting of thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); or (1) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by a group selected from the group consisting of alkyl, halogenoalkyl, and alkoxy),

or, R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, a ring selected from the group consisting of (1) 4- to 7-membered (C 4 -C 7 ) cycloalkene, (2) benzene, (3) non-aromatic heterocycle selected from the group consisting of pyrrolidine, piperidine, dihydroimidazole, imidazolidine, and piperazine, and (4) heteroarene selected from the group consisting of thiophene, and pyridine (said ring is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom),

R 3 is (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 halogen atoms; (c) cycloalkyl; or (d) a halogen atom,

R 4 is a hydrogen atom, or alkyl,

R 5 is alkyl,

or, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , nitrogen-containing non-aromatic heterocycle selected from the group consisting of azetidine, pyrrolidine, pyrazolidine, piperidine, morpholine, and azabicyclo[3.1.0]hexane (said nitrogen-containing non-aromatic heterocycle is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of amino optionally substituted by a group selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl, and a halogen atom),

›DESCRIPTION OF EMBODIMENTS · 9 of 25

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, cycloalkane, or a pharmacologically acceptable salt thereof can be mentioned.

A specifically preferable embodiment of the present invention including the above-mentioned embodiment A (hereinafter sometimes to be abbreviated as embodiment B) is a compound wherein a part represented by the following formula in the aforementioned formula (I):

(hereinafter sometimes to be referred to as partial structure B) is the following formula (v):

wherein the symbols are as defined above, or a pharmacologically acceptable salt thereof.

When the compound (I) of the present invention including the aforementioned embodiment B is more specifically explained, a compound of the formula (I), wherein

R 2 is (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of alkylidene, amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, 5- to 11-membered monocyclic or bicyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by 1 or 2 oxos), and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) cycloalkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and a halogen atom; (d) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenylalkyl; (e) alkoxy optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (f) phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom (g) 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); or (h) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy),

or, R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, a ring selected from the group consisting of 4- to 7-membered (C 4 -C 7 ) cycloalkene, benzene, a 4- to 7-membered monocyclic non-aromatic heterocycle containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and 5- to 6-membered monocyclic heteroarene containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said ring is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom),

R 3 is (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 halogen atoms; (c) cycloalkyl; or (d) a halogen atom,

›DESCRIPTION OF EMBODIMENTS · 10 of 25

R 4 and R 5 are each independently a hydrogen atom, or alkyl,

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, cycloalkane, or a pharmacologically acceptable salt thereof can be mentioned.

Of the embodiments, a more preferable embodiment is a compound wherein

ring A is an aromatic group selected from the group consisting of phenyl, tetrahydronaphthyl, furyl, thienyl, pyrazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazyl, dihydrobenzofuranyl, benzodioxolanyl, and triazolopyridine (said aromatic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of (1) alkyl optionally substituted by a group selected from the group consisting of amino optionally substituted by 1 or 2 alkyls, and alkoxy; (2) halogenoalkyl; (3) cyano; (4) amino optionally substituted by 1 or 2 alkyls; (5) alkoxy; and (6) a halogen atom),

R 2 is (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkylidene, amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, isoindolinyl optionally substituted by 1 or 2 oxos, and a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) halogenoalkyl optionally substituted by a group selected from the group consisting of amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), alkoxy, phenylsulfonyl, phenyl, and pyridyl; (d) cycloalkyl optionally substituted by a group selected from the group consisting of alkoxyalkyl, halogenoalkyl, cyano, hydroxy, and alkoxy; (e) halogenocycloalkyl; (f) amino optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenylalkyl; (g) alkoxy optionally substituted by amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (h) halogenoalkoxy; (i) phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (j) heteroaryl selected from the group consisting of thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); or (k) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by a group selected from the group consisting of alkyl, halogenoalkyl, and alkoxy),

R 3 is (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 halogen atoms; (c) cycloalkyl; or (d) a halogen atom,

R 4 is a hydrogen atom, or alkyl,

R 5 is alkyl,

›DESCRIPTION OF EMBODIMENTS · 11 of 25

azabicyclo[3.1.0]hexane (said nitrogen-containing non-aromatic heterocycle is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of amino optionally substituted by a group selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl, and a halogen atom),

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, cycloalkane, or a pharmacologically acceptable salt thereof can be mentioned.

In the compound of the above-mentioned embodiment B, a compound wherein Z 1 is a group represented by —C(R 6 )(R 7 )—NH— is more preferable.

In the embodiment of the present invention including the above-mentioned embodiment A, other preferable embodiment (hereinafter sometimes to be abbreviated as embodiment C) is specifically a compound wherein a part represented by the following formula:

(partial structure B) is shown by the formula (vi):

wherein the symbols are as defined above, or a pharmacologically acceptable salt thereof.

When the compound (I) of the present invention including the aforementioned embodiment C is more specifically explained, a compound of the formula (I), wherein

ring A is a 5- to 11-membered monocyclic or bicyclic aromatic group optionally containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said aromatic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of (1) alkyl optionally substituted by 1-7 halogen atoms; (2) alkoxy optionally substituted by 1-7 halogen atoms; and (3) a halogen atom),

R 1 is (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 alkoxyphenyls; (c) a halogen atom; or (d) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom,

R 2 is (a) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of cyano, a halogen atom, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom; (b) cycloalkyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, alkanoyloxy, and a halogen atom; (c) amino optionally substituted by 1 or 2 alkyls; (d) alkoxy optionally substituted by 1, 2 or 3 halogen atoms; (e) cycloalkoxy optionally substituted by alkyl; (f) phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy optionally substituted by 1, 2 or 3 halogen atoms, and a halogen atom; (g) 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by 1, 2 or 3 alkyls); or (h) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 alkyls),

or, R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, a ring selected from the group consisting of 4- to 7-membered (C 4 -C 7 ) cycloalkene, and benzene (said ring is optionally substituted by 1, 2 or 3 halogen atoms),

R 3 is a hydrogen atom,

R 4 and R 5 are each independently a hydrogen atom, or alkyl,

or, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , a 4- to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle containing, besides carbon atom, at least one nitrogen atom and 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom,

R 6 and R 7 are each independently a hydrogen atom, or alkyl,

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, cycloalkane, or a pharmacologically acceptable salt thereof can be mentioned.

Of the embodiments, a more preferable embodiment is a compound wherein

ring A is an aromatic group selected from the group consisting of phenyl, tetrahydronaphthyl, indanyl, indolinyl, tetrahydroquinolyl, and thienopyridyl (said aromatic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, and a halogen atom),

R 1 is a hydrogen atom, alkyl optionally substituted by alkoxyphenyl, a halogen atom, or tetrahydropyranyl,

R 2 is (a) alkyl optionally substituted by a group selected from the group consisting of cyano, and morpholinyl; (b) halogenoalkyl; (c) cycloalkyl optionally substituted by a group selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and alkanoyloxy; (d) halogenocycloalkyl; (e) amino optionally substituted by 1 or 2 alkyls; (f) halogenoalkoxy; (g) cycloalkoxy optionally substituted by alkyl; (h) phenyl optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy optionally substituted by 1, 2 or 3 halogen atoms, and a halogen atom; (i) oxadiazolyl optionally substituted by alkyl; or (j) a nonaromatic heterocyclic group selected from the group consisting of piperidyl, oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by alkyl),

›DESCRIPTION OF EMBODIMENTS · 12 of 25

R 3 is a hydrogen atom,

R 4 and R 5 are each alkyl,

or, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , a nitrogen-containing non-aromatic heterocycle selected from the group consisting of pyrrolidine, and piperidine,

R 6 and R 7 are each independently a hydrogen atom, or alkyl,

or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, cycloalkane, or a pharmacologically acceptable salt thereof.

In the compound of the above-mentioned embodiment C, a compound wherein R 4 and R 5 are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, pyrrolidine is more preferable.

In the compound (I) of the present invention including the above-mentioned each embodiment, preferable examples of a part represented by the following formula:

(partial structure A) include a group represented by the following formula (iv-a), (iv-b), (iv-c), (iv-d), or (iv-e):

wherein the symbols are as defined above. Of these, a group represented by the formula (iv-a), (iv-c), or (iv-d) is more preferable, and a group represented by the formula (iv-a) is particularly preferable.

Examples of embodiment in the present invention other than the above (hereinafter sometimes to be abbreviated as embodiment D) include a compound of the aforementioned formula (I) wherein a part represented by the following formula:

(partial structure A) is a cyclic group shown by the following formula:

a part represented by the following formula:

is a group represented by the following formula:

namely, a compound represented by the following formula (I-I):

wherein ring A-1 is C 6 -C 11 monocyclic or bicyclic aryl, or 5- to 11-membered monocyclic or bicyclic heteroaryl containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom,

Z 1a is an oxygen atom, —C(R 6a )(R 7a )—, —NH—, —C(R 6a )(R 7a )—NH—, —NH—C(R 6a )(R 7a )—, —C(R 6a )(R 7a )—O—, —O—C(R 6a )(R 7a )—, or a single bond (wherein the left end shows a bond to ring A-i, and the right end shows a bond to the adjacent carbonyl),

(a) one of Z 2a and Z 3a is CH and the other is a nitrogen atom, or (b) both of them are nitrogen atoms,

R 1a is (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (c) cycloalkyl; (d) phenyl; or (e) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl),

R 2a is (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, alkanoyloxy, and a halogen atom; (d) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenyl; (e) alkoxy optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (f) cycloalkoxy optionally substituted by alkyl; (g) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (h) 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); or (i) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy),

or R 1a and R 2a are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, (a) a 4- to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle containing 1 or 2 nitrogen atoms besides carbon atom (said nitrogen-containing non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom); or (b) 5- to 6-membered monocyclic nitrogen-containing heteroarene containing, besides carbon atom, at least one nitrogen atom and 1 or 2 hetero atoms selected from the group consisting of sulfur atom and nitrogen atom (said nitrogen-containing heteroarene is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom),

›DESCRIPTION OF EMBODIMENTS · 13 of 25

R 4a and R 5a are each independently a hydrogen atom, or alkyl,

or, R 4a and R 5a are bonded to each other to form, together with the adjacent Z 2a and Z 3a , 4- to 7-membered monocyclic nitrogen-containing non-aromatic heterocycle containing, besides carbon atom, at least one nitrogen atom and 1 or 2 hetero atoms selected from the group consisting of oxygen atom, and nitrogen atom (said nitrogen-containing non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino optionally substituted by a group selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl, and a halogen atom), and

R 6a and R 7a are each independently (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkoxy, and a halogen atom; or (c) cycloalkyl, or R 6a and R 7a are bonded to each other to form, together with the adjacent carbon atom, cycloalkane,

R 8a , R 8b and R 8c are each independently (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, alkoxy, and a halogen atom; (c) cyano; (d) amino optionally substituted by 1 or 2 alkyls; (e) alkoxy optionally substituted by 1-7 halogen atoms; or (f) a halogen atom, and

n is 0 or 1, or a pharmacologically acceptable salt thereof can be mentioned.

Z 2a and Z 3a in the above-mentioned formula (I-I) are as defined above, and (a) Z 2a is CH, and Z 3a is a nitrogen atom, or (b) Z 2a is a nitrogen atom, and Z 3a is CH is preferable.

When ring A-1 in the above-mentioned formula (I-I) is “C 6 -C 11 monocyclic or bicyclic aryl”, preferable examples of the aryl include phenyl, indanyl, and tetrahydronaphthyl, of which phenyl is more preferable. In the above-mentioned formula (I-I), specific examples of “C 6 -C 11 monocyclic or bicyclic aryl, or 5- to 11-membered monocyclic or bicyclic heteroaryl containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom” for ring A-1 include phenyl, indanyl, tetrahydronaphthyl, furyl, thienyl, pyrazolyl, isoxazolyl, thiazolyl, dihydrobenzofuranyl, benzodioxolanyl, and tetrahydroquinolyl. Of these, phenyl, thienyl, or benzodioxolanyl is preferable, and phenyl is particularly preferable.

Preferable examples of Z 1a in the above-mentioned formula (I-I) include an oxygen atom, —C(R 6a )(R 7a )—, —NH—, —C(R 6a) (R 7a )—NH—, —NH—C(R 6a )(R 7a )—, —C(R 6a )(R 7a )—O—, and —O—C(R 6a )(R 7a )—, of which an oxygen atom, —C(R 6a )(R 7a )—, —C(R 6a) (R 7a )—NH—, —NH—C(R 6a )(R 7a )—, or —O—C(R 6a )(R 7a )— is more preferable.

Preferable examples of R 1a in the above-mentioned formula (I-I) include (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (c) cycloalkyl; (d) phenyl; or (e) a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, morpholinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl). Of these R 1a , (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and halogenoalkyl), alkoxy, a halogen atom, and a nonaromatic heterocyclic group selected from the group consisting of oxetanyl, and tetrahydropyranyl; (c) cycloalkyl; or (d) a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, oxetanyl, and tetrahydropyranyl is more preferable, (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkoxy, and oxetanyl; (c) cycloalkyl; or (d) tetrahydropyranyl is particularly preferable.

Preferable examples of R 2a in the above-mentioned formula (I-I) include (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, and a monocyclic nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and a halogen atom; (d) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenyl; (e) alkoxy optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (f) cycloalkoxy optionally substituted by alkyl; (g) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by 1-7 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (h) heteroaryl selected from the group consisting of thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); and (i) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy). Of these R 2a , (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxyalkyl), hydroxy, alkoxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, piperidyl, and morpholinyl; (c) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and a halogen atom; (d) amino optionally substituted by 1 or 2 alkyls; (e) alkoxy; (f) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl optionally substituted by 1, 2 or 3 halogen atoms, alkoxy, and a halogen atom; (g) heteroaryl selected from the group consisting of thienyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom); or (h) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by one group selected from the group consisting of alkyl, halogenoalkyl, and alkoxy) is more preferable, and (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of hydroxy, oxo, phenylsulfonyl, a halogen atom, phenyl, and piperidyl; (c) cycloalkyl optionally substituted by 1, 2 or 3 halogen atoms; (d) phenyl optionally substituted by 1, 2 or 3 halogen atoms; (e) oxadiazolyl optionally substituted by alkyl; or (f) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, and piperidyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy) is particularly preferable.

›DESCRIPTION OF EMBODIMENTS · 14 of 25

When R 1a and R 2a in the above-mentioned formula (I-I) are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, a ring, preferable examples of the ring include a non-aromatic heterocycle selected from the group consisting of pyrrolidine, piperidine, dihydroimidazole, imidazolidine, and piperazine (said non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom). Of these, a non-aromatic heterocycle selected from the group consisting of piperidine, dihydroimidazole, imidazolidine, and piperazine (said non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom) is more preferable, and a non-aromatic heterocycle selected from the group consisting of piperidine, and piperazine (said non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom) is particularly preferable.

Preferable examples of R 4a and R 5a in the above-mentioned formula (I-I) include alkyl. Other preferable examples of R 4a and R 5a include ring formed by them, bonded to each other, together with the adjacent Z 2a and Z 3a . Examples of such ring include a nitrogen-containing non-aromatic heterocycle selected from the group consisting of azetidine, pyrrolidine, and piperidine (said nitrogen-containing non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino optionally substituted by one group selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl, and a halogen atom). Of these, a nitrogen-containing non-aromatic heterocycle selected from the group consisting of pyrrolidine, and piperidine (said nitrogen-containing non-aromatic heterocycle is optionally substituted by 1, 2 or 3 halogen atoms) is more preferable.

Preferable examples of R 6a and R 7a in the above-mentioned formula (I-I) include, each independently, a hydrogen atom and alkyl.

Preferable examples of R 8a , R 8b and R 8c in the above-mentioned formula (I-I) include, each independently, (a) a hydrogen atom; (b) alkyl optionally substituted by one group selected from the group consisting of dialkylamino, and alkoxy; (c) cyano; (d) amino optionally substituted by 1 or 2 alkyls; (e) alkoxy; and (f) a halogen atom. Of these, a hydrogen atom, alkyl, and a halogen atom are more preferable, and a hydrogen atom and a halogen atom is particularly preferable.

In the above-mentioned formula (I-I), n is preferably 1.

Of the above-mentioned embodiment D, preferable examples include a compound wherein a part represented by the following formula in the formula (I-I) of said embodiment D:

is a group represented by the following formula:

namely, a compound represented by the following formula (I-II):

wherein the symbols are as defined above, or a pharmacologically acceptable salt thereof.

In the above-mentioned formula (I-II), specific examples of “C 6 -C 11 monocyclic or bicyclic aryl, or 5- to 11-membered monocyclic or bicyclic heteroaryl containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom” for ring A-1 include phenyl, furyl, thienyl, pyrazolyl, isoxazolyl, thiazolyl, dihydrobenzofuranyl, and benzodioxolanyl. Of these, phenyl, thienyl and benzodioxolanyl are preferable, and phenyl is particularly preferable.

Preferable examples of R 1a in the above-mentioned formula (I-II) include (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (c) cycloalkyl; (d) phenyl; or (e) a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, morpholinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl). Of these R 1a , (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and halogenoalkyl), alkoxy, a halogen atom, and a nonaromatic heterocyclic group selected from the group consisting of oxetanyl, and tetrahydropyranyl; (c) cycloalkyl; or (d) a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, oxetanyl, and tetrahydropyranyl is more preferable, (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkoxy, and oxetanyl; (c) cycloalkyl; or (d) tetrahydropyranyl is particularly preferable.

Preferable examples of R 2a in the above-mentioned formula (I-II) include (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, and a monocyclic nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and a halogen atom; (d) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenyl; (e) alkoxy optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (f) cycloalkoxy optionally substituted by alkyl; (g) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (h) heteroaryl selected from the group consisting of thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); and (i) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy). Of these R 2a , (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxyalkyl), hydroxy, alkoxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, piperidyl, and morpholinyl; (c) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and a halogen atom; (d) amino optionally substituted by 1 or 2 alkyls; (e) alkoxy; (f) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl optionally substituted by 1, 2 or 3 halogen atoms, alkoxy, and a halogen atom; (g) heteroaryl selected from the group consisting of thienyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom); or (h) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy) is more preferable, and (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of hydroxy, oxo, phenylsulfonyl, a halogen atom, phenyl, and piperidyl; (c) cycloalkyl optionally substituted by 1, 2 or 3 halogen atoms; (d) phenyl optionally substituted by 1, 2 or 3 halogen atoms; (e) oxadiazolyl optionally substituted by alkyl; or (f) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, and piperidyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy) is particularly preferable.

›DESCRIPTION OF EMBODIMENTS · 15 of 25

When R 1a and R 2a in the above-mentioned formula (I-II) are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, a ring, preferable examples of the ring include a non-aromatic heterocycle selected from the group consisting of pyrrolidine, piperidine, dihydroimidazole, imidazolidine, and piperazine (said non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, alkoxycarbonyl, and a halogen atom). Of these, a non-aromatic heterocycle selected from the group consisting of piperidine, dihydroimidazole, imidazolidine, and piperazine (said non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom) is more preferable, and a non-aromatic heterocycle selected from the group consisting of piperidine, and piperazine (said non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom) is particularly preferable.

Preferable examples of R 4a and R 5a in the above-mentioned formula (I-II) include alkyl. Other preferable examples of R 4a and R 5a include ring formed by them, bonded to each other, together with the adjacent nitrogen atom and carbon atom. Examples of such ring include a nitrogen-containing non-aromatic heterocycle selected from the group consisting of azetidine, pyrrolidine, and piperidine (said nitrogen-containing non-aromatic heterocycle is optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino optionally substituted by one group selected from the group consisting of alkoxycarbonyl and phenylalkoxycarbonyl, and a halogen atom). Of these, a nitrogen-containing non-aromatic heterocycle selected from the group consisting of pyrrolidine, and piperidine (said nitrogen-containing non-aromatic heterocycle is optionally substituted by 1, 2 or 3 halogen atoms) is more preferable.

Preferable examples of R 6a and R 7a in the above-mentioned formula (I-II) include, each independently, a hydrogen atom and alkyl.

Preferable examples of R 8a , R 8b and R 8c in the above-mentioned formula (I-II) include, each independently, (a) a hydrogen atom; (b) alkyl optionally substituted by one group selected from the group consisting of dialkylamino, and alkoxy; (c) cyano; (d) amino optionally substituted by 1 or 2 alkyls; (e) alkoxy; and (f) a halogen atom. Of these, a hydrogen atom, alkyl, and a halogen atom are more preferable, and a hydrogen atom or a halogen atom is particularly preferable.

In the above-mentioned formula (I-II), n is preferably 1.

In the embodiments of the present invention, examples of the preferable embodiment include compound (I-I) and compound (I-II) defined above, wherein R 4a and R 5a are bonded to each other to form, together with the adjacent Z 2a and Z 3a , or a nitrogen atom and carbon atom, pyrrolidine, and R 6a and R 7a are both hydrogen atoms, or a pharmacologically acceptable salt thereof.

In the embodiments of the present invention, examples of other preferable embodiment include a compound wherein R 4a is C 1 -C 6 alkyl, R 5a is C 1 -C 6 alkyl, and R 6a and R 7a are both hydrogen atoms, or a pharmacologically acceptable salt thereof.

Of the above-mentioned embodiment D, other preferable examples include a compound wherein a part represented by the following formula in the formula (I-I) of said embodiment D:

is a cyclic group shown by the following formula:

and a part represented by the following formula:

is a group represented by the following formula:

namely, a compound represented by the following formula (I-III):

wherein R 1b is (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (c) cycloalkyl; (d) phenyl; or (e) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl),

R 2b is (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (c) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, alkanoyloxy, and a halogen atom; (d) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenyl; (e) alkoxy optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (f) cycloalkoxy optionally substituted by alkyl; (g) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (h) 5- to 6-membered monocyclic heteroaryl containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); or (i) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, and nitrogen atom (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy),

›DESCRIPTION OF EMBODIMENTS · 16 of 25

and other symbols are as defined above, or a pharmacologically acceptable salt thereof can be mentioned.

In the above-mentioned formula (I-III), specific examples of “C 6 -C 11 monocyclic or bicyclic aryl, or 5- to 11-membered monocyclic or bicyclic heteroaryl containing, besides carbon atom, 1, 2 or 3 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom” for ring A-1 include phenyl, indanyl, tetrahydronaphthyl, and tetrahydroquinolyl. Of these, phenyl is particularly preferable.

Preferable examples of Z 1a in the above-mentioned formula (I-III) include an oxygen atom, —C(R 6a )(R 7a )—, —NH—, —C(R 6a )(R 7a )—NH—, and —C(R 6a )(R 7a )—O—. Of these, an oxygen atom, and —C(R 6a )(R 7a )— are more preferable.

Preferable examples of R 1b in the above-mentioned formula (I-III) include (a) a hydrogen atom; (b) alkyl optionally substituted by 1-7 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl); (c) a nonaromatic heterocyclic group selected from the group consisting of pyrrolidyl, piperidyl, morpholinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl). Of these R 1b , (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 alkoxyphenyls; or (c) tetrahydropyranyl is more preferable, and (a) a hydrogen atom; or (b) alkyl is particularly preferable.

Preferable examples of R 2b in the above-mentioned formula (I-III) include (a) alkyl optionally substituted by 1-7 groups selected from the group consisting of cyano, amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, alkylsulfonyloxy, oxo, phenylsulfonyl, a halogen atom, phenyl, pyridyl, isoindolyl optionally substituted by 1 or 2 oxos, and a monocyclic nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by alkoxy); (b) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, hydroxy, alkoxy, and a halogen atom; (c) amino optionally substituted by 1 or 2 groups selected from the group consisting of alkyl and alkoxyphenyl; (d) alkoxy optionally substituted by 1, 2 or 3 groups selected from the group consisting of amino (said amino is optionally substituted by 1 or 2 groups selected from the group consisting of alkyl, and alkoxycarbonyl), and a halogen atom; (e) cycloalkoxy optionally substituted by alkyl; (f) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl (said alkyl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, hydroxy, and a halogen atom), alkoxy optionally substituted by 1, 2 or 3 halogen atoms, alkylsulfonyl, and a halogen atom; (g) heteroaryl selected from the group consisting of thienyl, pyrazolyl, oxadiazolyl, pyridyl, and pyrimidinyl (said heteroaryl is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy, and a halogen atom); and (h) a nonaromatic heterocyclic group selected from the group consisting of azetidinyl, pyrrolidyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl, and morpholinyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxy). Of these R 2b , (a) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of cyano, a halogen atom, and morpholinyl; (b) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, alkoxy, and a halogen atom; (c) amino optionally substituted by 1 or 2 alkyls; (d) alkoxy optionally substituted by 1, 2 or 3 halogen atoms; (e) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy optionally substituted by 1, 2 or 3 halogen atoms, and a halogen atom; (f) oxadiazolyl optionally substituted by alkyl; or (g) a nonaromatic heterocyclic group selected from the group consisting of piperidyl, oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by alkyl) is more preferable, and (a) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of cyano, and a halogen atom; (b) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, alkoxy, and a halogen atom; (c) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, and a halogen atom; (d) oxadiazolyl optionally substituted by alkyl; or (e) a nonaromatic heterocyclic group selected from the group consisting of oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by alkyl) is particularly preferable.

Preferable examples of R 6a and R 7a in the above-mentioned formula (I-III) include, each independently, a hydrogen atom and alkyl.

Preferable examples of R 8a , R 8b and R 8c in the above-mentioned formula (I-III) include, each independently, (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkylamino, dialkylamino, alkoxy, and a halogen atom; (c) alkoxy optionally substituted by 1, 2 or 3 halogen atoms; or (d) a halogen atom. Of these, (a) a hydrogen atom; (b) alkyl optionally substituted by 1, 2 or 3 halogen atoms; (c) alkoxy optionally substituted by 1, 2 or 3 halogen atoms; or (d) a halogen atom is more preferable, and a hydrogen atom, alkyl, or a halogen atom is particularly preferable.

›DESCRIPTION OF EMBODIMENTS · 17 of 25

In the above-mentioned formula (I-III), n is preferably 1.

Of the compound (I-III) defined as above, examples of preferable compound include a compound wherein ring A-1 is phenyl,

Z 1a is an oxygen atom,

R 1b is (a) a hydrogen atom; (b) alkyl optionally substituted by phenyl (said phenyl is optionally substituted by 1, 2 or 3 alkoxys); or (c) tetrahydropyranyl,

R 2b is (a) alkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of cyano, a halogen atom, and morpholinyl; (b) cycloalkyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxyalkyl, halogenoalkyl, cyano, alkoxy, and a halogen atom; (c) amino optionally substituted by 1 or 2 alkyls; (d) alkoxy optionally substituted by 1, 2 or 3 halogen atoms; (e) cycloalkoxy optionally substituted by alkyl; (f) phenyl optionally substituted by 1, 2 or 3 groups selected from the group consisting of alkyl, alkoxy optionally substituted by 1, 2 or 3 halogen atoms, and a halogen atom; (g) oxadiazolyl optionally substituted by alkyl; or (h) a nonaromatic heterocyclic group selected from the group consisting of piperidyl, oxetanyl, and tetrahydropyranyl (said nonaromatic heterocyclic group is optionally substituted by 1, 2 or 3 alkyls),

R 8a , R 8b and R 8c are each independently (a) a hydrogen atom, (b) alkyl optionally substituted by 1, 2 or 3 halogen atoms, (c) alkoxy optionally substituted by 1, 2 or 3 halogen atoms, or (d) a halogen atom, and

n is 1.

Specific examples of the compound (I) or a pharmacologically acceptable salt thereof of the present invention non-limitatively include the compounds described in the following Examples, and a pharmacologically acceptable salt thereof. Of these, examples of preferable compound or a pharmacologically acceptable salt thereof include compounds selected from the group consisting of

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester; (R)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester; (R)-2-[7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester; (R)-2-(5-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester; (R)-2-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester; and (R)-2-[6-methyl-7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester; or a pharmacologically acceptable salt thereof,

or compounds selected from the group consisting of

(R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(6-methyl-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(2,6-difluorophenyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[6-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(1-fluorocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(5-difluoromethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[6-methyl-7-oxo-5-(piperidin-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(2-fluorophenyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(5-difluoromethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(2,6-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[5-(2-hydroxypropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; and (R)-N-benzyl-1-[7-oxo-5-(piperidin-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; or a pharmacologically acceptable salt thereof.

The compound (I) of the present invention can be present in the form of tautomer or a mixture thereof. The compound (I) of the present invention can be present in the form of a stereoisomer such as enantiomer, diastereomer and the like or a mixture thereof. The compound (I) of the present invention encompasses a mixture of tautomer or stereoisomer and a pure or substantially pure isomer thereof.

When compound (I) is obtained in the form of a diastereomer or enantiomer, it can be resolved by a method conventionally used in the pertinent field, for example, chromatography, and a fractional crystallization method.

The present invention encompasses compound (I) wherein one or more atoms are substituted by one or more isotopes. Examples of the isotope include 2 H(D), 3 H, 13 C, and 14 C.

Examples of the pharmacologically acceptable salt of compound (I) include alkali metal salts such as lithium, sodium, potassium and the like; group 2 metal salts such as magnesium, calcium and the like; salts with aluminum or zinc; salts with amine such as ammonia, choline, diethanolamine, lysine, ethylenediamine, tert-butylamine, tert-octylamine, tris(hydroxymethyl)aminomethane, N-methyl-glucosamine, triethanolamine, dehydroabiethylamine and the like; salts with inorganic acids such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, nitric acid, phosphoric acid and the like; salts with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid and the like; and salts with acidic amino acid such as aspartic acid, glutamic acid and the like.

›DESCRIPTION OF EMBODIMENTS · 18 of 25

Moreover, the pharmacologically acceptable salt of compound (I) encompasses intramolecular salt, hydrate, solvate of compound (I).

The compound (I) or a pharmacologically acceptable salt thereof of the present invention can be administered orally or parenterally. In addition, it can be used as a conventionally-used drug preparation such as tablet, granule, capsule, powder, injection, inhalant and the like.

While the dose of the compound (I) or a pharmacologically acceptable salt thereof of the present invention varies depending on the administration method, age, body weight and condition of the patient, generally, it is preferably set to 0.001-500 mg/kg, particularly 0.01-10 mg/kg.

The compound (I) or a pharmacologically acceptable salt thereof of the present invention has a superior KAT-II inhibitory activity. A pharmaceutical composition containing compound (I) or a pharmacologically acceptable salt thereof of the present invention is useful for the treatment or prophylaxis of a disease or symptom (e.g., dementia, depression, stress vulnerability) in which inhibition of KAT-II activity is expected to improve the pathology. More specific examples of such disease and symptom include, for example, schizophrenia, bipolar disorder, attention deficit/hyperactivity disorder, Alzheimer's disease, major depression, autism, cerebrovascular dementia, HIV encephalopathy, and age-related cognitive dysfunction. Preferably, a pharmaceutical composition containing the compound (I) or a pharmacologically acceptable salt thereof of the present invention is useful for the treatment or prophylaxis of schizophrenia, attention deficit/hyperactivity disorder, Alzheimer's disease, or major depression, particularly for the treatment or prophylaxis of schizophrenia.

A therapeutic or prophylactic method including administering an effective amount of compound (I) or a pharmacologically acceptable salt thereof of the present invention to a patient (individual to be the target of treatment or prophylaxis) is also applied to the aforementioned object and encompassed in the present invention.

Also, use of compound (I) or a pharmacologically acceptable salt thereof of the present invention for the production of a medicament having a KAT-II inhibitory action is also applied to the aforementioned object and encompassed in the present invention.

According to the present invention, compound (I) or a pharmacologically acceptable salt thereof can be produced by the following method, but the method is not limited thereto.

In each production step of compound (I) to be described below, when protection of functional group contained in the compound is necessary, the functional group can be appropriately protected by a conventional method. The protecting group and general description of the use thereof are contained in T. W. Greene et al., “Protective Groups in Organic Synthesis”, John Wiley & Sons, New York, 2006. The protecting group is removed by a conventional method in a subsequent step.

[Production of Compound (I)]

Of compound (I), a compound represented by the formula (I-a):

wherein the symbols are as defined above, can be produced by reacting a compound represented by the formula (II):

wherein the symbols are as defined above, with a compound represented by the formula (III-a):

wherein G 1 is a leaving group, and other symbols are as defined above, in a solvent in the presence of a base.

G 1 represented by Examples of the leaving group include halogen atom (particularly, chlorine atom), optionally substituted aryloxy (particularly, methoxyphenyloxy) can be mentioned.

Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) and the like.

The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like; ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; alkylnitrile such as acetonitrile, propionitrile and the like; or a mixed solvent thereof.

The amount of compound (III-a) to be used in this reaction is 0.5-20 mol, preferably 1.0-7.0 mol, per 1 mol of compound (II). The amount of the base to be used is 0.5-30 mol, preferably 0.9-7.0 mol, per 1 mol of compound (II). This reaction can be performed at 0-150° C., preferably 20-90° C.

Of compound (I), a compound represented by the formula (I-b):

wherein G 2 is —C(R 6 )(R 7 )— or a single bond, and other symbols are as defined above, can be produced by reacting the aforementioned compound (II) with a compound represented by the formula (III-b):

wherein the symbols are as defined above, in a solvent in the presence of a base.

Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) and the like.

The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like.

The amount of compound (III-b) to be used in this reaction is 0.5-10 mol, preferably 1.0-1.5 mol, per 1 mol of compound (II). The amount of the base to be used is 0.5-15 mol, preferably 0.8-2.0 mol, per 1 mol of compound (II). This reaction can be performed at 0-50° C., preferably 10-30° C.

Alternatively, compound (I-b) can be produced from the aforementioned compound (II) according to a method describe below. Compound (II) is reacted with a carbonylating agent to give a reactive intermediate. Furthermore, the reactive intermediate is reacted with a compound represented by the formula (III-c):

wherein the symbols are as defined above, whereby compound (I-b) can be produced.

The reaction of compound (II) and a carbonylating agent can be performed in a solvent in the presence of a base.

Examples of the carbonylating agent include triphosgene, phosgene, and carbonyldiimidazole. Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like; aromatic hydrocarbon such as benzene, toluene, xylene and the like. The amount per carbonyl of the carbonylating agent to be used in this reaction is 0.5-10 mol, preferably 1.5-2.5 mol, per 1 mol of compound (II). The amount of the base to be used is 0.5-15 mol, preferably 1.8-3.0 mol, per 1 mol of compound (II). This reaction can be performed at −20 to 50° C., preferably 0-30° C.

›DESCRIPTION OF EMBODIMENTS · 19 of 25

The reaction of the obtained reactive intermediate and compound (III-c) can be performed in a solvent in the presence of a base.

Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, N,N-dimethyl-4-aminopyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like. The amount of compound (III-c) to be used in this reaction is 1.0-10 mol, preferably 3.0-7.0 mol, per 1 mol of compound (II). The amount of the base to be used is 1.0-15 mol, preferably 3.0-8.0 mol, per 1 mol of compound (II). This reaction can be performed at 0-50° C., preferably 10-30° C.

Of compound (I), a compound represented by the formula (I-c):

wherein ring A-a is optionally substituted nitrogen-containing heteroaryl wherein a bond of the ring is a nitrogen atom, can be produced from the aforementioned compound (II) according to a method describe below. Compound (II) is reacted with a compound represented by the formula (IV):

wherein G 3 and G 4 are each independently a leaving group, and other symbols are as defined above, to give a reactive intermediate. Furthermore, the reactive intermediate is reacted with a compound represented by the formula (V):

wherein the symbols are as defined above, whereby compound (I-c) can be produced.

The leaving groups for G 3 and G 4 are each independently, for example, a halogen atom (particularly, chlorine atom).

The reaction of compound (II) and compound (IV) can be performed in a solvent in the presence of a base.

Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like. The amount of compound (IV) to be used in this reaction is 0.5-10 mol, preferably 1.0-1.2 mol, per 1 mol of compound (II). The amount of the base to be used is 0.5-15 mol, preferably 1.0-1.3 mol, per 1 mol of compound (II). This reaction can be performed at 0-50° C., preferably 10-30° C.

The reaction of the obtained reactive intermediate and compound (V) can be performed in a solvent with or without additive in the presence of a base.

Examples of the base include alkali metal carbonate such as potassium carbonate, cesium carbonate, sodium carbonate and the like; alkali metal hydride such as sodium hydride and the like. As the additive, alkali metal iodide such as potassium iodide, sodium iodide and the like can be mentioned. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; alkylnitrile such as acetonitrile, propionitrile and the like; or a mixed solvent thereof can be mentioned. The amount of compound (V) to be used in this reaction is 1.0-3.0 mol, preferably 1.1-1.8 mol, per 1 mol of compound (II). The amount of the base to be used is 1.0-15 mol, preferably 1.2-2.0 mol, per 1 mol of compound (II). The amount of the additive to be used is 1.0-10 mol, preferably 1.1-2.5 mol, per 1 mol of compound (II). This reaction can be performed at 20-120° C., preferably 60-100° C.

Of compound (I), a compound represented by the formula (I-d):

wherein the symbols are as defined above, can be produced by reacting a compound represented by the formula (VI):

wherein the symbols are as defined above, in a solvent in the presence of a condensation agent in the presence of a base.

Examples of the condensation agent include chlorotrialkylsilane such as chlorotrimethylsilane and the like, N,O-bis(trialkylsilyl)acetamide such as N,O-bis(trimethylsilyl)acetamide and the like. Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like; amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like. The amount of the condensation agent to be used in this reaction is 1.0-500 mol, preferably 5.0-100 mol, per 1 mol of compound (VI). The amount of the base to be used is 3.0-1500 mol, preferably 15-300 mol, per 1 mol of compound (VI). This reaction can be performed at 0-50° C., preferably 10-30° C.

Alternatively, compound (I-d) can be produced by reacting compound (VI) in a solvent (e.g., acetic acid) in the presence of an acid (e.g., concentrated sulfuric acid).

Alternatively, compound (I-d) can be produced by reacting a compound represented by the formula (VII):

wherein the symbols are as defined above, with a compound represented by the formula (VIII-a):

wherein the symbols are as defined above, in a solvent in the presence of a base.

The amount of compound (VIII-a) to be used in this reaction is 3.0-100 mol, preferably 5.0-30 mol, per 1 mol of compound (VII). The amount of the base to be used is 3.0-100 mol, preferably 5.0-30 mol, per 1 mol of compound (VII) This reaction can be performed at 0-150° C., preferably 20-100° C.

Alternatively, compound (I-d) can be produced by reacting the aforementioned compound (VII) with a compound represented by the formula (VIII-b):

wherein G 5 is alkyl, and other symbols are as defined above, without solvent in the presence of acid anhydride (e.g., acetic anhydride).

The amount of compound (VIII-b) to be used in this reaction is 1.0-30 mol, preferably 5.0-20 mol, per 1 mol of compound (VII). The amount of acid anhydride to be used is 1.0-30 mol, preferably 5.0-20 mol, per 1 mol of compound (VII). This reaction can be performed at 60-180° C., preferably 100-150° C.

›DESCRIPTION OF EMBODIMENTS · 20 of 25

Of compound (I), a compound represented by the formula (I-e):

wherein R 2x is an optionally substituted nitrogen-containing nonaromatic heterocyclic group wherein a bond of the group is a nitrogen atom, optionally substituted amino, optionally substituted alkoxy, or optionally substituted cycloalkoxy, and other symbols are as defined above, can be produced by reacting a compound represented by the formula (IX):

wherein G 6 is a leaving group, and other symbols are as defined above, with a compound represented by the formula (X):

HR 2x (X)

wherein the symbols are as defined above.

Examples of the leaving group for G 6 include alkylsulfinyl (particularly, methylsulfinyl), and alkylsulfonyl (particularly, methylsulfonyl).

When R 2x is an optionally substituted nitrogen-containing nonaromatic heterocyclic group wherein a bond of the group is a nitrogen atom or optionally substituted amino, this reaction can be performed in a solvent.

The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like.

The amount of compound (X) to be used in this reaction is 1.0-20 mol, preferably 3.0-8.0 mol, per 1 mol of compound (IX). This reaction can be performed at 0-60° C., preferably 10-30° C.

When R 2x is optionally substituted alkoxy or optionally substituted cycloalkoxy, this reaction can be performed in a solvent in the presence of a base.

Examples of the base include alkali metal tert-butoxide such as potassium tert-butoxide, sodium tert-butoxide and the like; and alkali metal hydride such as sodium hydride and the like.

The solvent may be any as long as it does not influence the reaction, and examples thereof include amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like.

The amount of compound (X) to be used in this reaction is 1.0-3.0 mol, preferably 1.2-1.8 mol, per 1 mol of compound (IX). The amount of the base to be used is 0.9-2.7 mol, preferably 1.1-1.7 mol, per 1 mol of compound (IX). This reaction can be performed at 20-100° C., preferably 40-80° C.

Of compound (I), a compound represented by the formula (I-f):

wherein the symbols are as defined above, can be produced by reacting a compound represented by the formula (XI):

wherein G 7 is a leaving group, and other symbols are as defined above, with a compound represented by the formula (XII):

wherein the symbols are as defined above, or a salt thereof.

Examples of the leaving group for G 7 include halogen atom (particularly, bromine atom), alkylsulfinyl (particularly, methylsulfinyl), and alkylsulfonyl (particularly, methylsulfonyl).

This reaction can be performed in a solvent in the presence of a base, in the presence of a copper salt in the presence of a ligand.

Examples of the base include trialkali metal phosphate such as trisodium phosphate, tripotassium phosphate and the like. Examples of the copper salt include copper (I) halide such as copper (I) iodide and the like. Examples of the ligand include diamine such as trans-N,N′-dimethylcyclohexane-1,2-diamine, trans-cyclohexane-1,2-diamine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like.

The amount of compound (XII) to be used in this reaction is 0.5-10 mol, preferably 1.0-6.0 mol, per 1 mol of compound (XI). The amount of the base to be used is 1.0-10 mol, preferably 1.2-3.0 mol, per 1 mol of compound (XI). The amount of the copper salt to be used is 0.05-1.0 mol, preferably 0.1-0.3 mol, per 1 mol of compound (XI). The amount of the ligand to be used is 0.05-1.0 mol, preferably 0.1-0.3 mol, per 1 mol of compound (XI). This reaction can be performed at 50-150° C., preferably 80-120° C.

Alternatively, this reaction can be performed in a solvent or without solvent, in the presence of a base.

The amount of compound (XII) to be used in this reaction is 0.5-10 mol, preferably 1.0-6.0 mol, per 1 mol of compound (XI). The amount of the base to be used is 0.9-10 mol, preferably 1.0-5.0 mol, per 1 mol of compound (XI). This reaction can be performed at 80-200° C., preferably 120-180° C.

Of compound (I), a compound represented by the formula (I-g)

wherein the symbols are as defined above, can be produced by reacting a compound represented by the formula (XIII):

wherein E 1 is a leaving group, and other symbols are as defined above, with a compound represented by the formula (XIV):

wherein the symbols are as defined above, in a solvent or without solvent, in the presence of a base.

Examples of the leaving group for E 1 include halogen atom (particularly, bromine atom), optionally substituted alkylsulfinyl (particularly, methylsulfinyl, benzylsulfinyl), and optionally substituted alkylsulfonyl (particularly, methylsulfonyl, benzylsulfonyl).

Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like; and alkali metal carbonate such as sodium carbonate, potassium carbonate, cesium carbonate and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone and the like; amine such as pyridine and the like; or a mixed solvent thereof.

The amount of compound (XIV) to be used in this reaction is 0.9-30 mol, preferably 1.2-5.0 mol, per 1 mol of compound (XIII). The amount of the base to be used is 1.0-100 mol, preferably 1.2-10 mol, per 1 mol of compound (XIII). This reaction can be performed at 60° C.-180° C., preferably 100° C. 150° C.

›DESCRIPTION OF EMBODIMENTS · 21 of 25

Of compound (I), a compound represented by the formula (I-h):

wherein E 2 is —C(R 6 )(R 7 )—, or a single bond, and other symbols are as defined above, can be produced from the aforementioned compound (XIII) according to a method describe below.

Compound (XIII) and a compound represented by the formula (XV-a):

wherein the symbols are as defined above, are reacted to give a compound represented by the formula (XVI-a):

wherein the symbols are as defined above. The compound (XVI-a) is reacted with a compound represented by the formula (XVII):

wherein the symbols are as defined above, whereby compound (I-h) can be produced.

Compound (XVI-a) can be produced by reacting compound (XIII) and compound (XV-a), which is similar to the method of producing the aforementioned compound (I-g) from compound (XIII) and compound (XIV).

Compound (I-h) can be produced by reacting compound (XVI-a) and compound (XVII) in a solvent with or without an activator, in the presence of a condensation agent, in the presence of a base.

Examples of the condensation agent include 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC hydrochloride), and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU). Examples of the activator include 1-hydroxybenzotriazole monohydrate (HOBt monohydrate), 1-hydroxy-7-azabenzotriazole (HOAt). Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone and the like; or a mixed solvent thereof.

The amount of compound (XVII) to be used in this reaction is 0.9-5.0 mol, preferably 1.2-3.0 mol, per 1 mol of compound (XVI-a). The amount of the condensation agent to be used is 0.9-5.0 mol, preferably 1.2-3.0 mol, per 1 mol of compound (XVI-a). The amount of the base to be used is 0.9-5.0 mol, preferably 1.2-3.0 mol, per 1 mol of compound (XVI-a). The amount of the activator to be used is 0.9-5.0 mol, preferably 1.2-3.0 mol, per 1 mol of compound (XVI-a). This reaction can be performed at 0° C.-80° C., preferably 10-40° C.

Alternatively, compound (I-h) can be produced the aforementioned compound (XIII) according to a method describe below.

Compound (XIII) and a compound represented by the formula (XV-b):

wherein E 3 is a carboxylic acid-protecting group, and other symbols are as defined above, are reacted to give a compound represented by the formula (XVI-b):

wherein the symbols are as defined above. E 3 of the compound (XVI-b) is removed to give compound (XVI-a). This is reacted with the aforementioned compound (XVII) to give compound (I-h).

Examples of the protecting group for E 3 include optionally substituted alkyl (tert-butyl etc.).

Compound (XVI-b) can be produced by reacting the aforementioned compound (XIII) and compound (XV-b), which is similar to the method of producing compound (I-g) from compound (XIII) and compound (XIV).

Compound (XVI-a) can be produced by a conventional method such as acid treatment, base treatment and the like according to the kind of E 3 of compound (XVI-b).

For example, compound (XVI-b) wherein E 3 is tert-butyl can be deprotected in a solvent in the presence of an acid.

Examples of the acid include trifluoroacetic acid, formic acid, hydrogen chloride. The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform and 1,2-dichloroethane and the like. This reaction can be performed at 0° C.-100° C.

Compound (I-h) can be produced by reacting compound (XVI-a) and compound (XVII) in a solvent with or without an activator, in the presence of a condensation agent, in the presence of a base, as mentioned above.

Of compound (I), a compound represented by the formula (I-i):

wherein E 4 is an oxygen atom, or NH, and other symbols are as defined above, can be produced from the aforementioned compound (XIII) according to a method describe below.

Compound (XIII) and a compound represented by the formula (XVIII):

wherein the symbols are as defined above, are reacted to give a compound represented by the formula (XIX):

wherein the symbols are as defined above. The compound (XIX) is oxidized by a conventional method, whereby compound (I-i) can be produced.

Compound (XIX) can be produced by reacting compound (XIII) and compound (XVIII), which is similar to the method of producing the aforementioned compound (I-g) from compound (XIII) and compound (XIV)

Compound (I-i) can be produced by reacting, for example, compound (XIX) in a solvent (e.g., methylene chloride), in the presence of dimethyl sulfoxide, in the presence of oxalyl chloride, in the presence of a base (e.g., triethylamine).

Of compound (I), a compound represented by the formula (I-j):

wherein the symbols are as defined above, can be produced by removing E 5 of a compound represented by the formula (XX):

wherein E 5 is a hydroxy-protecting group, and other symbols are as defined above, by a conventional method such as acid treatment, base treatment and the like according to the kind thereof.

Examples of the protecting group for E 5 include optionally substituted alkyl (p-methoxybenzyl etc.).

For example, compound (XX) wherein E 5 is p-methoxybenzyl can be deprotected in a solvent (e.g., methylene chloride) or without solvent, with or without water and with or without trialkylsilane (e.g., triethylsilane), in the presence of an acid (e.g., trifluoroacetic acid). This reaction can be performed at 0° C.-100° C.

Of compound (I), a compound represented by the formula (I-k)

wherein the symbols are as defined above, can be produced by reacting a compound represented by the formula (XXI):

wherein the symbols are as defined above, in a solvent in the presence of trimethylsilyl trifluoromethanesulfonate, and a base.

›DESCRIPTION OF EMBODIMENTS · 22 of 25

Of compound (I), a compound represented by the formula (I-m):

wherein R 2z is optionally substituted alkenyl, or optionally substituted cycloalkyl, and other symbols are as defined above, can be produced by reacting a compound represented by the formula (XXII):

wherein E 6 is a halogen atom, and other symbols are as defined above, with a compound represented by the formula (XXIII): R 2z -E 7 (XXIII)

wherein E 7 is trialkylstannyl or dihydroxyboryl, and other symbols are as defined above, to give a compound represented by the formula (XXIV):

wherein the symbols are as defined above, and E 3 of compound (XXIV) is removed to give a compound represented by the formula (XXV):

wherein the symbols are as defined above. This is reacted with the aforementioned compound (XVII), whereby compound (I-m) can be produced.

Compound (XXIV) can be produced by reacting compound (XXII) and compound (XXIII) in a solvent in the presence of palladiums, in the presence or absence of a ligand, in the presence or absence of a base.

Examples of the palladiums include tris(dibenzylideneacetone)dipalladium (0), tetrakis(triphenylphosphine)palladium (0), palladium (II) acetate, palladium (II) chloride, bis(triphenylphosphine)dichloropalladium (II), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium (II), dichlorobis(tricyclohexylphosphine)palladium (II). Examples of the ligand include phosphine ligand such as triphenylphosphine, 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-dicyclohexyl-phosphino-2′,6′-dimethoxybiphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl and the like. Examples of the base include alkali metal carbonate such as sodium carbonate, potassium carbonate, cesium carbonate and the like; alkali metal phosphate such as trisodium phosphate, disodium hydrogen phosphate and tripotassium phosphate and the like; alkali metal fluoride such as potassium fluoride, cesium fluoride and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane and the like; alcohol such as tert-butanol and the like; aromatic hydrocarbon such as toluene, xylene and the like; amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like; water, or a mixed solvent thereof.

The amount of compound (XXIII) to be used in this reaction is 0.9-10 mol, preferably 1.2-3.0 mol, per 1 mol of compound (XXII). The amount of the palladiums to be used is 0.001-1.0 mol, preferably 0.01-0.3 mol, per 1 mol of compound (XXII). The amount of the ligand to be used is 0.001-3.0 mol, preferably 0.01-1.0 mol, per 1 mol of compound (XXII). The amount of the base to be used is 0.9-10 mol, preferably 1.0-3.0 mol, per 1 mol of compound (XXII). This reaction can be performed at 50-180° C., preferably 60-150° C.

Compound (XXV) can be produced by treating compound (XXIV) by a conventional method, which is similar to the removal of E 3 from the aforementioned compound (XVI-b).

Compound (I-m) can be produced by reacting compound (XXV) and compound (XVII) in a solvent in the presence of a condensation agent, in the presence of a base, in the presence or absence of an activator, which is similar to the reaction of the aforementioned compound (XVI-a) and compound (XVII).

Compound (I) produced by the above-mentioned production method may be subjected to interconversion of substituents by a conventional method. As a method of interconversion of substituents, the following methods 1-28 can be specifically mentioned.

These methods can also be applied to an intermediate compound obtained during production of compound (I).

Method 1:

Compound (I) having optionally substituted amino as a substituent, an optionally substituted nitrogen-containing nonaromatic heterocyclic group wherein a bond of the group is a nitrogen atom, or optionally substituted nitrogen-containing heteroaryl wherein a bond of the group is a nitrogen atom can be produced by, for example, reacting corresponding compound (I) having a halogen atom (particularly, chlorine atom) as a substituent, in a solvent (e.g., alkylnitrile such as acetonitrile and the like), in the presence of a base (e.g., alkali metal carbonate such as potassium carbonate and the like), with corresponding optionally substituted amine, optionally substituted nitrogen-containing nonaromatic heterocyclic group, or optionally substituted nitrogen-containing heteroarene to perform amination.

Method 2:

Compound (I) wherein X 2 is a nitrogen atom and R 1 is optionally substituted alkyl can be produced by reacting, for example, corresponding compound (I) wherein X 2 is a nitrogen atom and R 1 is a hydrogen atom with corresponding alkyl iodide in a solvent (e.g., alkylnitrile such as acetonitrile and the like), in the presence of a base (e.g., alkali metal carbonate such as potassium carbonate and the like).

Method 3:

Compound (I) wherein X 2 is a nitrogen atom and R 1 is optionally substituted alkyl can be produced by reacting compound (I) wherein X 2 is a nitrogen atom and R 1 is a hydrogen atom in a solvent in the presence of corresponding optionally substituted alkyl halide, in the presence of a base.

Examples of the base include alkali metal carbonate such as potassium carbonate and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like.

The amount of alkyl halide to be used in this reaction is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (I). The amount of the base to be used is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (I). This reaction can be performed at 0-120° C., preferably 15-80° C.

›DESCRIPTION OF EMBODIMENTS · 23 of 25

Method 4:

Compound (I) wherein X 2 is a nitrogen atom and R 1 is a hydrogen atom can be produced by reacting compound (I) wherein X 2 is a nitrogen atom and R 1 is alkoxyphenylmethyl in a solvent in the presence of an acid, in the presence or absence of a hydrogenating agent.

Examples of the acid include trifluoroacetic acid. Examples of the hydrogenating agent include trialkylsilane such as triethylsilane and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include a solvent amount of the above-mentioned acid, a solvent amount of the above-mentioned trialkylsilane, water, or a mixed solvent thereof.

Method 5:

Compound (I) wherein R 1 is a hydrogen atom can be produced by reacting, for example, corresponding compound (I) wherein R 1 is 2,4-dimethoxybenzyl in a solvent in the presence or absence of trialkylsilane, in the presence or absence of iodotrialkylsilane.

Examples of trialkylsilane include triethylsilane. Examples of iodotrialkylsilane include trimethylsilyl iodide. The solvent may be any as long as it does not influence the reaction, and examples thereof include alkylnitrile such as acetonitrile, propionitrile and the like; halogenohydrocarbon to such as methylene chloride, chloroform, 1,2-dichloroethane and the like; trifluoroacetic acid; water; and a mixed solvent thereof.

Method 6:

Compound (I) wherein R 1 or R 3 is a halogen atom can be produced by reacting compound (I) wherein R 1 or R 3 is a hydrogen atom in a solvent in the presence of a halogenating agent.

Examples of the halogenating agent include corresponding N-halogenosuccinimide. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,2-dimethoxyethane and the like, amide such as N,N-dimethylformamide, N-methylpyrrolidone and the like.

Method 7:

Compound (I) wherein R 2 is pyrazolyl can be produced by reacting compound (I) wherein R 2 is hydrazino in a solvent (e.g., alkyl alcohol such as ethanol and the like, water, or a mixed solvent thereof) in the presence of 1,1,3,3-tetramethoxypropane, in the presence of an acid (e.g., inorganic acid such as hydrogen chloride and the like).

Method 8:

Compound (I) wherein R 2 is optionally substituted cyclopropane can be produced by reacting compound (I) wherein R 2 is corresponding optionally substituted alkenyl in a solvent (e.g., aromatic hydrocarbon such as toluene and the like), in the presence of methylene iodide, in the presence of diethyl zinc.

Method 9:

Method 10:

Compound (I) wherein R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, an optionally substituted nitrogen-containing non-aromatic heterocycle can be produced from compound (I) wherein R 1 is (tert-butoxycarbonylamino)alkyl further optionally having substituent(s) and R 2 is hydroxyalkyl further optionally having substituent(s), according to a method describe below. Compound (I) wherein R 1 is (tert-butoxycarbonylamino)alkyl further optionally having substituent(s) and R 2 is hydroxyalkyl further optionally having substituent(s) is reacted in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like), in the presence of methanesulfonyl chloride in the presence of a base (e.g., trialkylamine such as triethylamine and the like) to give a compound wherein corresponding R 2 is methanesulfonyloxyalkyl further optionally having substituent(s). This is reacted in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like, an acid in a solvent amount or less, or a mixed solvent thereof) in the presence of an acid (e.g., trifluoroacetic acid), whereby compound (I) wherein R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, an optionally substituted nitrogen-containing non-aromatic heterocycle can be produced.

Method 11:

Compound (I) wherein R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, an optionally substituted nitrogen-containing non-aromatic heterocycle can be produced by reacting compound (I) wherein X 2 is a nitrogen atom and R 1 is a hydrogen atom and R 2 is (hydroxyalkyl)amino further optionally having substituent(s) in the presence of a solvent amount of concentrated sulfuric acid.

Method 12:

Compound (I) wherein R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, an optionally substituted nitrogen-containing non-aromatic heterocycle can be produced by reacting compound (I) wherein X 2 is a nitrogen atom and R 1 is a hydrogen atom and R 2 is (gem-dialkoxyalkyl)amino further optionally having substituent(s) in the presence of a solvent amount of concentrated sulfuric acid.

Method 13:

Compound (I) wherein R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom and carbon atom, an optionally substituted nitrogen-containing non-aromatic heterocycle can be produced by reacting compound (I) wherein X 2 is a nitrogen atom and R 1 is a hydrogen atom and R 2 is hydroxyalkyl further optionally having substituent(s) in a solvent (e.g., amide such as N,N-dimethylformamide and the like) in the presence of methyl triphenoxyphosphonium iodide in the presence of a base (e.g., trialkylamine such as triethylamine and the like).

Method 14:

Compound (I) having hydroxy as a substituent can be produced by hydrolysis of compound (I) having alkanoyloxy as a substituent by a conventional method.

›DESCRIPTION OF EMBODIMENTS · 24 of 25

The hydrolysis can be performed by reacting compound (I) having alkanoyloxy as a substituent in a solvent (e.g., tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water, or these used in combination), in the presence of a base (e.g., alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; alkali metal alkoxide such as sodium methoxide, sodium ethoxide and the like).

Method 15:

Compound (I) having hydroxy as a substituent can be produced by reacting compound (I) having alkoxycarbonyl as a substituent in a solvent (e.g., ether such as tetrahydrofuran and the like) in the presence of a reducing agent (e.g., lithium aluminum hydride).

Method 16:

Compound (I) having hydroxy as a substituent can be produced by reacting compound (I) having methoxy as a substituent in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like) in the presence of boron tribromide.

Method 17:

Compound (I) having hydroxy as a substituent can be produced by reacting compound (I) having halogen (e.g., fluorine atom) as a substituent in a solvent (e.g., alkylnitrile such as acetonitrile and the like, water, or a mixed solvent thereof), in the presence of a base (e.g., alkali metal carbonate such as sodium hydrogen carbonate and the like)

Method 18:

Compound (I) having oxo as a substituent can be produced by reacting compound (I) having hydroxy as a substituent in a solvent (e.g., halogenohydrocarbon such as chloroform and the like), in the presence of an oxidant (e.g., manganese dioxide).

Method 19:

Compound (I) having optionally substituted alkoxy as a substituent can be produced by reacting compound (I) having hydroxy as a substituent in a solvent (e.g., amide such as N,N-dimethylformamide and the like), in the presence of the corresponding optionally substituted alkyl halide (e.g., alkyl iodide), in the presence of a base (e.g., alkali metal hydride such as sodium hydride and the like).

Method 20:

Compound (I) having optionally substituted alkoxy as a substituent can be produced by reacting compound (I) having halogen atom (e.g., fluorine atom) as a substituent in the presence of a solvent amount of the corresponding optionally substituted alkylalcohol, in the presence of a base (e.g., alkali metal carbonate such as potassium carbonate and the like).

Method 21:

Compound (I) having optionally substituted amino as a substituent can be produced by reacting compound (I) having halogen atom (e.g., chlorine atom) as a substituent in a solvent (e.g., alkylnitrile such as acetonitrile and the like) in the presence of the corresponding optionally substituted amine, in the presence of a base (e.g., alkali metal carbonate such as potassium carbonate and the like) in the presence of an additive (e.g., alkali metal iodide such as potassium iodide and the like).

Method 22:

Compound (I) having optionally substituted amino as a substituent can be produced from compound (I) having hydroxy as a substituent according to a method describe below. Compound (I) having hydroxy as a substituent is reacted in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like), in the presence of methanesulfonyl chloride, in the presence of a base (e.g., trialkylamine such as triethylamine and the like) to give a compound having methanesulfonyloxy as the corresponding substituent. This is reacted in a solvent (e.g., alkylnitrile such as acetonitrile and the like), in the presence of an excess amount of the corresponding optionally substituted amine in the presence or absence of an additive (e.g., alkali metal iodide such as sodium iodide and the like), whereby compound (I) having optionally substituted amino as a substituent can be produced.

Method 23:

Compound (I) having carbobenzoxyamino as a substituent can be produced from compound (I) having hydroxy as a substituent, according to a method describe below. Compound (I) having hydroxy as a substituent is reacted in a solvent (e.g., ether such as tetrahydrofuran and the like, aromatic hydrocarbon such as toluene and the like, or a mixed solvent thereof) in the presence of diphenylphosphoryl azide, in the presence of triarylphosphine such as triphenylphosphine and the like, in the presence of dialkyl azodicarboxylate such as diethyl azodicarboxylate and the like to give a compound having an azide group as the corresponding substituent. This is reacted in a solvent (e.g., alkylalcohol such as methanol and the like), in the presence of tin(II) chloride to give a compound having amino as a substituent. This is reacted in a solvent (e.g., dialkylketone such as acetone and the like, water, or a mixed solvent thereof) in the presence of N-(carbobenzoxy)succinimide in the presence of a base (e.g., alkali metal carbonate such as sodium hydrogen carbonate and the like), whereby compound (I) having carbobenzoxyamino as a substituent can be produced.

Method 24:

Compound (I) having optionally substituted alkylamino can be produced by reacting compound (I) having NH in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like) in the presence of the corresponding compound having is carbonyl in the presence of a reducing agent (e.g., boron hydride compound such as sodium triacetoxyborohydride and the like).

Method 25:

Compound (I) having NH can be produced by reacting compound (I) having tert-butoxycarbonylamino in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like, acid in a solvent amount or less, or a mixed solvent thereof), in the presence of an acid (e.g., trifluoroacetic acid).

Method 26:

Compound (I) having NH can be produced by reacting compound (I) having carbobenzoxyamino in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like), in the presence of iodotrialkylsilane such as trimethylsilyl iodide and the like.

Method 27:

Compound (I) having an optionally substituted nitrogen-containing nonaromatic heterocyclic group as a substituent can be produced by reacting compound (I) having a halogen atom (e.g., chlorine atom) as a substituent in a solvent (e.g., alkylnitrile such as acetonitrile and the like), in the presence of the corresponding optionally substituted nitrogen-containing non-aromatic heterocyclic compound, in the presence of a base (e.g., alkali metal carbonate such as potassium carbonate and the like) in the presence or absence of an additive (e.g., alkali metal iodide such as potassium iodide and the like).

›DESCRIPTION OF EMBODIMENTS · 25 of 25

Method 28:

Compound (I) having phthalimidoyl as a substituent can be produced by reacting compound (I) having hydroxy as a substituent in a solvent (e.g., ether such as tetrahydrofuran and the like, aromatic hydrocarbon such as toluene and the like, or a mixed solvent thereof) in the presence of phthalimide, in the presence of triarylphosphine such as triphenylphosphine and the like, in the presence of dialkyl azodicarboxylate such as diisopropyl azodicarboxylate and the like.

[Production of Intermediate Compound]

Of the aforementioned compound (VII) of the present invention, a compound represented by the formula (VII-a):

wherein the symbols are as defined above, can be produced, for example, by the method shown in the following scheme 1.

in the scheme, G 8 is alkyl, and other symbols are as defined above.

Compound (1-1) and compound (1-2) are reacted to give compound (1-3). This is cyclized to give compound (1-4) or a salt thereof. This is converted to give compound (1-5). This is reacted with compound (1-6) to give compound (VII-a).

›Step 1-1

Compound (1-3) can be produced by reacting compound (1-1) and compound (1-2) in a solvent in the presence of a condensation agent, in the presence of a base.

Examples of the condensation agent include chloroformic acid alkyl ester such as methyl chloroformate, ethyl chloroformate, propyl chloroformate, isopropyl chloroformate, butyl chloroformate, isobutyl chloroformate and the like. Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like.

The amount of compound (1-2) to be used in this reaction is 0.5-2.0 mol, preferably 0.9-1.0 mol, per 1 mol of compound (1-1). The amount of the condensation agent to be used is 0.8-3.0 mol, preferably 1.0-1.1 mol, per 1 mol of compound (1-1). The amount of the base to be used is 1.5-5.0 mol, preferably 2.0-2.5 mol, per 1 mol of compound (1-1). This reaction can be performed at −20-60° C., preferably 0-30° C.

›Step 1-2

Compound (1-4) or a salt thereof can be produced by reacting compound (1-3), in a solvent in the presence of a sulfating agent, in the presence of a base and, when desired, converting the resultant product to a salt thereof.

Examples of the sulfating agent include Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide). Examples of the base include amine such as triethylamine, N,N-diisopropylethylamine, pyridine and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include aromatic hydrocarbon such as toluene, xylene and the like; ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like.

The amount of the sulfating agent to be used in this reaction is 0.4-2.0 mol, preferably 0.5-0.7 mol, per 1 mol of compound (1-3). The amount of the base to be used is 1.0-20 mol, preferably 2.0-7.0 mol, per 1 mol of compound (1-3). This reaction can be performed at 50-180° C., preferably 80-130° C.

›Step 1-3

Compound (1-5) can be produced by hydrolysis of compound (1-4) by a conventional method.

The hydrolysis can be performed by, for example, treating compound (1-4) with a base in a solvent.

Examples of the base include alkali metal hydroxide such as sodium hydroxide, potassium hydroxide and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include alkylalcohol such as methanol, ethanol, isopropylalcohol and the like; water; or a mixed solvent thereof.

The amount of the base to be used in this reaction is 1.0-10 mol, preferably 2.0-5.0 mol, per 1 mol of compound (1-4). This reaction can be performed at 20-100° C., preferably 60-90° C.

›Step 1-4

Compound (VII-a) can be produced by reacting compound (1-5) and compound (1-6) or a salt thereof in a solvent in the presence of a condensation agent, in the presence or absence of an activator, in the presence or absence of a base.

Examples of the condensation agent include carbodiimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC hydrochloride) and the like, uronium salt such as O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and the like. Examples of the activator include 1-hydroxybenzotriazole monohydrate (HOBt monohydrate). The solvent may be any as long as it does not influence the reaction, and examples thereof include amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like.

The amount of compound (1-6) to be used in this reaction is 0.5-10 mol, preferably 1.0-5.0 mol, per 1 mol of compound (1-5). The amount of the condensation agent to be used is 1.0-10 mol, preferably 1.2-5.0 mol, per 1 mol of compound (1-5). The amount of the activator to be used is 1.0-10 mol, preferably 1.2-5.0 mol, per 1 mol of compound (XVII). The amount of the base to be used is 1.0-20 mol, preferably 1.2-10 mol, per 1 mol of compound (1-5). This reaction can be performed at 0-50° C., preferably 10-300° C.

Of the aforementioned compound (VI) of the present invention, a compound represented by the formula (VI-a):

wherein the symbols are as defined above, can be produced, for example, by the method shown in the following scheme 2.

[in the scheme, the symbols are as defined above.]

Compound (VI-a) can be produced by reacting compound (VII-a) and compound (2-1) or a reactive derivative thereof.

›Step 2-1

Compound (VI-a) can be produced by treating compound (VII-a) and compound (2-1) as in the aforementioned Scheme 1, step 1-4.

Alternatively, compound (VI-a) can be produced by reacting compound (VII-a) and a reactive derivative of the above-mentioned compound (2-1) in a solvent in the presence of a base.

The amount of the reactive derivative of compound (2-1) to be used in this reaction is 1.0-5.0 mol, preferably 1.1-3.0 mol, per 1 mol of compound (VII-a). The amount of the base to be used is 1.0-10 mol, preferably 1.1-5.0 mol, per 1 mol of compound (VII-a). This reaction can be performed at 0-50° C., preferably 10-30° C.

The reactive derivative of compound (2-1) to be used can be a commercially available reactive derivative.

Alternatively, the reactive derivative of compound (2-1) can be produced by reacting compound (2-1) or a salt thereof, in a solvent or without solvent, in the presence of a halogenating agent, in the presence or absence of an activator.

Examples of the halogenating agent include oxalyl chloride, thionyl chloride. Examples of the activator include N,N-dimethylformamide. The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like; alkylnitrile such as acetonitrile, propionitrile and the like.

The amount of the halogenating agent to be used in this reaction is 0.5-2.0 mol, preferably 0.8-1.2 mol, per 1 mol of compound (2-1) or a salt thereof. The amount of the activator to be used is a catalytic amount of 1 mol of compound (2-1) or a salt thereof. This reaction can be performed at 0-100° C., preferably 10-30° C.

Of the aforementioned compound (IX) of the present invention, a compound represented by the formula (IX-a):

wherein G 6a is alkylsulfinyl or alkylsulfonyl, and other symbols are as defined above, can be produced, for example, by the method shown in the following Scheme 3.

[in the scheme, G 6a is alkylsulfinyl or alkylsulfonyl, G 9 is alkyl, G 10 is alkali metal, G 11 is alkyl, G 12 is a leaving group, and other symbols are as defined above.]

Compound (VII) and compound (3-1) are reacted to give compound (3-2). This is reacted with compound (3-3) to give compound (3-4). The compound (3-4) is oxidized, whereby compound (IX-a) can be produced.

›Step 3-1

Compound (3-2) can be produced by reacting compound (VII) and compound (3-1) in a solvent.

The alkali metal for G 10 is preferably sodium or potassium, and potassium is particularly preferable. The solvent may be any as long as it does not influence the reaction, and examples thereof include alkylalcohol such as methanol, ethanol, isopropylalcohol and the like. The amount of compound (3-1) to be used in this reaction is 1.0-10 mol, preferably 2.0-5.0 mol, per 1 mol of compound (VII). This reaction can be performed at 40-150° C., preferably 60-100° C.

›Step 3-2

Compound (3-4) can be produced by reacting compound (3-2) and compound (3-3) in a solvent in the presence of a base.

The alkyl for G 11 is preferably C 1 -C 6 alkyl, and particularly preferably methyl. Examples of the leaving group for G 12 include halogen atom (particularly, iodine atom). Examples of the base include alkali metal carbonate such as potassium carbonate, cesium carbonate, sodium carbonate and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like.

The amount of compound (3-3) to be used in this reaction is 1.0-5.0 mol, preferably 1.2-1.8 mol, per 1 mol of compound (3-2). The amount of the base to be used is 1.0-5.0 mol, preferably 1.2-1.8 mol, per 1 mol of compound (3-2). This reaction can be performed at 0-50° C., preferably 10-40° C.

›Step 3-3

Compound (IX-a) can be produced by treating compound (3-4) with an oxidant in a solvent.

Examples of the oxidant include methachloroperbenzoic acid (mCPBA). The solvent may be any as long as it does not influence the reaction, and examples thereof include halogenohydrocarbon such as methylene chloride, chloroform, 1,2-dichloroethane and the like.

When compound (IX-a) wherein G 6a is alkylsulfinyl is produced in this reaction, the amount of the oxidant to be used is 0.9-1.5 mol, preferably 1.0-1.2 mol, per 1 mol of compound (3-4). When compound (IX-a) wherein G 6a is alkylsulfonyl is produced in this reaction, the amount of the oxidant to be used is 2.0-5.0 mol, preferably 2.4-3.5 mol, per 1 mol of compound (3-4). This reaction can be performed at −20 to 30° C., preferably −10 to 10° C.

The aforementioned compound (II) of the present invention can be produced from compound (I-z) having carbobenzoxy by, for example, a method shown in the following Scheme 4.

[in the scheme, the symbols are as defined above.]

Compound (II) can be produced by de-carbobenzoxylation of compound (I-z) by a conventional method.

Compound (II) can be produced by, for example, treating compound (I-z) with iodosilane in a solvent in the presence or absence of a silane compound.

Examples of iodosilane include iodotrialkylsilane such as trimethylsilyl iodide and the like. Examples of the silane compound include trialkylsilane such as triethylsilane and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include alkylnitrile such as acetonitrile, propionitrile and the like.

The amount of iodosilane to be used in this reaction is 1.0-10 mol, preferably 1.5-5.0 mol, per 1 mol of compound (I-z). The amount of the silane compound to be used is 1.0-20 mol, preferably 3.0-10 mol, per 1 mol of compound (I-z). This reaction can be performed at 0-50° C., preferably 10-30° C.

Compound (II) can be produced by treating compound (I-z) with palladium hydroxide carbon under a hydrogen atmosphere, in a solvent (e.g., methanol).

Alternatively, compound (II) can be produced by treating compound (I-z) with an acid (e.g., hydrogen bromide-acetic acid solution, sulfuric acid-acetic acid solution) in a solvent (e.g., methylene chloride, acetic acid, or a mixed solvent thereof).

Of the aforementioned compound (II) of the present invention, a compound represented by the formula (II-a):

wherein the symbols are as defined above, can be produced by, for example, a method shown in the following Scheme 5-1 or 5-2.

[In the Scheme, G 13 is a hydroxy-protecting group, G 14 is a leaving group, G 15 is amino-protecting group, and other symbols are as defined above.]

Compound (5-1) and compound (5-2) are reacted to give compound (5-3). The compound (5-3) is subjected to cyclization reaction to give compound (5-4). This is deprotected to give compound (II-a).

As the hydroxy-protecting group for G 13 , conventionally-used hydroxy-protecting groups can be used and, for example, methyl, methoxybenzyl, dimethoxybenzyl can be mentioned. As the leaving group for G 14 , conventionally-used leaving groups can be used and, for example, a halogen atom (particularly, chlorine atom, bromine atom) can be mentioned. As the amino-protecting group for G 15 , conventionally-used amino-protecting groups can be used and, for example, carbobenzoxy, tert-butoxycarbonyl, nitrophenylsulfonyl can be mentioned.

›Step 5-1

In the same manner as in the aforementioned Scheme 2, step 2-1, compound (5-3) can be produced by converting compound (5-2) to a reactive derivative of compound (5-2), and reacting the reactive derivative with compound (5-1).

›Step 5-2

Compound (5-4) can be produced in the same manner as in the aforementioned Scheme 1, step 1-2 by reacting compound (5-3) in a solvent in the presence of a sulfating agent, in the presence of a base.

›Step 5-3

Compound (II-a) can be produced by removing the protecting groups G 13 and G 15 of compound (5-4) by a is conventional method, each according to the kind of the protecting group used.

When methyl, methoxybenzyl, or dimethoxybenzyl is used as the protecting group G 13 , for example, the protecting group can be removed by treating compound (5-4) with trialkylsilane (e.g., triethylsilane) and iodotrialkylsilane (e.g., trimethylsilyl iodide) in a solvent (e.g., alkylnitrile such as acetonitrile and the like).

When carbobenzoxy is used as the protecting group G 15 , for example, the protecting group can be removed by treating compound (5-4) with trialkylsilane (e.g., triethylsilane) and iodotrialkylsilane (e.g., trimethylsilyl iodide) in a solvent (e.g., alkylnitrile such as acetonitrile and the like).

When tert-butoxycarbonyl is used as the protecting group G 15 , for example, the protecting group can be removed by treating compound (5-4) with an acid (e.g., trifluoroacetic acid) in a solvent (e.g., halogenohydrocarbon such as methylene chloride and the like), or without solvent.

When nitrophenylsulfonyl is used as the protecting group G 15 , for example, the protecting group can be removed by treating compound (5-4) with arylthiol (e.g., methylbenzenethiol) in a solvent (e.g., alkylnitrile such as acetonitrile and the like), in the presence of a base (e.g., alkali metal carbonate such as cesium carbonate and the like)

[In the Scheme, G 14a is a halogen atom, and other symbols are as defined above.]

Compound (5-5) is reduced to give compound (5-6). This is converted to give compound (5-7). This is reacted with compound (5-2) to give compound (5-8). This is reacted with compound (5-9) to give compound (5-10). This is converted to give compound (5-11). This is reacted with compound (5-12) to give compound (5-13). The compound (5-13) is oxidized to give compound (5-14). This is reacted with compound (5-9) to give compound (5-4). This is deprotected to give compound (II-a)

›Step 5-4

Compound (5-6) can be produced by reacting compound (5-5) in a solvent (e.g., mixed solvent of alkylalcohol such as methanol and the like and halogenohydrocarbon chloroform and the like), in the presence of palladium carbon, under a hydrogen atmosphere.

The amount of palladium carbon to be used in this reaction is 0.001-1.0 mol, preferably 0.01-0.5 mol, per 1 mol of compound (5-5). This reaction can be performed at 0-80° C., preferably 20-60° C.

›Step 5-5

Compound (5-7) can be produced by treating compound (5-6) with a halogenating agent (e.g., N-halogenosuccinimide) corresponding to G 14a in a solvent (e.g., amide such as N,N-dimethylformamide and the like).

The amount of the halogenating agent to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (5-6). This reaction can be performed at −20-100° C., preferably 0-60° C.

›Step 5-6

In the same manner as in the aforementioned Scheme 2, step 2-1, compound (5-8) can be produced by converting compound (5-2) to a reactive derivative of compound (5-2), and reacting the reactive derivative with compound (5-7).

›Step 5-7

Compound (5-10) can be produced by reacting compound (5-8) and compound (5-9) in a solvent (e.g., ether such as tetrahydrofuran and the like) in the presence of azodicarboxylic acid ester (e.g., diisopropyl azodicarboxylate), in the presence of triarylphosphine (e.g., triphenylphosphine).

The amount of compound (5-9) to be used in this reaction is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (5-8). The amount of azodicarboxylic acid ester to be used is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (5-8). The amount of triarylphosphine to be used is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (5-8). This reaction can be performed at 0-120° C., preferably 15-80° C.

›Step 5-8

Compound (5-11) can be produced in the same manner as in Scheme 1, step 1-2, by reacting compound (5-10) in a solvent in the presence of a sulfating agent, in the presence of a base.

›Step 5-9

Compound (5-13) can be produced in the same manner as in Scheme 3, step 3-2, by reacting compound (5-11) and compound (5-12) in a solvent in the presence of a base.

›Step 5-10

Compound (5-14) can be produced in the same manner as in Scheme 3, step 3-3, by treating compound (5-13) with an oxidant in a solvent.

›Step 5-11

Compound (5-4) can be produced by reacting compound (5-14) and compound (5-9) in a solvent (e.g., amide such as N,N-dimethylformamide and the like), in the presence of a base (e.g., alkali metal hydride such as sodium hydride and the like).

The amount of compound (5-9) to be used in this reaction is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (5-14). The amount of the base to be used is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (5-14). This reaction can be performed at −40-80° C., preferably −20-40° C.

›Step 5-12

Compound (II-a) can be produced in the same manner as in Scheme 5-1, step 5-3, by removing the protecting group of compound (5-4) by a conventional method.

Of the aforementioned compound (II) of the present invention, a compound represented by the formula (II-b):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Schemes 6-1, 6-2.

[In the Scheme, the symbols are as defined above.]

Compound (6-1) and compound (6-2) are reacted to give compound (6-3). This is cyclized to give compound (6-4) or a salt thereof. This is converted to give compound (6-5). This is reacted with compound (6-6) to give compound (6-7). This is reacted with compound (6-8) or a reactive derivative thereof to give compound (6-9). This is cyclized to give compound (6-10). This is converted to give compound (II-b).

Alternatively, compound (6-7) and compound (6-11a) or compound (6-11b) are reacted to give compound (6-10). This is converted to give compound (II-b).

›Step 6-1

Compound (6-3) can be produced in the same manner as in Scheme 1, step 1-1, by reacting compound (6-1) and compound (6-2) in a solvent in the presence of a condensation agent, in the presence of a base.

›Step 6-2

Compound (6-4) or a salt thereof can be produced in the same manner as in Scheme 1, step 1-2, by reacting compound (6-3) in a solvent in the presence of a sulfating agent, in the presence of a base and, when desired, converting the resultant product to a salt thereof.

›Step 6-3

Compound (6-5) can be produced in the same manner as in Scheme 1, step 1-3, by hydrolysis of compound (6-4) or a salt thereof by a conventional method.

›Step 6-4

Compound (6-7) can be produced in the same manner as in Scheme 1, step 1-4, by reacting compound (6-5) and compound (6-6) or a salt thereof in a solvent in the presence of a condensation agent, in the presence or absence of an activator, in the presence or absence of a base.

›Step 6-5

Compound (6-9) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (6-7) and compound (6-8) or a reactive derivative thereof.

›Step 6-6

Compound (6-10) can be produced by reacting compound (6-9) in a solvent in the presence of a condensation agent, in the presence of a base, in the same manner as in the method of producing compound (I-d) from compound (VI).

›Step 6-7

Compound (II-b) can be produced in the same manner as in Scheme 5, step 5-3, by removing the protecting group G 15 of compound (6-10), by a conventional method according to the kind of the protecting group used.

›Step 6-8

Compound (6-10) can be produced by reacting compound (6-7) with compound (6-11a) or compound (6-11b), in the same manner as in the method of producing compound (I-d) from compound (VII) and compound (VIII-a) or compound (VIII-b).

Of the aforementioned compound (II) of the present invention, a compound represented by the formula (II-c):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 7.

[In the Scheme, G 16 is alkyl, and other symbols are as defined above.]

Compound (7-1) and compound (7-2) are reacted to give compound (7-3). This is cyclized to give compound (7-4). This is reacted with compound (7-5) to give compound (7-6). This is converted to give compound (II-c).

›Step 7-1

Compound (7-3) can be produced by reacting compound (7-1) and compound (7-2) in a solvent in the presence of a condensation agent, in the presence or absence of an activator, in the presence or absence of a base.

Examples of the condensation agent include carbodiimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC hydrochloride) and the like. Examples of the activator include 1-hydroxybenzotriazole monohydrate (HOBt monohydrate). The solvent may be any as long as it does not influence the reaction, and examples thereof include amide such as N,N-dimethylformamide, N,N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like.

The amount of compound (7-2) to be used in this reaction is 0.5-2.0 mol, preferably 0.8-1.5 mol, per 1 mol of compound (7-1). The amount of the condensation agent to be used is 1.0-2.0 mol, preferably 1.1-1.5 mol, per 1 mol of compound (7-1). The amount of the activator to be used is 1.0-2.0 mol, preferably 1.1-1.5 mol, per 1 mol of compound (7-1). The amount of the base to be used is 1.0-2.0 mol, preferably 1.1-1.5 mol, per 1 mol of compound (7-1). This reaction can be performed at 0-50° C., preferably 10-30° C.

›Step 7-2

Compound (7-4) can be produced by reacting compound (7-3) in a solvent in the presence of an acid.

Examples of the acid include alkylsulfonic acid such as methanesulfonic acid and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include aromatic hydrocarbon such as toluene, xylene and the like.

The amount of the acid to be used in this reaction is 1.0-5.0 mol, preferably 1.2-1.8 mol, per 1 mol of compound (7-3). This reaction can be performed at 50-180° C., preferably 80-150° C.

›Step 7-3

Compound (7-6) can be produced by reacting compound (7-4) and compound (7-5) without solvent in the presence of an acid.

Examples of the acid include sulfuric acid.

The amount of compound (7-5) to be used in this reaction is 0.9-5.0 mol, preferably 1.2-2.0 mol, per 1 mol of compound (7-4). The amount of the acid to be used is 10-200 mol, preferably 40-80 mol, per 1 mol of compound (7-4). This reaction can be performed at 30-120° C., preferably 60-1000° C.

›Step 7-4

Compound (II-c) can be produced in the same manner as in Scheme 5, step 5-3 by removing the protecting group G 15 of compound (7-6) by a conventional method according to the kind of the protecting group used.

Of the aforementioned compound (XI) of the present invention, a compound represented by the formula (XI-a):

wherein G 7a is a halogen atom, and other symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 8.

[In the Scheme, the symbols are as defined above.]

Compound (8-1) and compound (8-2) are reacted to give compound (8-3). This is reacted with compound (8-4) or a reactive derivative thereof to give compound (8-5). This is cyclized to give compound (XI-a).

›Step 8-1

Compound (8-3) can be produced in the same manner as in Scheme 1, step 1-4, by reacting compound (8-1) and compound (8-2) or a salt thereof in a solvent in the presence of a condensation agent, in the presence or absence of an activator, in the presence or absence of a base.

›Step 8-2

Compound (8-5) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (8-3) and compound (8-4) or a reactive derivative thereof.

›Step 8-3

Compound (XI-a) can be produced by reacting compound (8-5) in a solvent in the presence of a condensation agent, in the presence of a base, in the same manner as in the method of producing compound (I-d) from compound (VI).

The aforementioned compound (XII) in the present invention can be produced, for example, by a method shown in the following Scheme 9.

[In the Scheme, the symbols are as defined above.]

Compound (XII) can be produced by reacting compound (9-1) or a salt thereof with compound (9-2) or a reactive derivative thereof.

›Step 9-1

Compound (XII) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (9-1) or a salt thereof with compound (9-2) or a reactive derivative thereof.

Of the aforementioned compound (XII) of the present invention, a compound represented by the formula (XII-a):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 10.

[In the Scheme, the symbols are as defined above.]

›Step 10-1

Compound (XII-a) can be produced by reacting compound (10-1) with a carbonylating agent (e.g., triphosgene) in a solvent (e.g., toluene), in the presence of a base (e.g., pyridine) to give a reactive intermediate, and further reacting the reactive intermediate with compound (10-2) or a salt thereof in a solvent (e.g., methylene chloride), in the presence of a base (e.g., triethylamine).

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-a):

wherein E 1a is alkylsulfinyl, alkoxyphenylalkylsulfinyl, alkylsulfonyl, or alkoxyphenylalkylsulfonyl, and other symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 11.

[In the Scheme, L 1a is alkylsulfanyl, or alkoxyphenylalkylsulfanyl, L 2a is alkyl, and other symbols are as defined above.]

Compound (11-1) and compound (11-2) or a salt thereof are reacted to give compound (11-3). This is reacted with compound (11-4a) or a reactive derivative thereof to give compound (11-5). This is cyclized to give compound (11-6). This is oxidized to give compound (XIII-a).

Alternatively, compound (11-6) can be obtained by reacting compound (11-3) and compound (11-4b) or compound (11-4c).

›Step 11-1

Compound (11-3) can be produced in the same manner as in Scheme 1, step 1-4, by reacting compound (11-1) and compound (11-2) or a salt thereof in a solvent in the presence of a condensation agent, in the presence or absence of an activator, in the presence or absence of a base.

›Step 11-2

Compound (11-5) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (11-3) and compound Jo (11-4a) or a reactive derivative thereof.

›Step 11-3

Compound (11-6) can be produced by reacting compound (11-5) in a solvent in the presence of a condensation agent, in the presence of a base, in the same manner as in the method of producing compound (I-d) from compound (VI).

›Step 11-4

Compound (XIII-a) can be produced by treating compound (11-6) with an oxidant in a solvent.

When compound (XIII-a) wherein E 1a is alkylsulfinyl or alkoxyphenylalkylsulfinyl is produced by this reaction, the amount of the oxidant to be used is 0.9-1.5 mol, preferably 1.0-1.2 mol, per 1 mol of compound (11-6). When compound (XIII-a) wherein E 1a is alkylsulfonyl or alkoxyphenylalkylsulfonyl is produced by this reaction, the amount of the oxidant to be used is 2.0-5.0 mol, preferably 2.4-3.5 mol, per 1 mol of compound (11-6). This reaction can be performed at −20-30° C., preferably −10-30° C.

›Step 11-5

Compound (11-6) can be produced by reacting compound (11-3) with compound (11-4b) or compound (11-4c), in the same manner as in the method of producing compound (I-d) from compound (VII) and compound (VIII-a) or compound (VIII-b).

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-b):

wherein E 1b is a halogen atom, and other symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 12.

[In the Scheme, L 1b is a hydrogen atom or NH 2 , and other symbols are as defined above.]

Compound (12-1) and compound (12-2a) or a reactive derivative thereof are reacted to give compound (12-3). This is cyclized to give compound (12-4). Said L 1b is halogenated to give compound (XIII-b).

Alternatively, compound (12-4) can be obtained by reacting compound (12-1) and compound (12-2b) or compound (12-2c).

›Step 12-1

Compound (12-3) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (12-1) and compound (12-2a) or a reactive derivative thereof.

›Step 12-2

Compound (12-4) can be produced by reacting compound (12-3) in a solvent in the presence of a condensation agent, in the presence of a base, in the same manner as in the method of producing compound (I-d) from compound (VI).

›Step 12-3

Compound (XIII-b) can be produced by treating compound (12-4) wherein L 1b is a hydrogen atom with a halogenating agent in a solvent.

Examples of the halogenating agent include N-halogenosuccinimide corresponding to E 1b . The solvent may be any as long as it does not influence the reaction, and examples thereof include alkylnitrile such as acetonitrile, propionitrile and the like.

The amount of the halogenating agent to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (12-4). This reaction can be performed at 0-100° C., preferably 20-80° C.

Alternatively, compound (XIII-b) can be produced by reacting compound (12-4) wherein L 1b is NH 2 in a solvent (alkylnitrile such as acetonitrile and the like), in the presence of copper(I) halide corresponding to E 1b and nitrous acid alkyl ester (tert-butyl nitrite etc.).

The amount of copper(I) halide to be used in this reaction is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (12-4). The amount of nitrous acid alkyl ester to be used is 0.9-5.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (12-4). This reaction can be performed at 0-120° C., preferably 20-80° C.

›Step 12-4

Compound (12-4) can be produced by reacting compound (12-1) with compound (12-2b) or compound (12-2c), in the same manner as in the method of producing compound (I-d) from compound (VII) and compound (VIII-a) or compound (VIII-b).

Alternatively, compound (XIII-b) can be produced, for example, by a method shown in the following Scheme 13.

[In the Scheme, the symbols are as defined above.]

Compound (13-1) and compound (13-2) or a salt thereof are reacted to give compound (13-3). This is reacted with compound (13-4a) or a reactive derivative thereof to give compound (13-5). This is cyclized to give compound (XIII-b).

Alternatively, compound (13-3) can be obtained by halogenating L 1b of compound (13-6).

Compound (XIII-b) can be produced by reacting compound (13-3) and compound (13-4b) or compound (13-4c).

›Step 13-1

Compound (13-3) can be produced in the same manner as in Scheme 1, step 1-4, by reacting compound (13-1) and compound (13-2) or a salt thereof in a solvent in the presence of a condensation agent, in the presence or absence of an activator, in the presence or absence of a base.

›Step 13-2

Compound (13-5) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (13-3) and compound (13-4a) or a reactive derivative thereof.

›Step 13-3

Compound (XIII-b) can be produced by reacting compound (13-5) in a solvent in the presence of a condensation agent, in the presence of a base, in the same manner as in the method of producing compound (I-d) from compound (VI).

›Step 13-4

Compound (13-3) can be produced in the same manner as in Scheme 12, step 12-3, by halogenation corresponding to E 1b of compound (13-3) and L 1b of compound (13-6).

›Step 13-5

Compound (XIII-b) can be produced by reacting compound (13-3) with compound (13-4b) or compound (13-4c), in the same manner as in the method of producing compound (I-d) from compound (VII) and compound (VIII-a) or compound (VIII-b).

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-c):

wherein R 2x is optionally substituted amino, optionally substituted alkoxy, or an optionally substituted nitrogen-containing nonaromatic heterocyclic group wherein a bond of the ring is a nitrogen atom, and other symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 14.

[In the Scheme, L 4a is alkyl, and other symbols are as defined above.]

Compound (14-1) and compound (14-2) are reacted to give compound (14-3). This is converted to give compound (14-4) This is reacted with compound (14-5) to give compound (14-6). This is oxidized to give compound (XIII-c).

Alternatively, compound (14-4) is oxidized to give compound (14-7). This is reacted with compound (14-5) to give compound (XIII-c).

›Step 14-1

Compound (14-3) can be produced by reacting compound (14-1) and compound (14-2) in a solvent (e.g., alkylalcohol such as ethanol and the like), in the presence of a base (e.g., amine such as DBU and the like).

The amount of compound (14-2) to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (14-1). The amount of the base to be used is 1.0-5.0 mol, preferably 1.0-3.0 mol, per 1 mol of compound (14-1). This reaction can be performed at 0-100° C., preferably 20-80° C.

›Step 14-2

Compound (14-4) can be produced by reacting compound (14-3) in a solvent (e.g., a mixed solvent of halogenohydrocarbon such as 1,2-dichloroethane and the like and amide such as N,N-dimethylformamide and the like), in the presence of a chlorinating agent (e.g., oxalyl chloride, phosphorus oxychloride).

The amount of the chlorinating agent to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (14-3). This reaction can be performed at 0-100° C., preferably 20-80° C.

›Step 14-3

Compound (14-6) wherein R 2x is optionally substituted amino, or optionally substituted nitrogen-containing nonaromatic heterocyclic group wherein a bond of the ring is a nitrogen atom can be produced by reacting compound (14-4) with the corresponding compound (14-5), in a solvent (e.g., ether such as tetrahydrofuran and the like), in the presence of a base (e.g., trialkylamine such as N,N-diisopropylethylamine and the like).

The amount of compound (14-5) to be used in this reaction is 1.0-10 mol, preferably 1.2-3.0 mol, per 1 mol of compound (14-4). The amount of the base to be used is 1.2-10 mol, preferably 1.2-3.0 mol, per 1 mol of compound (14-4). This reaction can be performed at 0-100° C., preferably 20-60° C.

Compound (14-6) wherein R 2x is optionally substituted is alkoxy can be produced by reacting compound (14-4) with the corresponding compound (14-5), in a solvent (e.g., amide such as N,N-dimethylformamide and the like), in the presence of a base (e.g., alkali metal hydride such as sodium hydride and the like).

The amount of compound (14-5) to be used in this reaction is 0.9-5.0 mol, preferably 1.2-2.0 mol, per 1 mol of compound (14-4). The amount of the base to be used is 0.9-5.0 mol, preferably 1.2-2.0 mol, per 1 mol of compound (14-4). This reaction can be performed at 0-100° C., preferably 2-60° C.

›Step 14-4

Compound (XIII-c) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (14-6) with an oxidant.

›Step 14-5

Compound (14-7) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (14-4) with an oxidant.

›Step 14-6

Compound (XIII-c) can be produced by reacting compound (14-7) and compound (14-5) in the same manner as in step 14-3.

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-d):

wherein R 2y is optionally substituted aryl, and other symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 15.

[In the Scheme, L 2b and L 2c are each a hydrogen atom, or L 2b and L 2c are bonded to each other to form alkylene, and other symbols are as defined above.]

Compound (15-1) and compound (15-2) are reacted to give compound (15-3). This is oxidized to give compound (XIII-d).

›Step 15-1

Compound (15-3) can be produced by reacting compound (15-1) and compound (15-2) in a solvent in the presence of palladiums and a base, in the presence or absence of a ligand.

Examples of the palladiums include tris(dibenzylideneacetone)dipalladium (0), tetrakis(triphenylphosphine)palladium (0), palladium (II) acetate, palladium (II) chloride, bis(triphenylphosphine)dichloropalladium (II), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium (II), dichlorobis(tricyclohexylphosphine)palladium (II). Examples of the base include alkali metal carbonate such as sodium carbonate, potassium carbonate, cesium carbonate and the like; alkali metal phosphate such as trisodium phosphate, disodium hydrogen phosphate, tripotassium phosphate and the like; alkali metal fluoride such as potassium fluoride, cesium fluoride and the like. Examples of the ligand include phosphine ligand such as triphenylphosphine, 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-dicyclohexyl-phosphino-2′,6′-dimethoxybiphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include ether such as tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane and the like; alcohol such as tert-butanol and the like; aromatic hydrocarbon such as toluene, xylene and the like; water, or a mixed solvent thereof.

The amount of compound (15-2) to be used in this reaction is 0.9-5.0 mol, preferably 1.2-2.0 mol, per 1 mol of compound (15-1). The amount of the palladiums to be used is 0.001-1.0 mol, preferably 0.01-0.1 mol, per 1 mol of compound (15-1). The amount of the base to be used is 0.9-5.0 mol, preferably 1.0-3.0 mol, per 1 mol of compound (15-1). The amount of the ligand to be used is 0.001-1.0 mol, preferably 0.01-0.1 mol, per 1 mol of compound (15-1). This reaction can be performed at 20-150° C., preferably 50-100° C.

›Step 15-2

Compound (XIII-d) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (15-3) with an oxidant.

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-e):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 16.

[In the Scheme, L 1c is a halogen atom, L 2d is alkyl, L 4b is alkyl, L 4c is alkyl, L 5a is alkyl, L 6a is alkali metal, L 7a is alkyl or alkoxyphenylalkyl, L 8a is a leaving group, and other symbols are as defined above.]

Compound (16-1) and compound (16-2) are reacted, and then, compound (16-3) is reacted to give compound (16-4). This is reduced to give compound (16-5). This is halogenated to give compound (16-6). This is reacted with compound (16-7) to give compound (16-8). This is reacted with compound (16-9) to give compound (16-10). This is oxidized to give compound (XIII-e)

›Step 16-1

Compound (16-4) can be produced by reacting compound (16-1) and compound (16-2) without solvent and then reacting the resulting compound with compound (16-3) in a solvent (e.g., alkylalcohol such as ethanol and the like), in the presence of a base (e.g., trialkylamine such as triethylamine and the like).

The amount of compound (16-2) to be used in this reaction is 1.0-5.0 mol, preferably 1.2-3.0 mol, per 1 mol of compound (16-1). The amount of compound (16-3) to be used is 1.0-3.0 mol, preferably 1.2-2.0 mol, per 1 mol of compound (16-1). The amount of the base to be used is 1.0-5.0 mol, preferably 1.2-3.0 mol, per 1 mol of compound (16-1). This reaction can be performed at 20-150° C., preferably 40-100° C.

›Step 16-2

Compound (16-5) can be produced by reacting compound (16-4) in a solvent (e.g., a mixed solvent of alkylalcohol such as methanol and the like, and halogenohydrocarbon such as chloroform and the like), in the presence of palladium carbon, under a hydrogen atmosphere.

The amount of palladium carbon to be used in this reaction is 0.001-1.0 mol, preferably 0.01-0.5 mol, per 1 mol of compound (16-4). This reaction can be performed at 0-80° C., preferably 20-60° C.

›Step 16-3

Compound (16-6) can be produced by treating compound (16-5) with a halogenating agent (e.g., N-halogenosuccinimide) corresponding to L 1 c in a solvent (e.g., amide such as N,N-dimethylformamide and the like).

The amount of the halogenating agent to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (16-5). This reaction can be performed at −20-100° C., preferably 0-60° C.

›Step 16-4

Compound (16-8) can be produced by reacting compound (16-6) and compound (16-7) in a solvent (e.g., amide such as N,N-dimethylformamide and the like).

The amount of compound (16-7) to be used in this reaction is 1.0-3.0 mol, preferably 1.2-2.0 mol, per 1 mol of compound (16-6). This reaction can be performed at 80-200° C., preferably 100-150° C.

›Step 16-5

Compound (16-10) can be produced by reacting compound (16-8) with compound (16-9) having L 7a corresponding to L 1a in a solvent in the presence of a base.

Examples of the leaving group for L 8a include halogen atom. Examples of the base include alkali metal carbonate such as sodium hydrogen carbonate, sodium carbonate and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include amide such as N,N-dimethylformamide and the like.

The amount of alkylating agent or alkoxyphenylalkylating agent to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (16-8). The amount of the base to be used is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (16-8). This reaction can be performed at −20-60° C., preferably 0-30° C.

›Step 16-6

Compound (XIII-e) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (16-9) with an oxidant.

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-f):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 17.

[In the Scheme, L 4d is alkyl, and other symbols are as defined above.]

Compound (17-1) and compound (17-2) are reacted to give compound (17-3). This is reacted with compound (17-4) to give compound (17-5). This is hydrolyzed to give compound (17-6). This is reacted with compound (17-7) to give compound (17-8). This is halogenated to give compound (XIII-f).

›Step 17-1

Compound (17-3) can be produced by reacting compound (17-1) and compound (17-2) in a solvent in the presence of a base.

Examples of the base include alkali metal alkoxide corresponding to L 4d such as sodium alkoxide and the like. The solvent may be any as long as it does not influence the reaction, and examples thereof include alkylalcohol corresponding to L 4d .

The amount of compound (17-2) to be used in this reaction is 0.9-2.0 mol, preferably 1.1-1.6 mol, per 1 mol of compound (17-1). The amount of the base to be used is 0.9-2.0 mol, preferably 1.1-1.6 mol, per 1 mol of compound (17-1). This reaction can be performed at 0-120° C., preferably 20-80° C.

›Step 17-2

Compound (17-5) can be produced by reacting compound (17-3) and compound (17-4) in a solvent (e.g., halogenohydrocarbon such as carbon tetrachloride and the like, alkylalcohol corresponding to L 4d ), in the presence of sulfuryl chloride.

The amount of compound (17-4) to be used in this reaction is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (17-3). The amount of sulfuryl chloride to be used is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (17-3). This reaction can be performed at 0-80° C., preferably 20-60° C.

›Step 17-3

Compound (17-6) can be produced in the same manner as in Scheme 1, step 1-3, by hydrolysis by a conventional method.

›Step 17-4

Compound (17-8) can be produced by reacting compound (17-6) and compound (17-7) in a solvent (e.g., a mixed solvent of aromatic hydrocarbon such as toluene and the like and amide such as N-methylpyrrolidone and the like).

The amount of compound (17-7) to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (17-6). This reaction can be performed at 80-200° C., preferably 100-150° C.

›Step 17-5

Compound (XIII-f) can be produced in the same manner as in Scheme 12, step 12-3, by reacting compound (17-8) in a solvent in the presence of copper(I) halide corresponding to E 1b and nitrous acid alkyl ester.

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-g):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 18.

[In the Scheme, L 4f is alkyl, and other symbols are as defined above.]

Compound (18-1) and compound (18-2) are reacted to give compound (XIII-g).

›Step 18-1

Compound (XIII-g) can be produced by reacting compound (18-1) and compound (18-2) in the presence of polyphosphoric acid.

The amount of compound (18-2) to be used in this reaction is 0.9-3.0 mol, preferably 1.0-2.0 mol, per 1 mol of compound (18-1). This reaction can be performed at 60-200° C., preferably 80-120° C.

Of the aforementioned compound (XIII) of the present invention, a compound represented by the formula (XIII-h):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 19.

[In the Scheme, the symbols are as defined above.]

Compound (19-1) and compound (19-2) are reacted to give compound (19-3). This is oxidized to give compound (XIII-h).

›Step 19-1

Compound (19-3) can be produced by reacting compound (19-1) and compound (19-2) in a solvent (e.g., ether such as tetrahydrofuran and the like) and then reacting the resulting compound in the presence of phosphoric acid.

The amount of compound (19-2) to be used in this reaction is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (19-1). This reaction can be performed at 0-200° C., preferably 20-120° C.

›Step 19-2

Compound (XIII-h) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (19-3) with an oxidant.

Of the aforementioned compound (XIV) of the present invention, a compound represented by the formula (XIV-a):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 20.

[In the Scheme, L 5b is alkyloxycarbonyl or aralkyloxycarbonyl, and other symbols are as defined above.]

Compound (20-1) and compound (XVII) are reacted to give compound (20-2). L 5b therein is removed to give compound (XIV-a).

›Step 20-1

Compound (20-2) can be produced in the same manner as in Scheme 1, step 1-4, by reacting compound (20-1) and compound (XVII)

›Step 20-2

Compound (XIV-a) can be produced by removing L 5b of compound (20-2) by a conventional method such as acid treatment, hydrogenation and the like according to the kind of L 5b .

The aforementioned compound (XVIII) in the present invention can be produced, for example, by a method shown in the following Scheme 21.

[In the Scheme, L 5c is alkyloxycarbonyl or aralkyloxycarbonyl, and other symbols are as defined above.]

Compound (21-1) and compound (21-2) are reacted to give compound (21-3). This is reduced to give compound (21-4). L 5c therein is removed to give compound (XVIII).

›Step 21-1

Compound (21-3) can be produced by reacting compound (21-1) and compound (21-2) in a solvent (e.g., amide such as N,N-dimethylformamide and the like), in the presence of a base (e.g., alkali metal carbonate such as potassium carbonate and the like) in the presence of potassium iodide.

The amount of compound (21-2) to be used in this reaction is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (21-1). The amount of the base to be used is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (21-1). The amount of potassium iodide to be used is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (21-1). This reaction can be performed at 0-80° C., preferably 20-60° C.

›Step 21-2

Compound (21-4) can be produced by reacting compound (21-3) in a solvent (e.g., alkylalcohol such as methanol and the like), in the presence of a hydrogenating agent (e.g., boron hydride compound such as sodium borohydride and the like).

The amount of the hydrogenating agent to be used in this reaction is 0.9-2.0 mol, preferably 1.0-1.5 mol, per 1 mol of compound (21-3). This reaction can be performed at 20-150° C., preferably 50-100° C.

›Step 21-3

Compound (XVIII) can be produced by removing L 5C of compound (21-4) by a conventional method such as acid treatment, hydrogenation and the like according to the kind of L 5C .

Of the aforementioned compound (XX) of the present invention, a compound represented by the formula (XX-a):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 22.

[In the Scheme, L 8b is a leaving group, and other symbols are as defined above.]

Compound (22-1) is cyclized to give compound (22-2). This is reacted with compound (22-3) to give compound (22-4). This is oxidized to give compound (22-5). This is reacted with compound (XIV) to give compound (XX-a).

›Step 22-1

Compound (22-2) can be produced by reacting compound (22-1) in a solvent in the presence of a condensation agent, in the presence of a base, in the same manner as' in the method of producing compound (I-d) from compound (VI).

›Step 22-2

Compound (22-4) can be produced by reacting compound (22-2) and compound (22-3) by a conventional method according to the kind of E 5 .

Examples of the leaving group for L 8b include a halogen atom.

›Step 22-3

Compound (22-5) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (22-4) with an oxidant.

›Step 22-4

Compound (XX-a) can be produced by reacting compound (22-5) and compound (XIV) in the same manner as in the method of producing compound (I-g) from compound (XIII) and compound (XIV).

Of the aforementioned compound (XX) of the present invention, a compound represented by the formula (XX-b):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 23.

[In the Scheme, L 1d is a halogen atom, L 2e is alkyl, L 4h is alkyl, L 6b is alkali metal, and other symbols are as defined above.]

Compound (23-1) is halogenated to give compound (23-2) This is reacted with compound (23-3) to give compound (23-4). L 2e therein is removed to give compound (23-5). This is reacted with compound (23-6) to give compound (23-7). This is oxidized to give compound (23-8). This is reacted with compound (23-9) to give compound (23-10). This is reacted with compound (XIV) to give compound (XX-b).

›Step 23-1

Compound (23-2) can be produced in the same manner as in Scheme 12, step 12-3, by treating compound (23-1) with a halogenating agent in a solvent.

›Step 23-2

Compound (23-4) can be produced in the same manner as in Scheme 16, step 16-4, by reacting compound (23-2) and compound (23-3) in a solvent.

›Step 23-3

Compound (23-5) can be produced by deprotecting compound (23-4) by a conventional method according to the kind of L 2e .

›Step 23-4

Compound (23-7) can be produced in the same manner as in Scheme 16, step 16-5, by reacting compound (23-5) and compound (23-6).

›Step 23-5

Compound (23-8) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (23-7) with an oxidant.

›Step 23-6

Compound (23-10) can be produced by reacting compound (23-8) and compound (23-9) by a conventional method according to the kind of E 5 .

›Step 23-7

Compound (XX-b) can be produced by reacting compound (23-10) and compound (XIV) in the same manner as in the method of producing compound (I-g) from compound (XIII) and compound (XIV).

The aforementioned compound (XXI) in the present invention can be produced, for example, by a method shown in the following Scheme 24.

[In the Scheme, the symbols are as defined above.]

Compound (24-1) and compound (XIV) are reacted to give compound (24-2). This is reacted with compound (24-3) or a reactive derivative thereof to give compound (XXI).

›Step 24-1

Compound (24-2) can be produced by reacting compound (24-1) and compound (XIV) in the same manner as in the method of producing compound (I-g) from compound (XIII) and compound (XIV).

›Step 24-2

Compound (XXI) can be produced in the same manner as in Scheme 2, step 2-1, by reacting compound (24-2) and compound (24-3) or a reactive derivative thereof.

Of the aforementioned compound (XXII) of the present invention, a compound represented by the formula (XXII-a):

wherein the symbols are as defined above, can be produced, for example, by a method shown in the following Scheme 25.

[In the Scheme, L 8c is a leaving group, and other symbols are as defined above.]

Compound (25-1) and compound (25-2) are reacted to give compound (25-3). This is reacted with compound (25-4) to give compound (25-5). This is reacted with compound (25-6) to give compound (25-7). This is oxidized to give compound (25-8). This is reacted with compound (XV-b) to give compound (XXII-a).

›Step 25-1

Compound (25-3) can be produced in the same manner as in Scheme 16, step 16-4, by reacting compound (25-1) and compound (25-2) in a solvent.

›Step 25-2

Compound (25-5) can be produced in the same manner as in Scheme 16, step 16-5, by reacting compound (25-3) and compound (25-4).

›Step 25-3

Compound (25-7) can be produced by reacting compound (25-5) and compound (25-6) by a conventional method according to the kind of R 1 .

Examples of the leaving group for L 8c include a halogen atom.

›Step 25-4

Compound (25-8) can be produced in the same manner as in Scheme 11, step 11-4, by treating compound (25-7) with an oxidant.

›Step 25-5

Compound (XXII-a) can be produced by reacting compound (25-8) and compound (XV-b) in the same manner as in the method of producing compound (I-g) from compound (XIII) and compound (XIV).

Other starting compounds of the aforementioned production methods ([Production of compound (I)], and [Production of intermediate compound]) are commercially available, or can be easily produced by a method well known to those of ordinary skill in the art.

›EXAMPLES

The present invention is explained in more detail in the following by referring to Examples and the like, which are not to be construed as limitative. Note that % described in the following Examples and the like means wt % unless specifically indicated, and the solvent ratio in column chromatography means volume ratio.

›Examples611

›Example 1

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (50.0 mL) of the compound (1.68 g) obtained in Reference Example 10 in 1,2-dichloroethane were added chlorotrimethylsilane (2.30 mL) and triethylamine (7.50 mL), and the reaction mixture was stirred at room temperature for 3 hr. Water and 1.0 mol/L hydrochloric acid were added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (1.45 g).

MS (ESI) m/z; 453 [M+H] +

›Example 2

(R)-2-[6-methyl-5-(5-methyl-[1,2,4]oxadiazol-3-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (760 mg) obtained in Reference Example 11 was treated by a method similar to that in Example 1 to give the title compound (700 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 3

(R)-2-[6-methyl-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1800 mg) obtained in Reference Example 12 was treated by a method similar to that in Example 1 to give the title compound (1300 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 4

(R)-2-(5-chloromethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid benzyl ester

The compound (775 mg) obtained in Reference Example 13 was treated by a method similar to that in Example 1 to give the title compound (626 mg).

MS (ESI) m/z; 419 [M+H] +

›Example 5

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1960 mg) obtained in Reference Example 15 was treated by a method similar to that in Example 1 to give the title compound (1600 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 6

(R)-2-[7-oxo-6-(propan-2-yl)-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (60 mL) of the compound (2.45 g) obtained in Reference Example 8 in methylene chloride was added dropwise trifluoroacetic anhydride (6.7 g), and the reaction mixture was stirred at room temperature for 1 hr. Pyridine (2.50 g) was added dropwise, and the reaction mixture was stirred at room temperature overnight. Furthermore, 1,2-dichloroethane (10 mL), trifluoroacetic anhydride (13.4 g) and pyridine (5.00 g) were added dropwise, and the reaction mixture was heated under reflux for 4 hr. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in ethyl acetate, and the solution was washed with 1.0 mol/L hydrochloric acid, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=80/20-60/40) to give the title compound (2.46 g).

MS (ESI) m/z; 467 [M+H] +

›Example 7

(R)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid benzyl ester

A mixture of the compound (3.00 g) obtained in Reference Example 7, acetic anhydride (8.5 g) and trimethyl orthopropionate (11.2 g) was stirred with heating at 120° C. for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=100/0-60/40) to give the title compound (0.47 g).

MS (ESI) m/z; 399 [M+H] +

›Example 8

(R)-2-{6-methyl-5-[(morpholin-4-yl)methyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid benzyl ester

To a solution (3.0 mL) of the compound (259 mg) obtained in Example 4 in acetonitrile were added potassium carbonate (171 mg) and morpholine (80.6 mg), and the reaction mixture was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (285 mg).

MS (ESI) m/z; 470 [M+H] +

›Example 9

(R)-N-benzyl-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxamide

To a solution (9 mL) of the compound (300 mg) obtained in Reference Example 21, and N,N-diisopropylethylamine (0.24 mL) in methylene chloride was added dropwise benzyl isocyanate (0.15 mL) under ice-cooling. The reaction mixture was stirred at room temperature for 1 hr. 0.5 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=90/10-20/80) to give the title compound (483 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 10

(R)-N-(2-chlorobenzyl)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 21 was treated by a method similar to that in Example 9 to give the title compound (210 mg).

MS (ESI) m/z; 432 [M+H] +

›Example 11

(R)-N-(2-chlorobenzyl)-2-[7-oxo-6-(propan-2-yl)-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 20 was treated by a method similar to that in Example 9 to give the title compound (120 mg).

MS (ESI) m/z; 500 [M+H] +

›Example 12

(R)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(1-phenylcyclopropyl)pyrrolidine-1-carboxamide

To a solution (60 mL) of 1-phenylcyclopropylamine (2.00 g) in chloroform were added triethylamine (4.11 mL) and 4-methoxyphenyl chloroformate (1.92 mL), and the reaction mixture was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was washed with diethyl ether, filtered and dried to give (1-phenylcyclopropyl)-carbamic acid-4-methoxyphenyl ester (2.59 g) To a solution (6.0 mL) of the compound (80 mg) obtained in Reference Example 21 and DBU (0.32 mL) in acetonitrile was added (1-phenylcyclopropyl)-carbamic acid-4-methoxyphenyl ester (595 mg), and the reaction mixture was stirred with heating at 85° C. for 4 hr. 0.5 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (65 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 13

(R)-5-ethyl-2-{1-[((R)-indan-1-yl)aminocarbonyl]pyrrolidin-2-yl}-6-methyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (80 mg) obtained in Reference Example 21 was treated by a method similar to that in Example 12 to give the title compound (100 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 14

(R)-2-{1-[2-(3,4-dihydro-2H-quinolin-1-yl)acetyl]pyrrolidin-2-yl}-5-ethyl-6-methyl-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

To a solution (7.5 mL) of the compound (200 mg) obtained in Reference Example 21 and N,N-diisopropylethylamine (0.16 mL) in methylene chloride was added dropwise chloroacetyl chloride (65 μL) under ice-cooling. The reaction mixture was stirred at room temperature for 1 hr. 0.5 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted is twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. To a solution (7.5 mL) of the residue in acetonitrile were added potassium iodide (150 mg), potassium carbonate (205 mg) and 1,2,3,4-tetrahydroquinoline (145 μL), and the reaction mixture was stirred with heating at 80° C. for 4 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=90/10-20/80) to give the title compound (330 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 15

(R)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(1-methyl-1-phenylethyl)pyrrolidine-1-carboxamide

To a solution (15 mL) of triphosgene (110 mg) in methylene chloride was added pyridine (0.1 mL) under ice-cooling, and the reaction mixture was stirred at the same temperature for 30 min. The compound (150 mg) obtained in Reference Example 21 was added, and the reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure, methylene chloride (10 mL), 4-dimethylaminopyridine (370 mg) and 2-phenylpropane-2-amine (390 mg) were added at room temperature, and the reaction mixture was stirred overnight. 0.5 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=60/40-0/100) to give the title compound (30 mg).

MS (ESI) m/z; 426 [M+H] +

›Example 16

(R)-5-ethyl-2-{1-[((R)-1,2,3,4-tetrahydronaphthalen-1-yl)aminocarbonyl]pyrrolidin-2-yl}-6-methyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (150 mg) obtained in Reference Example 21 was treated by a method similar to that in Example 15 to give the title compound (67 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 17

(R)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 21 was treated by a method similar to that in Example 15 to give the title compound (120 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 18

(R)-2-(7-oxo-6-(propan-2-yl)-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(1-phenylcyclopropyl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 20 was treated by a method similar to that in Example 15 to give the title compound (41 mg).

MS (ESI) m/z; 492 [M+H] +

›Example 19

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (5.0 mL) of the compound (80 mg) obtained in Reference Example 16 in methylene chloride were added N,N-diisopropylethylamine (55 μL) and phenyl chloroformate (40 mg), and the reaction mixture was stirred at room temperature for 30 min. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-20/80) to give the title compound (50 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 20

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 4-methylphenyl ester

The compound (50 mg) obtained in Reference Example 16 was treated by a method similar to that in Example 19 to give the title compound (68 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 21

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 4-methoxyphenyl ester

The compound (30 mg) obtained in Reference Example 16 was treated by a method similar to that in Example 19 to give the title compound (27 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 22

6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (70 mg) obtained in Reference Example 16 was treated by a method similar to that in Example 19 to give the title compound (90 mg).

MS (ESI) m/z; 437 [M+H] +

›Example 23

6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-[(R)-1-(3-methylphenylacetyl)pyrrolidin-2-yl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (70 mg) obtained in Reference Example 16 was treated by a method similar to that in Example 19 to give the title compound (90 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 24

(R)-2-[6-methyl-5-(5-methyl-[1,2,4]oxadiazol-3-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (330 mg) obtained in Reference Example 17 was treated by a method similar to that in Example 19 to give the title compound (440 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 25

(R)-2-[6-methyl-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (100 mg) obtained in Reference Example 18 was treated by a method similar to that in Example 19 to give the title compound (130 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 26

6-methyl-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (100 mg) obtained in Reference Example 18 was treated by a method similar to that in Example 19 to give the title compound (130 mg).

MS (ESI) m/z; 437 [M+H] +

›Example 27

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (200 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 19 to give the title compound (270 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 28

(R)-2-(5-ethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (64 mg) obtained in Reference Example 21 was treated by a method similar to that in Example 19 to give the title compound (69 mg).

MS (ESI) m/z; 385 [M+H] +

›Example 29

5-ethyl-6-methyl-2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (100 mg) obtained in Reference Example 21was treated by a method similar to that in Example 19 to give the title compound (53 mg).

MS (ESI) m/z; 383 [M+H] +

›Example 30

2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-6-(propan-2-yl)-5-trifluoromethyl-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (210 mg) obtained in Reference Example 20 was treated by a method similar to that in Example 19 to give the title compound (85 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 31

(R)-2-{6-methyl-5-[(morpholin-4-yl)methyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid phenyl ester

The compound (43 mg) obtained in Reference Example 22 was treated by a method similar to that in Example 19 to give the title compound (28 mg).

MS (ESI) m/z; 456 [M+H] +

›Example 32

(R)-2-[5-methyl-7-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (60 mg) obtained in Reference Example 23 was treated by a method similar to that in Example 19 to give the title compound (14 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 33

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

To a solution (2.0 mL) of triphosgene (38 mg) in toluene were added 3-cresol (35 mg) and pyridine (33 μL) under ice-cooling, and the reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure, methylene chloride (5.0 mL), triethylamine (100 μL) and the compound (50 mg) obtained in Reference Example 16 were added, and the reaction mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (50 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 34

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 2-methylphenyl ester

The compound (70 mg) obtained in Reference Example 16 was treated by a method similar to that in Example 33 to give the title compound (66 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 35

(R)-2-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methoxyphenyl ester

The compound (50 mg) obtained in Reference Example 16 was treated by a method similar to that in Example 33 to give the title compound (50 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 36

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (100 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 33 to give the title compound (130 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 37

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methoxyphenyl ester

The compound (80 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 33 to give the title compound (115 mg).

MS (ESI) m/z; 471 [M+H] +

›Example 38

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-(trifluoromethoxy)phenyl ester

The compound (50 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 33 to give the title compound (57 mg).

MS (ESI) m/z; 525 [M+H] +

›Example 39

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-fluorophenyl ester

The compound (50 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 33 to give the title compound (44 mg).

MS (ESI) m/z; 459 [M+H] +

›Example 40

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-chlorophenyl ester

The compound (50 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 33 to give the title compound (60 mg).

MS (ESI) m/z; 475 [M+H] +

›Example 41

(R)-2-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-(trifluoromethyl)phenyl ester

The compound (50 mg) obtained in Reference Example 19 was treated by a method similar to that in Example 33 to give the title compound (60 mg).

MS (ESI) m/z; 509 [M+H] +

›Example 42

(R)-2-[6-(2,4-dimethoxybenzyl)-7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (15 mL) of the compound (1.80 g) obtained in Reference Example 26 in methylene chloride were added chlorotrimethylsilane (3.8 mL) and triethylamine (13.2 mL), and the reaction mixture was stirred at room temperature overnight. Water and 1.0 mol/L hydrochloric acid were added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-50/50) to give the title compound (1.46 g).

MS (ESI) m/z; 549 [M+H] +

›Example 43

(R)-2-[5-cyclopropyl-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.27 g) obtained in Reference Example 27 was treated by a method similar to that in Example 42 to give the title compound (1.05 g).

MS (ESI) m/z; 547 [M+H] +

›Example 44

(R)-2-[6-(2,4-dimethoxybenzyl)-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.74 g) obtained in Reference Example 28 was treated by a method similar to that in Example 42 to give the title compound (1.80 g).

MS (ESI) m/z; 583 [M+H] +

›Example 45

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.90 g) obtained in Reference Example 29 was treated by a method similar to that in Example 42 to give the title compound (1.90 g).

MS (ESI) m/z; 601 [M+H] +

›Example 46

(R)-2-[5-(2,4-difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.47 g) obtained in Reference Example 30 was treated by a method similar to that in Example 42 to give the title compound (1.22 g).

MS (ESI) m/z; 619 [M+H] +

›Example 47

(R)-2-{6-(2,4-dimethoxybenzyl)-7-oxo-5-[2-(trifluoromethoxy)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.90 g) obtained in Reference Example 31 was treated by a method similar to that in Example 42 to give the title compound (1.46 g).

MS (ESI) m/z; 667 [M+H] +

›Example 48

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(2-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.45 g) obtained in Reference Example 32 was treated by a method similar to that in Example 42 to give the title compound (1.40 g).

MS (ESI) m/z; 597 [M+H] +

›Example 49

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.90 g) obtained in Reference Example 33 was treated by a method similar to that in Example 42 to give the title compound (1.65 g).

MS (ESI) m/z; 613 [M+H] +

›Example 50

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.80 g) obtained in Reference Example 35 was treated by a method similar to that in Example 42 to give the title compound (1.75 g).

MS (ESI) m/z; 565 [M+H] +

›Example 51

(R)-2-[5-(1-chlorocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (180 mg) obtained in Reference Example 36 was treated by a method similar to that in Example 42 to give the title compound (175 mg).

MS (ESI) m/z; 581 [M+H] +

›Example 52

(R)-2-[5-(1,1-di fluoroethyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (335 mg) obtained in Reference Example 37 was treated by a method similar to that in Example 42 to give the title compound (348 mg).

MS (ESI) m/z; 571 [M+H] +

›Example 53

(R)-2-[5-(4,4-difluorocyclohexyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.90 g) obtained in Reference Example 38 was treated by a method similar to that in Example 42 to give the title compound (1.54 g).

MS (ESI) m/z; 625 [M+H] +

›Example 54

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-fluorocyclohexyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.34 g) obtained in Reference Example 39 was treated by a method similar to that in Example 42 to give the title compound (0.80 g).

MS (ESI) m/z; 607 [M+H] +

›Example 55

(R)-2-[5-(3,3-difluorocyclobutyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.68 g) obtained in Reference Example 40 was treated by a method similar to that in Example 42 to give the title compound (1.30 g).

MS (ESI) m/z; 597 [M+H] +

›Example 56

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-ethoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.40 g) obtained in Reference Example 41 was treated by a method similar to that in Example 42 to give the title compound (0.69 g).

MS (ESI) m/z; 591 [M+H] +

›Example 57

(R)-2-[5-(1-cyanocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (4.10 g) obtained in Reference Example 42 was treated by a method similar to that in Example 42 to give the title compound (1.85 g).

MS (ESI) m/z; 572 [M+H] +

›Example 58

(R)-2-[5-(2-cyanopropan-2-yl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (581 mg) obtained in Reference Example 43 was treated by a method similar to that in Example 42 to give the title compound (438 mg).

MS (ESI) m/z; 574 [M+H] +

›Example 59

(R)-2-[6-(2,4-dimethoxybenzyl)-5-[1-(fluoromethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (379 mg) obtained in Reference Example 44 was treated by a method similar to that in Example 42 to give the title compound (370 mg).

MS (ESI) m/z; 579 [M+H] +

›Example 60

(R)-2-[6-(2,4-dimethoxybenzyl)-7-oxo-5-[1-(trifluoromethyl)cyclopropyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.46 g) obtained in Reference Example 45 was treated by a method similar to that in Example 42 to give the title compound (1.15 g).

MS (ESI) m/z; 615 [M+H] +

›Example 61

(R)-2-[6-(2,4-dimethoxybenzyl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (580 mg) obtained in Reference Example 47 was treated by a method similar to that in Example 42 to give the title compound (498 mg).

MS (ESI) m/z; 575 [M+H] +

›Example 62

(R)-2-[5-difluoromethyl-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (560 mg) obtained in Reference Example 48 was treated by a method similar to that in Example 42 to give the title compound (499 mg).

MS (ESI) m/z; 557 [M+H] +

›Example 63

(R)-2-[7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (19 mL) of the compound (960 mg) obtained in Example 42 in acetonitrile were added triethylsilane (1.67 mL) and trimethylsilyl iodide (1.20 mL), and the reaction mixture was stirred at room temperature overnight. Triethylamine (1.95 mL) and phenyl chloroformate (663 μL) were added to the reaction mixture, and the reaction mixture was stirred at room temperature overnight. 1.0 mol/L Aqueous sodium hydroxide solution (4.0 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 15 min. The mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (379 mg).

MS (ESI) m/z; 385 [M+H] +

›Example 64

(R)-2-(5-cyclopropyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (1050 mg) obtained in Example 43 was treated by a method similar to that in Example 63 to give the title compound (275 mg).

MS (ESI) m/z; 383 [M+H] +

›Example 65

(R)-2-(7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (700 mg) obtained in Example 44 was treated by a method similar to that in Example 63 to give the title compound (280 mg).

MS (ESI) m/z; 419 [M+H] +

›Example 66

(R)-2-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (1000 mg) obtained in Example 45 was treated by a method similar to that in Example 63 to give the title compound (310 mg).

MS (ESI) m/z; 437 [M+H] +

›Example 67

(R)-2-[5-(2,4-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (600 mg) obtained in Example 46 was treated by a method similar to that in Example 63 to give the title compound (168 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 68

(R)-2-{7-oxo-5-[2-(trifluoromethoxy)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid phenyl ester

The compound (700 mg) obtained in Example 47 was treated by a method similar to that in Example 63 to give the title compound (410 mg).

MS (ESI) m/z; 503 [M+H] +

›Example 69

(R)-2-[5-(2-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (700 mg) obtained in Example 48 was treated by a method similar to that in Example 63 to give the title compound (170 mg).

MS (ESI) m/z; 433 [M+H] +

›Example 70

(R)-2-[5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (800 mg) obtained in Example 49 was treated by a method similar to that in Example 63 to give the title compound (360 mg).

MS (ESI) m/z; 449 [M+H] +

›Example 71

(R)-2-[5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (1.75 g) obtained in Example 50 was treated by a method similar to that in Example 63 to give the title compound (1.00 g).

MS (ESI) m/z; 401 [M+H] +

›Example 72

(R)-2-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (230 mg) obtained in Example 51 was treated by a method similar to that in Example 63 to give the title compound (33 mg).

MS (ESI) m/z; 417, 419 [M+H] +

›Example 73

(R)-2-[5-(1,1-difluoroethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (336 mg) obtained in Example 52 was treated by a method similar to that in Example 63 to give the title compound (86.0 mg).

MS (ESI) m/z; 407 [M+H] +

›Example 74

(R)-2-[5-(4,4-difluorocyclohexyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (750 mg) obtained in Example 53 was treated by a method similar to that in Example 63 to give the title compound (190 mg).

MS (ESI) m/z; 461 [M+H] +

›Example 75

(R)-2-[5-(1-fluorocyclohexyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (800 mg) obtained in Example 54 was treated by a method similar to that in Example 63 to give the title compound (40.0 mg).

MS (ESI) m/z; 443 [M+H] +

›Example 76

(R)-2-[5-(3,3-difluorocyclobutyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (1300 mg) obtained in Example 55 was treated by a method similar to that in Example 63 to give the title compound (100 mg).

MS (ESI) m/z; 433 [M+H] +

›Example 77

(R)-2-[5-(1-ethoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (690 mg) obtained in Example 56 was treated by a method similar to that in Example 63 to give the title compound (37.0 mg).

MS (ESI) m/z; 427 [M+H] +

›Example 78

(R)-2-[5-(1-cyanocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (1850 mg) obtained in Example 57 was treated by a method similar to that in Example 63 to give the title compound (711 mg).

MS (ESI) m/z; 408 [M+H] +

›Example 79

(R)-2-[5-(2-cyanopropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (300 mg) obtained in Example 58 was treated by a method similar to that in Example 63 to give the title compound (129 mg).

MS (ESI) m/z; 410 [M+H] +

›Example 80

(R)-2-{5-[1-(fluoromethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid phenyl ester

The compound (370 mg) obtained in Example 59 was treated by a method similar to that in Example 63 to give the title compound (70.0 mg).

MS (ESI) m/z; 415 [M+H] +

›Example 81

(R)-2-{7-oxo-5-[1-(trifluoromethyl)cyclopropyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid phenyl ester

The compound (575 mg) obtained in Example 60 was treated by a method similar to that in Example 63 to give the title compound (279 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 82

(R)-2-(7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (478 mg) obtained in Example 61 was treated is by a method similar to that in Example 63 to give the title compound (116 mg).

MS (ESI) m/z; 411 [M+H] +

›Example 83

(R)-2-(5-difluoromethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (267 mg) obtained in Example 62 was treated by a method similar to that in Example 63 to give the title compound (122 mg).

MS (ESI) m/z; 393 [M+H] +

›Example 84

N-methyl-N-{(R)-1-[7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]ethyl}carbamic acid phenyl ester

To a reaction mixture of trifluoroacetic acid (6.50 mL), triethylsilane (360 μL) and water (360 μL) was added the compound (800 mg) obtained in Reference Example 49 at 0° C., and the reaction mixture was stirred at room temperature for 2 hr. The solvent was evaporated under reduced pressure, 1.0 mol/L hydrochloric acid (10.0 mL) was added, and the mixture was washed with hexane. The aqueous layer was neutralized with 1.0 mol/L aqueous sodium hydroxide solution, sodium hydrogen carbonate (160 mg) and phenyl chloroformate (220 μL) were added at 0° C., and the reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was acidified with 1.0 mol/L hydrochloric acid and extracted once with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. To the residue was added diisopropyl ether, and the solid was collected by filtration and dried to give the title compound (420 mg).

MS (ESI) m/z; 373 [M+H] +

›Example 85

N-{(R)-1-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]ethyl}-N-methylcarbamic acid phenyl ester

The compound (765 mg) obtained in Reference Example 50 was treated by a method similar to that in Example 84 to give the title compound (310 mg).

MS (ESI) m/z; 405, 407 [M+H] +

›Example 86

(R)-2-(7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid 3-methylphenyl ester

To a solution (20 mL) of the compound (700 mg) obtained in Example 44 in acetonitrile were added triethylsilane (1.20 mL) and trimethylsilyl iodide (0.35 mL), and the reaction mixture was stirred at room temperature overnight (reaction mixture 1). To a solution (10.0 mL) of triphosgene (290 mg) in toluene were added m-cresol (260 mg) and pyridine (0.25 mL) under ice-cooling, and the reaction mixture was stirred at room temperature for 30 min (reaction mixture 2). The solvent of the above-mentioned reaction mixture 2 was evaporated under reduced pressure, and the obtained residue was dissolved in methylene chloride (5.0 mL), and added to the above-mentioned reaction mixture 1 at room temperature. Furthermore, triethylamine (1.0 mL) was added, and the reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (310 mg).

MS (ESI) m/z; 433 [M+H] +

›Example 87

(R)-2-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (900 mg) obtained in Example 45 was treated by a method similar to that in Example 86 to give the title compound (250 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 88

(R)-2-[5-(2,4-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (600 mg) obtained in Example 46 was treated by a method similar to that in Example 86 to give the title compound (225 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 89

(R)-2-{7-oxo-5-[2-(trifluoromethoxy)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (700 mg) obtained in Example 47 was treated by a method similar to that in Example 86 to give the title compound (450 mg).

MS (ESI) m/z; 517 [M+H] +

›Example 90

(R)-2-[5-(3-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (700 mg) obtained in Example 48 was treated by a method similar to that in Example 86 to give the title compound (150 mg).

MS (ESI) m/z; 447 [M+H] +

›Example 91

(R)-2-[5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (800 mg) obtained in Example 49 was treated by a method similar to that in Example 86 to give the title compound (430 mg).

MS (ESI) m/z; 463 [M+H] +

›Example 92

(R)-2-[5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (490 mg) obtained in Example 50 was treated by a method similar to that in Example 86 to give the title compound (245 mg).

MS (ESI) m/z; 415 [M+H] +

›Example 93

(R)-2-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (50 mg) obtained in Example 51 was treated by a method similar to that in Example 86 to give the title compound (27 mg).

MS (ESI) m/z; 431, 433 [M+H] +

›Example 94

(R)-2-[5-(1-cyanocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (350 mg) obtained in Example 57 was treated by a method similar to that in Example 86 to give the title compound (31.0 mg).

MS (ESI) m/z; 422 [M+H] +

›Example 95

(R)-2-{6-(2,4-dimethoxybenzyl)-5-[1-(methoxymethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid benzyl ester

The compound (2.50 g) obtained in Reference Example 51 was treated by a method similar to that in Example 42 to give the title compound (2.30 g).

MS (ESI) m/z; 591 [M+H] +

›Example 96

(R)-2-{5-[1-(methoxymethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid phenyl ester

To a solution (10 mL) of the compound (500 mg) obtained in Reference Example 52 in methylene chloride were added triethylamine (0.28 mL) and phenyl chloroformate (0.26 g), and the reaction mixture was stirred at room temperature for 1 hr. 1.0 mol/L Aqueous sodium hydroxide solution (8.0 mL) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 15 min. The reaction mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was is purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (130 mg).

MS (ESI) m/z; 427 [M+H] +

›Example 97

2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-5-[1-(trifluoromethyl)cyclopropyl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (45.0 mg) obtained in Reference Example 53 was treated by a method similar to that in Example 96 to give the title compound (45.0 mg).

MS (ESI) m/z; 449 [M+H] +

›Example 98

2-{(R)-1-[2-(3-methylphenyl)acetyl]pyrrolidin-2-yl}-5-[1-(trifluoromethyl)cyclopropyl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (60.0 mg) obtained in Reference Example 53 was treated by a method similar to that in Example 96 to give the title compound (40.0 mg).

MS (ESI) m/z; 463 [M+H] +

›Example 99

(R)-2-{5-[1-(methoxymethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-1-carboxylic acid 3-methylphenyl ester

To a solution (15 mL) of triphosgene (0.39 g) in toluene were added m-cresol (0.36 g) and pyridine (0.33 mL) under ice-cooling, and the reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure, methylene chloride (10 mL), triethylamine (1.4 mL) and the compound (0.50 g) obtained in Reference Example 52 were added, and the reaction mixture was stirred at room temperature for 1 hr. 1.0 mol/L Aqueous sodium hydroxide solution (8.0 mL) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 15 min. The reaction mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (190 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 100

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-methylcyclopropoxy)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (5.0 mL) of the compound (567 mg) obtained in Reference Example 56 in DMF were added 1-methylcyclopropanol (104 mg) and sodium hydride (60% oil dispersion, 48 mg) under ice-cooling. The reaction mixture was stirred at 60° C. for 2 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-50/50) and NH silica gel column chromatography (solvent; hexane/ethyl acetate=60/40-0/100) to give the title compound (239 mg).

MS (ESI) m/z; 577 [M+H] +

›Example 101

(R)-2-[6-(2,4-dimethoxybenzyl)-7-oxo-5-(2,2,2-trifluoroethoxy)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (4.0 mL) of the compound (250 mg) obtained in Reference Example 56 in DMF were added 2,2,2-trifluoroethanol (40 μL) and potassium tert-butoxide (59 mg) under ice-cooling. The reaction mixture was stirred at 60° C. for 1 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-30/70) to give the title compound (87 mg).

MS (ESI) m/z; 605 [M+H] +

›Example 102

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(N,N-dimethylamino)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (3.0 mL) of the compound (190 mg) obtained in Reference Example 56 in THF was added 2.0 mol/L dimethylamine THF solution (0.85 mL) under ice-cooling. The reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated, and the residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=60/40-40/60) to give the title compound (129 mg).

MS (ESI) m/z; 550 [M+H] +

›Example 103

(R)-2-[6-(2,4-dimethoxybenzyl)-7-oxo-5-(piperidin-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (216 mg) obtained in Reference Example 56 was treated by a method similar to that in Example 102 to give the title compound (150 mg).

MS (ESI) m/z; 590 [M+H] +

›Example 104

(R)-2-[5-(1-methylcyclopropoxy)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (180 mg) obtained in Example 100 was treated by a method similar to that in Example 63 to give the title compound (62 mg).

MS (ESI) m/z; 413 [M+H] +

›Example 105

(R)-2-[7-oxo-5-(2,2,2-trifluoroethoxy)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (168 mg) obtained in Example 101 was treated by a method similar to that in Example 63 to give the title compound (59 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 106

(R)-2-[5-(N,N-dimethylamino)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (126 mg) obtained in Example 102 was treated by a method similar to that in Example 63 to give the title compound (68 mg).

MS (ESI) m/z; 386 [M+H] +

›Example 107

(R)-2-[7-oxo-5-(piperidin-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (139 mg) obtained in Example 103 was treated by a method similar to that in Example 63 to give the title compound (61 mg).

MS (ESI) m/z; 426 [M+H] +

›Example 108

(R)-2-[6-(2,4-dimethoxybenzyl)-5-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (0.92 g) obtained in Reference Example 57 was treated by a method similar to that in Example 42 to give the title compound (0.89 g).

MS (ESI) m/z; 535 [M+H] +

›Example 109

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-methylcyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (1.27 g) obtained in Reference Example 58 was treated by a method similar to that in Example 42 to give the title compound (1.08 g).

MS (ESI) m/z; 561 [M+H] +

›Example 110

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(3-methyloxetan-3-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (2.1 g) obtained in Reference Example 59 was treated by a method similar to that in Example 42 to give the title compound (1.29 g).

MS (ESI) m/z; 577 [M+H] +

›Example 111

(R)-2-[6-(2,4-dimethoxybenzyl)-5-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (10 mL) of the compound (200 mg) obtained in Reference Example 60 in methylene chloride were added triethylamine (90 μL) and phenyl chloroformate (90.0 mg), and the reaction mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (200 mg).

MS (ESI) m/z; 521 [M+H] +

›Example 112

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-methylcyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (320 mg) obtained in Reference Example 61 was treated by a method similar to that in Example 111 to give the title compound (142 mg).

MS (ESI) m/z; 547 [M+H] +

›Example 113

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(3-methyloxetan-3-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (70.0 mg) obtained in Reference Example 62 was treated by a method similar to that in Example 111 to give the title compound (49 mg).

MS (ESI) m/z; 563 [M+H] +

›Example 114

(R)-2-(5-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

To the compound (180 mg) obtained in Example 111 was added a mixed solvent of triethylsilane (0.35 mL), water (0.35 mL) and trifluoroacetic acid (6.3 mL), and the reaction mixture was stirred at room temperature for 2 hr. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (118 mg).

MS (ESI) m/z; 371 [M+H] +

›Example 115

(R)-2-[5-(1-methylcyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (142 mg) obtained in Example 112 was treated by a method similar to that in Example 114 to give the title compound (80.0 mg).

MS (ESI) m/z; 397 [M+H] +

›Example 116

(R)-2-[5-(3-methyloxetan-3-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (49.0 mg) obtained in Example 113 was treated by a method similar to that in Example 114 to give the title compound (28.0 mg).

MS (ESI) m/z; 413 [M+H] +

›Example 117

(R)-2-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (30 mL) of the compound (1.30 g) obtained in Reference Example 64 in methylene chloride were added chlorotrimethylsilane (22.8 mL) and triethylamine (75.2 mL), and the reaction mixture was stirred at room temperature for 10 days. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (0.40 g).

MS (ESI) m/z; 417 [M+H] +

›Example 118

(R)-2-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (15 mL) of the compound (300 mg) obtained in Example 117 in acetonitrile were added triethylsilane (0.69 mL) and trimethylsilyl iodide (0.21 mL), and the mixture was stirred at room temperature overnight. Triethylamine (0.60 mL) and phenyl chloroformate (0.23 g) were added to the reaction mixture, and the reaction mixture was stirred at room temperature for 4 hr. 1.0 mol/L Aqueous sodium hydroxide solution (0.8 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 15 min. The mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (97 mg).

MS (ESI) m/z; 403 [M+H] +

›Example 119

(R)-2-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

(1) To a solution (5.0 mL) of the compound (100 mg) obtained in Example 117 in acetonitrile were added triethylsilane (0.23 mL) and trimethylsilyl iodide (70 μL), and the reaction mixture was stirred at room temperature overnight.

(2) To a solution (5.0 mL) of triphosgene (57 mg) in toluene were added m-cresol (52 mg) and pyridine (50 μL) under ice-cooling, and the reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure, the residue was dissolved in methylene chloride (5.0 mL), and added to the reaction mixture described in (1) at room temperature. Furthermore, triethylamine (0.20 mL) was added, and the reaction mixture was stirred at room temperature for 4 hr. The reaction mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (34 mg).

MS (ESI) m/z; 417 [M+H] +

›Example 120

(R)-2-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (24.0 mL) of the compound (2.40 g) obtained in Example 584 in methylene chloride solution (24.0 mL) were added triethylsilane (1.75 mL) and trimethylsilyl iodide (1.56 mL) at 0° C., and the mixture was stirred at room temperature for 15 hr. The solvent was evaporated under reduced pressure, and to the residue were added 1.0 mol/L hydrochloric acid (28.8 mL) and hexane (24.0 mL) to partition the mixture. The aqueous layer was adjusted to pH about 4 with 4.0 mol/L aqueous sodium hydroxide solution (7.20 mL). To the obtained aqueous layer were successively added THF (12.0 mL), sodium hydrogen carbonate (2.30 g) and phenyl chloroformate (0.868 mL) under ice-cooling, and the reaction mixture was stirred at room temperature for 3 hr. 5% Aqueous citric acid solution (60.0 mL) was added to the reaction mixture, and the mixture was extracted three times with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by reversed-phase chromatography (Capcellpak C18 UG80 φ30 mm×250 mm, 5 μm, A: 0.05% trifluoroacetic acid-water, B: 0.05% trifluoroacetic acid-acetonitrile, 35 mL/min, B: 35-50%), and the solvent was evaporated by freeze-drying. The obtained residue was separated by chiral column (CHIRALPAK ID φ30 mm×250 mm, solvent:methanol-THF-acetic acid 85:15:0.5), and the solvent was evaporated to give the title compound (729 mg).

MS (ESI) m/z; 425 [M+H] +

›Example 121

(R)-2-[5-(1-acetoxycyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (6.38 g) obtained in Reference Example 67 was treated by a method similar to that in Example 42 to give the title compound (6.20 g).

MS (ESI) m/z; 605 [M+H] +

›Example 122

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1-hydroxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (60.0 mL) of the compound (6.20 g) obtained in Example 121 in THF was added 1.0 mol/L aqueous sodium hydroxide solution (12.2 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was neutralized with 1.0 mol/L hydrochloric acid, and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (4.25 g).

MS (ESI) m/z; 563 [M+H] +

›Example 123

(R)-2-[6-(2,4-dimethoxybenzyl)-5-(1 l-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

To a solution (50.0 mL) of the compound (4.25 g) obtained in Example 122 in DMF were added methyl iodide (1.30 g) and sodium hydride (60% oil dispersion, 0.31 g) at 0° C., and the reaction mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (2.20 g).

MS (ESI) m/z; 577 [M+H] +

›Example 124

(R)-2-[5-(1-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (730 mg) obtained in Reference Example 68 was treated by a method similar to that in Example 96 to give the title compound (400 mg)

MS (ESI) m/z; 413 [M+H] +

›Example 125

(R)-2-[5-(1-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (150 mg) obtained in Reference Example 68 was treated by a method similar to that in Example 99 to give the title compound (33.0 mg).

MS (ESI) m/z; 427 [M+H] +

›Example 126

(R)-2-(5-tert-butyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

To a solution (5.0 mL) of the compound (120 mg) obtained in Reference Example 78 in methylene chloride were added triethylamine (80 μL) and phenyl chloroformate (68 mg), and the reaction mixture was stirred at room temperature for 1 hr. Furthermore, phenyl chloroformate (68 mg) was added, and the reaction mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was acidified with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (128 mg).

MS (ESI) m/z; 399 [M+H] +

›Example 127

2-[6-(2,4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrazolidine-1-carboxylic acid phenyl ester

A solution (30 mL) of the compound (0.97 g) obtained in Reference Example 87, the compound (0.59 g) obtained in Reference Example 79, copper(I) iodide (80 mg), trans-N,N′-dimethylcyclohexane-1,2-diamine (60 mg) and tripotassium phosphate (0.91 g) in 1,4-dioxane was heated under reflux for 2 hr. The reaction mixture was cooled to room temperature, water was added thereto, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-50/50) to give the title compound (0.35 g).

MS (ESI) m/z; 588 [M+H] +

›Example 128

2-[6-(2,4-dimethoxybenzyl)-5-(1-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrazolidine-1-carboxylic acid phenyl ester

The compound (0.68 g) obtained in Reference Example 88 was treated by a method similar to that in Example 127 to give the title compound (0.26 g).

MS (ESI) m/z; 564 [M+H] +

›Example 129

2-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrazolidine-1-carboxylic acid phenyl ester

To a solution (6.0 mL) of the compound (350 mg) obtained in Example 127 in methylene chloride was added a mixture of triethylsilane (0.58 mL), water (0.38 mL) and trifluoroacetic acid (6.0 mL), and the reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was neutralized with saturated aqueous sodium hydrogen carbonate solution, and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (170 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 130

2-[5-(1-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrazolidine-1-carboxylic acid phenyl ester

The compound (260 mg) obtained in Example 128 was treated by a method similar to that in Example 129 to give the title compound (60.0 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 131

2-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrazolidine-1-carboxylic acid phenyl ester

A solution (25 mL) of the compound (250 mg) obtained in Reference Example 91, the compound (930 mg) obtained in Reference Example 79, copper(I) iodide (33 mg), trans-N,N′-dimethylcyclohexane-1,2-diamine (25 mg) and tripotassium phosphate (386 mg) in 1,4-dioxane was heated under reflux for 1 hr. The reaction mixture was cooled to room temperature, water was added thereto, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (78.0 mg).

MS (ESI) m/z; 404 [M+H] +

›Example 132

2-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrazolidine-1-carboxylic acid 3-methylphenyl ester

The compound (300 mg) obtained in Reference Example 91 and the compound (420 mg) obtained in Reference Example 82 were treated by a method similar to that in Example 131 to give the title compound (49.0 mg).

MS (ESI) m/z; 418 [M+H] +

›Example 133

5-(2-fluoropropan-2-yl)-2-[2-(phenylacetyl)pyrazolidin-1-yl]-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

A mixture of the compound (200 mg) obtained in Reference Example 91, the compound (400 mg) obtained in Reference Example 80 and N,N-diisopropylethylamine (1.20 mL) was heated at 150° C. for 12 hr. The reaction mixture was cooled to room temperature, neutralized with 1.0 mol/L hydrochloric acid, and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (78.0 mg).

MS (ESI) m/z; 402 [M+H] +

›Example 134

5-(2-fluoropropan-2-yl)-2-{2-[2-(3-methylphenyl) acetyl]pyrazolidin-1-yl}-6H-[1,3]thiazolo[5,4-d]pyrimidin-7-one

The compound (200 mg) obtained in Reference Example 91 and the compound (560 mg) obtained in Reference Example 81 were treated by a method similar to that in Example 133 to give the title compound (100 mg).

MS (ESI) m/z; 416 [M+H] +

›Example 135

(R)-2-[6-methyl-7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (5.0 mL) of the compound (379 mg) obtained in Example 63 in acetonitrile were added potassium carbonate (205 mg) and methyl iodide (307 μL), and the reaction mixture was stirred with heating at 60° C. for 1 hr. The reaction mixture was allowed to cool to room temperature, water was added thereto, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/20-0/100) to give the title compound (303 mg).

MS (ESI) m/z; 399 [M+H] +

›Example 136

(R)-2-[5-(1-fluorocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (100 mg) obtained in Example 71 was treated by a method similar to that in Example 135 to give the title compound (71 mg).

MS (ESI) m/z; 415 [M+H] +

›Example 137

(R)-2-[6-(2-fluorophenyl)-4-oxo-4,5-dihydro[1,3]thiazolo[4,5-c]pyridin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (9.5 mL) of the compound (300 mg) obtained in Reference Example 97 in acetonitrile were added triethylsilane (619 μL) and trimethylsilyl iodide (355 μL), and the reaction mixture was stirred at room temperature for 1.5 hr. Triethylamine (541 μL) and phenyl chloroformate (162 μL) were added to the reaction mixture, and the reaction mixture was stirred at room temperature for 2 days. Triethylamine (90 μL) and phenyl chloroformate (81 μL) were added, and the reaction mixture was further stirred at room temperature for 5 hr. Water (475 μL) was added to the reaction mixture under ice-cooling, and the reaction mixture was stirred at room temperature for 15 hr. Furthermore, 1.0 mol/L aqueous sodium hydroxide solution (6.5 mL) was added, and the reaction mixture was stirred at room temperature for 4 hr. The reaction mixture was ice-cooled, acidified with 1.0 mol/L hydrochloric acid and extracted twice with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/MeOH=100/0-95/5), to the obtained product was added hexane/diethyl ether/ethyl acetate=2/2/1, and the solid was collected by filtration to give the title compound (106 mg).

MS (ESI) m/z; 436 [M+H] +

›Example 138

(R)-2-(4-oxo-6-trifluoromethyl-4,5-dihydro[1,3]thiazolo[4,5-c]pyridin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (71 mg) obtained in Reference Example 98 was treated by a method similar to that in Example 137 to give the title compound (36 mg).

MS (ESI) m/z; 410 [M+H] +

›Example 139

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

To a solution (10.0 mL) of the compound (200 mg) obtained in Reference Example 114 in methylene chloride were added N,N-diisopropylethylamine (120 μL) and phenyl chloroformate (120 mg), and the reaction mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (280 mg).

MS (ESI) m/z; 385 [M+H] +

›Example 140

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 4-fluorophenyl ester

The compound (200 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 139 to give the title compound (300 mg).

MS (ESI) m/z; 403 [M+H] +

›Example 141

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 2-chlorophenyl ester

The compound (200 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 139 to give the title compound (310 mg).

MS (ESI) m/z; 419 [M+H] +

›Example 142

2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

The compound (258 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 139 to give the title compound (360 mg).

MS (ESI) m/z; 383 [M+H] +

›Example 143

2-{(R)-1-[2-(4-fluorophenyl)acetyl]pyrrolidin-2-yl}-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

The compound (200 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 139 to give the title compound (210 mg).

MS (ESI) m/z; 401 [M+H] +

›Example 144

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

The compound (100 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 139 to give the title compound (150 mg).

MS (ESI) m/z; 399 [M+H] +

›Example 145

2-[(R)-1-(2-phenoxyacetyl)pyrrolidin-2-yl]-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

The compound (200 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 139 to give the title compound (218 mg).

MS (ESI) m/z; 399 [M+H] +

›Example 146

(R)-2-(7-ethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (100 mg) obtained in Reference Example 115 was treated by a method similar to that in Example 139 to give the title compound (143 mg).

MS (ESI) m/z; 371 [M+H] +

›Example 147

(R)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (100 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 139 to give the title compound (135 mg).

MS (ESI) m/z; 371 [M+H] +

›Example 148

(R)-2-(6-ethyl-7-methyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (100 mg) obtained in Reference Example 117 was treated by a method similar to that in Example 139 to give the title compound (138 mg).

MS (ESI) m/z; 385 [M+H] +

›Example 149

(R)-2-(5-oxo-6,7,8,9-tetrahydro-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (200 mg) obtained in Reference Example 118 was treated by a method similar to that in Example 139 to give the title compound (280 mg).

MS (ESI) m/z; 397 [M+H] +

›Example 150

(R)-2-(5-oxo-6,7,8,9-tetrahydro-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl)pyrrolidine-1-carboxylic acid 4-fluorophenyl ester

The compound (230 mg) obtained in Reference Example 118 was treated by a method similar to that in Example 139 to give the title compound (320 mg).

MS (ESI) m/z; 415 [M+H] +

›Example 151

2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-6,7,8,9-tetrahydro-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one

The compound (200 mg) obtained in Reference Example 118 was treated by a method similar to that in Example 139 to give the title compound (280 mg).

MS (ESI) m/z; 395 [M+H] +

›Example 152

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]piperidine-1-carboxylic acid phenyl ester

The compound (130 mg) obtained in Reference Example 119 was treated by a method similar to that in Example 139 to give the title compound (187 mg).

MS (ESI) m/z; 399 [M+H] +

›Example 153

(R)-2-[6-chloro-5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid phenyl ester

The compound (150 mg) obtained in Reference Example 120 was treated by a method similar to that in Example 139 to give the title compound (210 mg).

MS (ESI) m/z; 419, 421 [M+H] +

›Example 154

6-chloro-2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

The compound (150 mg) obtained in Reference Example 120 was treated by a method similar to that in Example 139 to give the title compound (160 mg).

MS (ESI) m/z; 417, 419 [M+H] +

›Example 155

(R)-2-(7-fluoro-5-oxo-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl)pyrrolidine-1-carboxylic acid phenyl ester

The compound (250 mg) obtained in Reference Example 121 was treated by a method similar to that in Example 139 to give the title compound (230 mg).

MS (ESI) m/z; 411 [M+H] +

›Example 156

7-fluoro-2-[(R)-1-(phenylacetyl)pyrrolidin-2-yl]-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one

The compound (300 mg) obtained in Reference Example 121 was treated by a method similar to that in Example 139 to give the title compound (226 mg).

MS (ESI) m/z; 409 [M+H] +

›Example 157

(R)-N-benzyl-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxamide

To a solution (10.0 mL) of the compound (300 mg) obtained in Reference Example 114 and N,N-diisopropylethylamine (180 μL) in methylene chloride was added dropwise benzyl isocyanate (150 mg) under ice-cooling. The reaction mixture was stirred at room temperature for 1 hr. 0.5 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-20/80) to give the title compound (430 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 158

(R)-N-(2-chlorobenzyl)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxamide

The compound (100 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 157 to give the title compound (180 mg).

MS (ESI) m/z; 432, 434 [M+H] +

›Example 159

(R)-N-(4-chlorobenzyl)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxamide

The compound (100 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 157 to give the title compound (100 mg).

MS (ESI) m/z; 432, 434 [M+H] +

›Example 160

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]-N-phenylpyrrolidine-1-carboxamide

The compound (200 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 157 to give is the title compound (290 mg).

MS (ESI) m/z; 384 [M+H] +

›Example 161

(R)-N-benzyl-2-(7-ethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 115 was treated by a method similar to that in Example 157 to give the title compound (183 mg).

MS (ESI) m/z; 384 [M+H] +

›Example 162

(R)-N-benzyl-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 157 to give the title compound (174 mg).

MS (ESI) m/z; 384 [M+H] +

›Example 163

(R)-N-(2-chlorophenyl)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 157 to give the title compound (230 mg).

MS (ESI) m/z; 418, 420 [M+H] +

›Example 164

(R)-N-benzyl-2-(6-ethyl-7-methyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 117 was treated by a method similar to that in Example 157 to give the title compound (187 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 165

2-[(R)-1-(2,3-dihydro-1H-indol-1-ylacetyl)pyrrolidin-2-yl]-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

To a solution (10.0 mL) of the compound (200 mg) obtained in Reference Example 114 and N,N-diisopropylethylamine (120 mg) in methylene chloride was added dropwise chloroacetyl chloride (90 mg) at room temperature. The reaction mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give a viscous body (250 mg). To a solution (10.0 mL) of the obtained viscous body in THF were added indoline (100 mg) and sodium hydride (60% oil dispersion, 40 mg), and the reaction mixture was stirred with heating at 70° C. for 8 hr. The reaction mixture was cooled to room temperature, water was added thereto, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (36 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 166

2-{(R)-1-[(3,4-dihydroquinolin-1(2H)-yl)acetyl]pyrrolidin-2-yl}-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

To a solution (10.0 mL) of the compound (200 mg) obtained in Reference Example 114 and N,N-diisopropylethylamine (110 mg) in methylene chloride was added dropwise chloroacetyl chloride (90 mg) at room temperature. After stirring at room temperature for 1 hr, water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. To a solution (10.0 mL) of the residue in acetonitrile were added potassium iodide (160 mg), potassium carbonate (130 mg) and 1,2,3,4-tetrahydroquinoline (130 mg), and the reaction mixture was stirred with heating at 80° C. for 3 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (200 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 167

(R)-N-(1-phenylcyclopropyl)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxamide

To a solution (10 mL) of triphosgene (100 mg) in methylene chloride was added pyridine (92 μL) at 0° C., and the reaction mixture was stirred for 30 min. The compound (150 mg) obtained in Reference Example 114 was added, and the reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure, methylene chloride (10 mL), 4-dimethylaminopyridine (350 mg) and 1-phenylcyclopropylamine (490 mg) were added at room temperature, and the reaction mixture was stirred at the same temperature for 1 hr. 1.0 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (88 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 168

(R)-N-((R)-indan-1-yl)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 167 to give the title compound (100 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 169

(R)-2-[5-oxo-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 167 to give the title compound (43.0 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 170

2-[(R)-1-(2,3-dihydro-indole-1-carbonyl)pyrrolidin-2-yl]-7-(propan-2-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one

The compound (150 mg) obtained in Reference Example 114 was treated by a method similar to that in Example 167 to give the title compound (136 mg).

MS (ESI) m/z; 410 [M+H] +

›Example 171

(R)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 167 to give the title compound (119 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 172

(R)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-(1-methyl-1-phenylethyl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 167 to give the title compound (18.0 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 173

(R)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-(1-phenylcyclopropyl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 167 to give the title compound (75.0 mg).

MS (ESI) m/z; 410 [M+H] +

›Example 174

(R)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-((R)-indan-1-yl)pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 167 to give the title compound (190 mg).

MS (ESI) m/z; 410 [M+H] +

›Example 175

(R)-2-(6,7-dimethyl-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-(thieno[2,3-b]pyridin-3-yl)-pyrrolidine-1-carboxamide

The compound (150 mg) obtained in Reference Example 116 was treated by a method similar to that in Example 167 to give the title compound (10.5 mg).

MS (ESI) m/z; 427 [M+H] +

›Example 176

2-(5-oxo-7-propyl-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyrazolidine-1-carboxylic acid phenyl ester

To a solution (5.0 mL) of the compound (300 mg) obtained in Reference Example 122 in 1,4-dioxane were added N,N-diisopropylethylamine (0.76 mL) and pyrazolidine dihydrochloride (180 mg), and the mixture was stirred at room temperature for 1 hr. N,N-diisopropylethylamine (0.20 mL) and phenyl chloroformate (0.19 g) were added to the reaction mixture, and the reaction mixture was stirred at room temperature for 4 hr. After confirmation of the completion of the reaction, water and 1.0 mol/L hydrochloric acid were added, and the mixture was extracted twice with ethyl acetate. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) and concentrated to give the title compound (210 mg).

MS (ESI) m/z; 386 [M+H] +

›Example 177

(R)-2-[5-(4,4-difluorocyclohexyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid 3-methylphenyl ester

The compound (750 mg) obtained in Example 53 was treated is by a method similar to that in Example 86 to give the title compound (160 mg).

MS (ESI) m/z; 475 [M+H] +

›Example 178

(R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (350 mL) of the compound (35.0 g) obtained in Reference Example 268 in DMF were added (D)-proline (20.0 g) and cesium carbonate (86.2 g), and the reaction mixture was stirred with heating at 80° C. for 1 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and filtered. Chloroform was evaporated under reduced pressure from the filtrate, to the obtained mixture were added N,N-diisopropylethylamine (40 mL), benzylamine (24.6 g), EDC hydrochloride (44.1 g) and HOBt monohydrate (35.2 g), and the reaction mixture was stirred at room temperature overnight. Water was added, the mixture was extracted with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10). To the obtained product was added ethyl acetate, and the solid was collected by filtration and dried to give the title compound (33.0 g).

MS (ESI) m/z; 446 [M+H] +

›Example 179

(R)-N-benzyl-1-[5-(2-fluoropropan-2-yl)-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (157 mg) obtained in Reference Example 303 was treated by a method similar to that in Example 178 to give the title compound (170 mg).

MS (ESI) m/z; 430 [M+H] +

›Example 180

(R)-N-benzyl-1-(5, 6-dimethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (125 mg) obtained in Reference Example 305 was treated by a method similar to that in Example 178 to give the title compound (34 mg).

MS (ESI) m/z; 384 [M+H] +

›Example 181

(R)-N-benzyl-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (160 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 178 to give the title compound (70 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 182

(R)-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(2-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (337 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 178 to give the title compound (450 mg).

MS (ESI) m/z; 416 [M+H] +

›Example 183

(R)-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(3-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (337 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 178 to give the title compound (425 mg).

MS (ESI) m/z; 416 [M+H] +

›Example 184

(R)-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(4-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (337 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 178 to give the title compound (420 mg).

MS (ESI) m/z; 416 [M+H] +

›Example 185

(R)-N-benzyl-1-(5,6-diethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (839 mg) obtained in Reference Example 306 was treated by a method similar to that in Example 178 to give the title compound (659 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 186

(R)-N-benzyl-1-(6-cyclopropyl-5-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (270 mg) obtained in Reference Example 307 was treated by a method similar to that in Example 178 to give the title compound (300 mg).

MS (ESI) m/z; 410 [M+H] +

›Example 187

(R)-1-(6-cyclopropyl-5-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(2-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (108 mg) obtained in Reference Example 307 was treated by a method similar to that in Example 178 to give the title compound (135 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 188

(R)-1-(6-cyclopropyl-5-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(3-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (108 mg) obtained in Reference Example 307 was treated by a method similar to that in Example 178 to give the title compound (135 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 189

(R)-1-(6-cyclopropyl-5-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(4-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (1.08 g) obtained in Reference Example 307 was treated by a method similar to that in Example 178 to give the title compound (875 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 190

(R)-N-benzyl-1-(6-methyl-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (120 mg) obtained in Reference Example 309 was treated by a method similar to that in Example 178 to give the title compound (85 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 191

(R)-N-benzyl-1-[5-difluoromethyl-6-(2-methoxy-ethyl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (276 mg) obtained in Reference Example 313 was treated by a method similar to that in Example 178 to give the title compound (218 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 192

(R)-N-benzyl-1-[5-difluoromethyl-7-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (254 mg) obtained in Reference Example 316 was treated by a method similar to that in Example 178 to give the title compound (73 mg).

MS (ESI) m/z; 490 [M+H] +

›Example 193

(R)-1-[5-difluoromethyl-7-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (175 mg) obtained in Reference Example 316 was treated by a method similar to that in Example 178 to give the title compound (89 mg).

MS (ESI) m/z; 504 [M+H] +

›Example 194

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(pyridin-2-yl)-6, 7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (170 mg) obtained in Reference Example 326 was treated by a method similar to that in Example 178 to give the title compound (125 mg).

MS (ESI) m/z; 447 [M+H] +

›Example 195

(R)-N-benzyl-1-(6-methyl-7-oxo-5-propyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (760 mg) obtained in Reference Example 333 was treated by a method similar to that in Example 178 to give the title compound (185 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 196

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (1.96 g) obtained in Reference Example 334 was treated by a method similar to that in Example 178 to give the title compound (1.81 g).

MS (ESI) m/z; 412 [M+H] +

›Example 197

(R)-N-benzyl-1-(6-ethyl-5-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 335 was treated by a method similar to that in Example 178 to give the title compound (175 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 198

(R)-N-benzyl-1-[5-methyl-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (195 mg) obtained in Reference Example 336 was treated by a method similar to that in Example 178 to give the title compound (140 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 199

(R)-N-benzyl-1-(6-cyclopentyl-5-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (140 mg) obtained in Reference Example 337 was treated by a method similar to that in Example 178 to give the title compound (180 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 200

(R)-N-benzyl-1-[5-methyl-7-oxo-6-(2,2,2-trifluoroethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (210 mg) obtained in Reference Example 338 was treated by a method similar to that in Example 178 to give the title compound (160 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 201

(R)-N-benzyl-1-(5-methyl-7-oxo-6-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (215 mg) obtained in Reference Example 339 was treated by a method similar to that in Example 178 to give the title compound (230 mg).

MS (ESI) m/z; 446 [M+H] +

›Example 202

(R)-N-benzyl-1-[6-cyclopropyl-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (320 mg) obtained in Reference Example 340 was treated by a method similar to that in Example 178 to give the title compound (300 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 203

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(2,4,6-trifluorophenyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (5.0 mL) of the compound (249 mg) obtained in Reference Example 269 in DMF were added (D)-proline (119 mg) and potassium carbonate (380 mg), and the reaction mixture was stirred with heating at 80° C. for 3 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous sodium sulfate, and filtered. Chloroform was evaporated under reduced pressure from the filtrate, to the obtained mixture were added N,N-diisopropylethylamine (193 μL), benzylamine (150 μL), EDC hydrochloride (264 mg) and HOBt monohydrate (211 mg), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10) to give the title compound (171 mg).

MS (ESI) m/z; 500 [M+H] +

›Example 204

(R)-N-benzyl-1-[5-(2,6-difluorophenyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (325 mg) obtained in Reference Example 270 was treated by a method similar to that in Example 203 to give the title compound (382 mg).

MS (ESI) m/z; 482 [M+H] +

›Example 205

(R)-N-benzyl-1-[5-methoxymethyl-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (150 mg) obtained in Reference Example 272 was treated by a method similar to that in Example 203 to give the title compound (196 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 206

(R)-N-benzyl-1-[5-methyl-7-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (350 mg) obtained in Reference Example 274 was treated by a method similar to that in Example 203 to give the title compound (200 mg).

MS (ESI) m/z; 454 [M+H] +

›Example 207

(R)-N-benzyl-1-[6-(2-methoxy-2-methylpropyl)-5-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (340 mg) obtained in Reference Example 275 was treated by a method similar to that in Example 203 to give the title compound (120 mg).

MS (ESI) m/z; 456 [M+H] +

›Example 208

(R)-1-[5-(1,1-difluoro-2-methoxyethyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (84 mg) obtained in Reference Example 282 was treated by a method similar to that in Example 203 to give the title compound (87 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 209

(R)-N-benzyl-1-[6-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (217 mg) obtained in Reference Example 285 was treated by a method similar to that in Example 203 to give the title compound (170 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 210

(R)-N-benzyl-1-[6-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (283 mg) obtained in Reference Example 286 was treated by a method similar to that in Example 203 to give the title compound (130 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 211

(R)-N-benzyl-1-[6-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (160 mg) obtained in Reference Example 287 was treated by a method similar to that in Example 203 to give the title compound (114 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 212

(R)-1-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (133 mg) obtained in Reference Example 287 was treated by a method similar to that in Example 203 to give the title compound (159 mg).

MS (ESI) m/z; 466 [M+H] +

›Example 213

(R)-N-(4-fluorobenzyl)-1-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (133 mg) obtained in Reference Example 287 was treated by a method similar to that in Example 203 to give the title compound (171 mg).

MS (ESI) m/z; 470 [M+H] +

›Example 214

(R)-N-[(R)-1-(4-fluorophenyl)ethyl]-1-[6-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (133 mg) obtained in Reference Example 287 was treated by a method similar to that in Example 203 to give the title compound (177 mg).

MS (ESI) m/z; 484 [M+H] +

›Example 215

(R)-N-benzyl-1-[6-ethyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 288 was treated by a method similar to that in Example 203 to give the title compound (280 mg).

MS (ESI) m/z; 466 [M+H] +

›Example 216

(R)-1-[6-ethyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (160 mg) obtained in Reference Example 288 was treated by a method similar to that in Example 203 to give the title compound (170 mg).

MS (ESI) m/z; 480 [M+H] +

›Example 217

(R)-1-[6-ethyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-(4-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (160 mg) obtained in Reference Example 288 was treated by a method similar to that in Example 203 to give the title compound (180 mg).

MS (ESI) m/z; 484 [M+H] +

›Example 218

(R)-1-[6-ethyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)-azetidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 288 was treated by a method similar to that in Example 203 to give the title compound (156 mg).

MS (ESI) m/z; 466 [M+H] +

›Example 219

(R)-N-benzyl-1-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (170 mg) obtained in Reference Example 289 was treated by a method similar to that in Example 203 to give the title compound (213 mg).

MS (ESI) m/z; 480 [M+H] +

›Example 220

(R)-N-benzyl-1-[6-cyclopropyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (240 mg) obtained in Reference Example 290 was treated by a method similar to that in Example 203 to give the title compound (240 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 221

(R)-N-benzyl-1-[6-(2,2-difluoroethyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (170 mg) obtained in Reference Example 291 was treated by a method similar to that in Example 203 to give the title compound (197 mg).

MS (ESI) m/z; 502 [M+H] +

›Example 222

(R)-N-benzyl-1-[6-(2-methoxyethyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 292 was treated by a method similar to that in Example 203 to give the title compound (280 mg).

MS (ESI) m/z; 496 [M+H] +

›Example 223

(R)-N-benzyl-1-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (320 mg) obtained in Reference Example 293 was treated by a method similar to that in Example 203 to give the title compound (305 mg).

MS (ESI) m/z; 522 [M+H] +

›Example 224

(R)-N-benzyl-1-{6-[1-(methoxymethyl)cyclopropyl]-5-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (340 mg) obtained in Reference Example 296 was treated by a method similar to that in Example 203 to give the title compound (190 mg).

MS (ESI) m/z; 454 [M+H] +

›Example 225

(R)-N-benzyl-1-[5-(1-cyanocyclobutyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (282 mg) obtained in Reference Example 298 was treated by a method similar to that in Example 203 to give the title compound (304 mg).

MS (ESI) m/z; 449 [M+H] +

›Example 226

(R)-N-benzyl-1-[5-(2-methoxypropan-2-yl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (130 mg) obtained in Reference Example 299 was treated by a method similar to that in Example 203 to give the title compound (101 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 227

(R)-N-benzyl-1-{6-[(3-methyloxetan-3-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (270 mg) obtained in Reference Example 300 was treated by a method similar to that in Example 203 to give the title compound (120 mg).

MS (ESI) m/z; 508 [M+H] +

›Example 228

(R)-N-benzyl-1-(5-cyclopropyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (2.00 g) obtained in Reference Example 301 was treated by a method similar to that in Example 203 to give the title compound (2.35 g).

MS (ESI) m/z; 410 [M+H] +

›Example 229

(R)-1-(5,6-dimethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(2-methylbenzyl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 305 was treated by a method similar to that in Example 203 to give the title compound (277 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 230

(R)-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 203 to give the title compound (290 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 231

(R)-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((S)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 203 to give the title compound (283 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 232

(R)-N-benzyl-2-{[N′-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N′-methyl]amino}propionamide

The compound (300 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 203 to give the title compound (33 mg).

MS (ESI) m/z; 386 [M+H] +

›Example 233

(R)-N-benzyl-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)azetidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 203 to give the title compound (307 mg).

MS (ESI) m/z; 384 [M+H] +

›Example 234

(R)-N-benzyl-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)piperidine-2-carboxamide

The compound (800 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 203 to give the title compound (59 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 235

(R)-1-(5-ethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(2-methylbenzyl) piperidine-2-carboxamide

The compound (353 mg) obtained in Reference Example 304 was treated by a method similar to that in Example 203 to give the title compound (114 mg).

MS (ESI) m/z; 426 [M+H] +

›Example 236

(R)-N-benzyl-1-(5,6-diethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)piperidine-2-carboxamide

The compound (350 mg) obtained in Reference Example 306 was treated by a method similar to that in Example 203 to give the title compound (57 mg).

MS (ESI) m/z; 426 [M+H] +

›Example 237

(R)-1-(6-cyclopropyl-5-methyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(2-methylbenzyl)pyrrolidine-2-carboxamide

The compound (368 mg) obtained in Reference Example 307 was treated by a method similar to that in Example 203 to give the title compound (169 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 238

(R)-N-benzyl-1-(6-cyclopentyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 308 was treated by a method similar to that in Example 203 to give the title compound (340 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 239

(R)-N-benzyl-1-(6-methyl-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)piperidine-2-carboxamide

The compound (350 mg) obtained in Reference Example 309 was treated by a method similar to that in Example 203 to give the title compound (104 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 240

(R)-N-benzyl-1-(6-ethyl-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 311 was treated by a method similar to that in Example 203 to give the title compound (256 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 241

(R)-N-benzyl-1-[6-(2-methoxyethyl)-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (6.10 g) obtained in Reference Example 312 was treated by a method similar to that in Example 203 to give the title compound (5.30 g).

MS (ESI) m/z; 482 [M+H] +

›Example 242

(R)-1-[6-(2-methoxyethyl)-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (91 mg) obtained in Reference Example 312 was treated by a method similar to that in Example 203 to give the title compound (71 mg).

MS (ESI) m/z; 496 [M+H] +

›Example 243

(R)-N-benzyl-1-{6-[1-(methoxymethyl)cyclopropyl]-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (210 mg) obtained in Reference Example 314 was treated by a method similar to that in Example 203 to give the title compound (195 mg).

MS (ESI) m/z; 508 [M+H] +

›Example 244

(R)-N-benzyl-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (6.04 g) obtained in Reference Example 315 was treated by a method similar to that in Example 203 to give the title compound (6.51 g).

MS (ESI) m/z; 508 [M+H] +

›Example 245

(R)-N-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (12.0 g) obtained in Reference Example 315 was treated by a method similar to that in Example 203 to give the title compound (9.09 g).

MS (ESI) m/z; 522 [M+H] +

›Example 246

(R)-N-(4-fluorobenzyl)-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 315 was treated by a method similar to that in Example 203 to give the title compound (190 mg).

MS (ESI) m/z; 526 [M+H] +

›Example 247

(R)-N-benzyl-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (185 mg) obtained in Reference Example 315 was treated by a method similar to that in Example 203 to give the title compound (100 mg).

MS (ESI) m/z; 494 [M+H] +

›Example 248

(R)-N-(2-methylbenzyl)-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (185 mg) obtained in Reference Example 315 was treated by a method similar to that in Example 203 to give the title compound (95 mg).

MS (ESI) m/z; 508 [M+H] +

›Example 249

(R)-1-[7-oxo-6-(tetrahydro-2H-pyran-4-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)azetidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 315 was treated by a method similar to that in Example 203 to give the title compound (98 mg).

MS (ESI) m/z; 508 [M+H] +

›Example 250

(R)-N-benzyl-1-[7-oxo-6-((R)-tetrahydrofuran-3-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidine2-yl]pyrrolidine-2-carboxamide

The compound (380 mg) obtained in Reference Example 317 was treated by a method similar to that in Example 203 to give the title compound (330 mg).

MS (ESI) m/z; 494 [M+H] +

›Example 251

(R)-N-benzyl-1-[6-(oxetan-3-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (260 mg) obtained in Reference Example 318 was treated by a method similar to that in Example 203 to give the title compound (110 mg).

MS (ESI) m/z; 480 [M+H] +

›Example 252

(R)-N-benzyl-1-[7-oxo-6-(pyrrolidin-1-yl)-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (280 mg) obtained in Reference Example 319 was treated by a method similar to that in Example 203 to give the title compound (210 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 253

(R)-N-benzyl-1-[6-(morpholin-4-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (290 mg) obtained in Reference Example 320 was treated by a method similar to that in Example 203 to give the title compound (200 mg).

MS (ESI) m/z; 509 [M+H] +

›Example 254

(R)-N-benzyl-1-{5-difluoromethyl-7-oxo-6-[(tetrahydro-2H-pyran-4-yl)methyl]-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 328 was treated by a method similar to that in Example 203 to give the title compound (190 mg).

MS (ESI) m/z; 504 [M+H] +

›Example 255

(R)-1-{5-difluoromethyl-7-oxo-6-[(tetrahydro-2H-pyran-4-yl)methyl]-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl}-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 328 was treated by a method similar to that in Example 203 to give the title compound (300 mg).

MS (ESI) m/z; 518 [M+H] +

›Example 256

(R)-N-benzyl-1-(6-cyclopentyl-5-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)azetidine-2-carboxamide

The compound (137 mg) obtained in Reference Example 337 was treated by a method similar to that in Example 203 to give the title compound (66 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 257

(R)-N-benzyl-1-[6-methyl-7-oxo-5-((RS)-tetrahydrofuran-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

A mixture of the compound (260 mg) obtained in Reference Example 271, the compound (630 mg) obtained in Reference Example 341 and N,N-diisopropylethylamine (1.00 g) was heated at 150° C. for 4 hr. 1.0 mol/L Hydrochloric acid was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10), to the obtained product was added diethyl ether, and the solid was collected by filtration to give the title compound (115 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 258

(R)-N-benzyl-1-[6-cyclopropyl-5-methoxymethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (263 mg) obtained in Reference Example 273 was treated by a method similar to that in Example 257 to give the title compound (277 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 259

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 281 was treated by a method similar to that in Example 257 to give the title compound (215 mg).

MS (ESI) m/z; 454 [M+H] +

›Example 260

(R)-N-benzyl-1-[6-(2-methoxyethyl)-5-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 295 was treated by a method similar to that in Example 257 to give the title compound (100 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 261

(R)-N-benzyl-1-[5-(1-cyanocyclopentyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (155 mg) obtained in Reference Example 297 was treated by a method similar to that in Example 257 to give the title compound (140 mg).

MS (ESI) m/z; 463 [M+H] +

›Example 262

(R)-N-benzyl-1-(5-methoxymethyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (242 mg) obtained in Reference Example 302 was treated by a method similar to that in Example 257 to give the title compound (146 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 263

(R)-N-benzyl-1-[6-methyl-7-oxo-5-((RS)-tetrahydrofuran-3-yl)-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 322 was treated by a method similar to that in Example 257 to give the title compound (95 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 264

(R)-N-benzyl-1-[6-(1-methylpiperidin-4-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (220 mg) obtained in Reference Example 332 was treated by a method similar to that in Example 257 to give the title compound (95 mg).

MS (ESI) m/z; 521 [M+H] +

›Example 265

(R)-N-[dideuterio(phenyl)methyl]-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (6.0 mL) of the compound (233 mg) obtained in Reference Example 268 in DMF were added (D)-proline (110 mg) and cesium carbonate (479 mg), and the reaction mixture was stirred with heating at 70° C. for 1 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid. N,N-diisopropylethylamine (223 μL), benzyl-α, α-D 2 -amine (140 mg), EDC hydrochloride (245 mg) and HOBt monohydrate (196 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (210 mg).

MS (ESI) m/z; 448 [M+H] +

›Example 266

(R)-N-benzyl-1-[5-(1,1-difluoroethyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (327 mg) obtained in Reference Example 276 was treated by a method similar to that in Example 265 to give the title compound (389 mg).

MS (ESI) m/z; 434 [M+H] +

›Example 267

(R)-1-[5-(1,1-difluoroethyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (194 mg) obtained in Reference Example 276 was treated by a method similar to that in Example 265 to give the title compound (226 mg).

MS (ESI) m/z; 448 [M+H] +

›Example 268

(R)-N-benzyl-1-[5-(1-fluorocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (220 mg) obtained in Reference Example 277 was treated by a method similar to that in Example 265 to give the title compound (225 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 269

(R)-N-benzyl-1-[5-(1-chlorocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (54 mg) obtained in Reference Example 278 was treated by a method similar to that in Example 265 to give the title compound (54 mg).

MS (ESI) m/z; 444, 446 [M+H] +

›Example 270

(R)-1-[5-(1-fluorocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (153 mg) obtained in Reference Example 277 was treated by a method similar to that in Example 265 to give the title compound (166 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 271

(R)-1-[5-(1-chlorocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (38 mg) obtained in Reference Example 278 was treated by a method similar to that in Example 265 to give the title compound (44 mg).

MS (ESI) m/z; 458, 460 [M+H] +

›Example 272

(R)-N-benzyl-1-[5-(1,1-difluoropropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (254 mg) obtained in Reference Example 279 was treated by a method similar to that in Example 265 to give the title compound (303 mg).

MS (ESI) m/z; 448 [M+H] +

›Example 273

(R)-N-benzyl-1-{5-[difluoro(pyridin-2-yl)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (500 mg) obtained in Reference Example 280 was treated by a method similar to that in Example 265 to give the title compound (472 mg).

MS (ESI) m/z; 497 [M+H] +

›Example 274

(R)-1-{5-[difluoro(pyridin-2-yl)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (356 mg) obtained in Reference Example 280 was treated by a method similar to that in Example 265 to give the title compound (328 mg).

MS (ESI) m/z; 511 [M+H] +

›Example 275

(R)-N-benzyl-1-[5-(1,1-difluoro-2-methoxyethyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (129 mg) obtained in Reference Example 282 was treated by a method similar to that in Example 265 to give the title compound (152 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 276

(R)-N-benzyl-1-{6-ethyl-5-[2-(methylsulfonyl)phenyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (157 mg) obtained in Reference Example 283 was treated by a method similar to that in Example 265 to give the title compound (125 mg).

MS (ESI) m/z; 538 [M+H] +

›Example 277

1-{6-ethyl-5-[2-(methylsulfonyl)phenyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (146 mg) obtained in Reference Example 283 was treated by a method similar to that in Example 265 to give the title compound (120 mg).

MS (ESI) m/z; 552 [M+H] +

›Example 278

(R)-1-(6-ethyl-7-oxo-5-pyrimidin-2-yl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl) pyrrolidine-2-carboxamide

The compound (251 mg) obtained in Reference Example 284 was treated by a method similar to that in Example 265 to give the title compound (117 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 279

(R)-N-benzyl-1-[5-(1,1-difluoro-2-methoxyethyl)-6-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (135 mg) obtained in Reference Example 294 was treated by a method similar to that in Example 265 to give the title compound (135 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 280

(R)-N-benzyl-1-[6-ethyl-7-oxo-5-(pyridin-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 330 was treated by a method similar to that in Example 265 to give the title compound (371 mg).

MS (ESI) m/z; 461 [M+H] +

›Example 281

(R)-N-benzyl-1-(5-difluoromethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (247 mg) obtained in Reference Example 310 was treated by a method similar to that in Example 265 to give the title compound (333 mg).

MS (ESI) m/z; 420 [M+H] +

›Example 282

(R)-1-(5-difluoromethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 310 was treated by a method similar to that in Example 265 to give the title compound (253 mg).

MS (ESI) m/z; 434 [M+H] +

›Example 283

(R)-1-[5-difluoromethyl-6-(2-methoxyethyl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (317 mg) obtained in Reference Example 313 was treated by a method similar to that in Example 265 to give the title compound (284 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 284

(R)-1-[5-difluoromethyl-6-(2-methoxyethyl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-(4-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 313 was treated by a method similar to that in Example 265 to give the title compound (283 mg).

MS (ESI) m/z; 482 [M+H] +

›Example 285

(R)-N-benzyl-1-[6-ethyl-5-(3-fluoropyridin-4-yl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (400 mg) obtained in Reference Example 323 was treated by a method similar to that in Example 265 to give the title compound (311 mg).

MS (ESI) m/z; 479 [M+H] +

›Example 286

(R)-N-benzyl-1-[6-ethyl-5-(4-fluoropyridin-2-yl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 324 was treated by a method similar to that in Example 265 to give the title compound (114 mg).

MS (ESI) m/z; 479 [M+H] +

›Example 287

(R)-1-[6-ethyl-5-(4-fluoropyridin-2-yl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 324 was treated by a method similar to that in Example 265 to give the title compound (113 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 288

(R)-N-benzyl-1-[5-(4-chloropyridin-2-yl)-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (140 mg) obtained in Reference Example 325 was treated by a method similar to that in Example 265 to give the title compound (147 mg).

MS (ESI) m/z; 495, 497 [M+H] +

›Example 289

(R)-N-benzyl-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (12.1 g) obtained in Reference Example 327 was treated by a method similar to that in Example 265 to give the title compound (12.4 g).

MS (ESI) m/z; 434 [M+H] +

›Example 290

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 327 was treated by a method similar to that in Example 265 to give the title compound (287 mg).

MS (ESI) m/z; 448 [M+H] +

›Example 291

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(4-fluorophenyl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 327 was treated by a method similar to that in Example 265 to give the title compound (314 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 292

(R)-N-benzyl-2-{[N′-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N′-methyl]amino}propionamide

The compound (200 mg) obtained in Reference Example 327 was treated by a method similar to that in Example 265 to give the title compound (150 mg).

MS (ESI) m/z; 422 [M+H] +

›Example 293

(R)-N-benzyl-2-[N′-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)amino]propionamide

The compound (200 mg) obtained in Reference Example 327 was treated by a method similar to that in Example 265 to give the title compound (89 mg).

MS (ESI) m/z; 408 [M+H] +

›Example 294

(R)-N-benzyl-1-{6-[3-(N′,N′-dimethylamino)propyl]-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (190 mg) obtained in Reference Example 331 was treated by a method similar to that in Example 265 to give the title compound (90 mg).

MS (ESI) m/z; 509 [M+H] +

›Example 295

(R)-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

To a solution (3.0 mL) of the compound (172 mg) obtained in Reference Example 268 in DMF were added (D)-proline (89 mg) and potassium carbonate (143 mg), and the reaction mixture was heated at 70° C. for 3 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (173 μL). N,N-diisopropylethylamine (135 μL), (R)-N-benzyl-1-phenylethylamine (139 μL), EDC hydrochloride (149 mg) and HOBt monohydrate (119 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (167 mg).

MS (ESI) m/z; 460 [M+H] +

›Example 296

(R)-N-benzyl-1-{6-[(oxetan-3-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (90 mg) obtained in Reference Example 321 was treated by a method similar to that in Example 295 to give the title compound (72 mg).

MS (ESI) m/z; 494 [M+H] +

›Example 297

(R)-1-{6-[(oxetan-3-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl}-N-((R)-1-phenylethyl) pyrrolidine-2-carboxamide

The compound (90 mg) obtained in Reference Example 321 was treated by a method similar to that in Example 295 to give the title compound (59 mg).

MS (ESI) m/z; 508 [M+H] +

›Example 298

(R)-N-benzyl-1-[5-(3-fluoropyridin-2-yl)-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (213 mg) obtained in Reference Example 329 was treated by a method similar to that in Example 295 to give the title compound (185 mg).

MS (ESI) m/z; 465 [M+H] +

›Example 299

(R)-N-[(R)-cyclopropyl(phenyl)methyl]-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (4.0 mL) of the compound (200 mg) obtained in Reference Example 124 in DMF were added (R)-cyclopropylphenylmethylamine hydrochloride (160 mg), N,N-diisopropylethylamine (304 μL), EDC hydrochloride (167 mg) and HOBt monohydrate (133 mg), and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-20/80) to give the title compound (225 mg).

MS (ESI) m/z; 474 [M+H] +

›Example 300

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((S)-2-methoxy-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 299 to give the title compound (197 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 301

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-N-((S)-2,2,2-trifluoro-1-phenylethyl)-2-carboxamide

The compound (200 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 299 to give the title compound (201 mg).

MS (ESI) m/z; 502 [M+H] +

›Example 302

(R)-N-(3-cyanobenzyl)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (0.5 mL) of the compound (48 mg) obtained in Reference Example 124 in DMF were added 3-cyanobenzylamine (16 mg), EDC hydrochloride (35 mg), HOBt monohydrate (24 mg) and N,N-diisopropylethylamine (23 mg), and the reaction mixture was stirred at room temperature for 3 hr. After confirmation of the completion of the reaction, water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The solvent was evaporated under reduced pressure, and the residue was purified by Waters XTerra® column (solvent; 10 mmol/L aqueous ammonium carbonate solution/methanol) to give the title compound (21 mg).

MS (ESI) m/z; 459 [M+H] +

›Example 303

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[(2,3-dihydrobenzofuran-5-yl)methyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (36 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 304

(R)-N-[(benzo[1,3]dioxo-5-yl)methyl]-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (43 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 305

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(3-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (43 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 306

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[4-(N′,N′-dimethylamino)benzyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (41 mg).

MS (ESI) m/z; 477 [M+H] +

›Example 307

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[(furan-2-yl)methyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (43 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 308

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(4-methoxybenzyl)pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (43 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 309

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[(thiophen-2-yl)methyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (46 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 310

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(3,4-dimethoxybenzyl)pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (29 mg).

MS (ESI) m/z; 494 [M+H] +

›Example 311

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[(5-methyl-isoxazol-3-yl)methyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (39 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 312

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-(2-fluorobenzyl)pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (44 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 313

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[(2,5-dimethyl-2H-pyrazol-3-yl)methyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (45 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 314

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[(1,3-thiazol-2-yl)methyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (44 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 315

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[3-(N′,N′-dimethylamino) benzyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (44 mg).

MS (ESI) m/z; 477 [M+H] +

›Example 316

(R)-N-(4-cyanobenzyl)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (40 mg).

MS (ESI) m/z; 459 [M+H] +

›Example 317

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[2-(N′,N′-dimethylamino)benzyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (47 mg).

MS (ESI) m/z; 477 [M+H] +

›Example 318

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-{2-[(N′,N′-dimethylamino)methyl]benzyl}pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (49 mg).

MS (ESI) m/z; 491 [M+H] +

›Example 319

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[2-(methoxymethyl)benzyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (31 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 320

(R)-1-(5-difluoromethyl-6-ethyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-[4-(methoxymethyl)benzyl]pyrrolidine-2-carboxamide

The compound (48 mg) obtained in Reference Example 124 was treated by a method similar to that in Example 302 to give the title compound (48 mg).

MS (ESI) m/z; 478 [M+H] +

›Example 321

(R)-N-benzyl-1-{5-[(3-methoxyazetidin-1-yl)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (148 mg) obtained in Reference Example 355 was treated by a method similar to that in Example 178 to give the title compound (18 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 322

(R)-N-benzyl-1-{6-methyl-5-[(morpholin-4-yl)methyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (68 mg) obtained in Reference Example 351 was treated by a method similar to that in Example 257 to give the title compound (51 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 323

(R)-N-benzyl-1-{5-[(N′,N′-dimethylamino)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (306 mg) obtained in Reference Example 352 was treated by a method similar to that in Example 257 to give the title compound (252 mg).

MS (ESI) m/z; 427 [M+H] +

›Example 324

(R)-N-benzyl-1-{6-methyl-7-oxo-5-[(pyrrolidin-1-yl)methyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (346 mg) obtained in Reference Example 356 was treated by a method similar to that in Example 257 to give the title compound (217 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 325

(R)-N-benzyl-1-{6-methyl-7-oxo-5-[(piperidin-1-yl)methyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (359 mg) obtained in Reference Example 357 was treated by a method similar to that in Example 257 to give the title compound (357 mg).

MS (ESI) m/z; 467 [M+H] +

›Example 326

(R)-N-benzyl-1-{5-[(N′-ethyl-N′-methylamino)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (206 mg) obtained in Reference Example 353 was treated by a method similar to that in Example 295 to give the title compound (110 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 327

(R)-1-{5-[(azetidin-1-yl)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}-N-benzylpyrrolidine-2-carboxamide

The compound (227 mg) obtained in Reference Example 354 was treated by a method similar to that in Example 295 to give the title compound (59 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 328

(R)-N-benzyl-1-{5-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (296 mg) obtained in Reference Example 358 was treated by a method similar to that in Example 295 to give the title compound (143 mg).

MS (ESI) m/z; 501 [M+H] +

›Example 329

(R)-N-benzyl-1-{5-[(N′,N′-dimethylamino)methyl]-6-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (214 mg) obtained in Reference Example 359 was treated by a method similar to that in Example 295 to give the title compound (184 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 330

(R)-N-benzyl-1-{6-ethyl-5-[(N′-ethyl-N′-methylamino)methyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (267 mg) obtained in Reference Example 360 was treated by a method similar to that in Example 295 to give the title compound (134 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 331

(R)-N-benzyl-1-{5-[(N′,N′-dimethylamino)methyl]-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (120 mg) obtained in Reference Example 361 was treated by a method similar to that in Example 295 to give the title compound (89 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 332

(R)-N-benzyl-1-[5-{[N′-(2-methoxyethyl)-N′-methylamino]methyl}-7-oxo-6-(propan-2-yl)-6, 7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (142 mg) obtained in Reference Example 362 was treated by a method similar to that in Example 295 to give the title compound (136 mg).

MS (ESI) m/z; 499 [M+H] +

›Example 333

(R)-N-benzyl-1-[6-methyl-5-{[N′-methyl-N′-(2,2,2-trifluoroethyl)amino]methyl}-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (747 mg) obtained in Reference Example 363 was treated by a method similar to that in Example 295 to give the title compound (216 mg).

MS (ESI) m/z; 495 [M+H] +

›Example 334

(R)-N-benzyl-1-[6-(2-methoxyethyl)-5-(4-methylpiperazin-1-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide hydrochloride

To a solution (4.0 mL) of the compound (174 mg) obtained in Reference Example 374 in DMF were added (D)-proline (81 mg) and cesium carbonate (344 mg), and the reaction mixture was heated at 80° C. for 2 hr. The reaction mixture was cooled to room temperature, and neutralized with concentrated hydrochloric acid (180 μL). N,N-diisopropylethylamine (163 μL), benzylamine (102 μL), EDC hydrochloride (180 mg) and HOBt monohydrate (143 mg) were added to the reaction mixture, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5). To a solution (2.0 mL) of the obtained product in ethyl acetate was added hydrogen chloride (4.0 mol/L ethyl acetate solution, 57 μL), and the mixture was stirred for 5 min. The solvent was evaporated under reduced pressure, to the residue was added ethyl acetate, and the solid was collected by filtration and dried to give the title compound (75 mg).

MS (ESI) m/z; 512 [M+H] +

›Example 335

(R)-N-benzyl-1-[5-(N′,N′-dimethylamino)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (278 mg) obtained in Reference Example 370 was treated by a method similar to that in Example 203 to give the title compound (241 mg).

MS (ESI) m/z; 413 [M+H] +

›Example 336

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(pyrrolidin-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (274 mg) obtained in Reference Example 371 was treated by a method similar to that in Example 203 to give the title compound (108 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 337

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(piperidin-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (205 mg) obtained in Reference Example 372 was treated by a method similar to that in Example 203 to give the title compound (96 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 338

(R)-N-benzyl-1-[5-(3-methoxyazetidin-1-yl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (277 mg) obtained in Reference Example 373 was treated by a method similar to that in Example 203 to give the title compound (74 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 339

(R)-N-benzyl-1-[6-methyl-5-(morpholin-4-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (214 mg) obtained in Reference Example 376 was treated by a method similar to that in Example 257 to give the title compound (166 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 340

(R)-N-benzyl-1-{5-[N′-(4-methoxybenzyl)-N′-(propan-2-yl)amino]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (49.0 mg) obtained in Reference Example 379 was treated by a method similar to that in Example 203 to give the title compound (38.0 mg).

MS (ESI) m/z; 547 [M+H] +

›Example 341

(R)-N-benzyl-1-{6-methyl-7-oxo-5-[(propan-2-yl)amino]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (98 mg) obtained in Example 340 was dissolved in a mixture of trifluoroacetic acid/water/triethylsilane=90/5/5 (v/v) (2 mL), and the mixture was stirred with heating at 65° C. for 4 hr. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10). To the obtained product was added diisopropyl ether, and the solid was collected by filtration to give the title compound (80 mg).

MS (ESI) m/z; 427 [M+H] +

›Example 342

(R)-N-benzyl-1-{6-methyl-7-oxo-5-[(propan-2-yl)oxy]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (207 mg) obtained in Reference Example 383 was treated by a method similar to that in Example 178 to give the title compound (160 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 343

(R)-N-benzyl-1-[5-ethoxy-6-(2-methoxyethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (122 mg) obtained in Reference Example 384 was treated by a method similar to that in Example 178 to give the title compound (77 mg).

MS (ESI) m/z; 458 [M+H] +

›Example 344

(R)-N-benzyl-1-{6-(2-methoxyethyl)-7-oxo-5-[(propan-2-yl)oxy]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (180 mg) obtained in Reference Example 385 was treated by a method similar to that in Example 178 to give the title compound (124 mg).

MS (ESI) m/z; 472 [M+H] +

›Example 345

(R)-N-benzyl-1-[5-(2-fluorophenyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (147 mg) obtained in Reference Example 389 was treated by a method similar to that in Example 203 to give the title compound (164 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 346

(R)-N-benzyl-1-[5-(2-methoxyphenyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (326 mg) obtained in Reference Example 390 was treated by a method similar to that in Example 203 to give the title compound (250 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 347

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(2,3,4,5,6-pentadeuteriophenyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (350 mg) obtained in Reference Example 391 was treated by a method similar to that in Example 265 to give the title compound (363 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 348

(S)-3-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}pyrrolidine-1-carboxylic acid tert-butyl ester

The compound (500 mg) obtained in Reference Example 413 was treated by a method similar to that in Example 203 to give the title compound (522 mg).

MS (ESI) m/z; 593 [M+H] +

›Example 349

(R)-3-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}pyrrolidine-1-carboxylic acid tert-butyl ester

The compound (500 mg) obtained in Reference Example 414 was treated by a method similar to that in Example 203 to give the title compound (486 mg).

MS (ESI) m/z; 593 [M+H] +

›Example 350

4-[{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}methyl]piperidine-1-carboxylic acid tert-butyl ester

The compound (2.40 g) obtained in Reference Example 415 was treated by a method similar to that in Example 203 to give the title compound (2.20 g).

MS (ESI) m/z; 521 [M+H-Boc] +

›Example 351

(RS)-3-[{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}methyl]pyrrolidine-1-carboxylic acid tert-butyl ester

The compound (1.36 g) obtained in Reference Example 416 was treated by a method similar to that in Example 203 to give the title compound (1.27 g).

MS (ESI) m/z; 507 [M+H-Boc] +

›Example 352

(S)-2-[{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}methyl]pyrrolidine-1-carboxylic acid tert-butyl ester

The compound (899 mg) obtained in Reference Example 417 was treated by a method similar to that in Example 203 to give the title compound (790 mg).

MS (ESI) m/z; 507 [M+H-Boc] +

›Example 353

(R)-2-[{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}methyl]pyrrolidine-1-carboxylic acid tert-butyl ester

The compound (1.30 g) obtained in Reference Example 418 was treated by a method similar to that in Example 203 to give the title compound (1.29 g).

MS (ESI) m/z; 507 [M+H-Boc] +

›Example 354

4-[{2-[N-((R)-1-benzylamino-1-oxopropan-2-yl)-N-methylamino]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}methyl]piperidine-1-carboxylic acid tert-butyl ester

The compound (700 mg) obtained in Reference Example 415 was treated by a method similar to that in Example 265 to give the title compound (540 mg).

MS (ESI) m/z; 509 [M+H-Boc] +

›Example 355

N-[2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-7-oxo-5-trifluoromethyl-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}ethyl]-N-methylcarbamic acid tert-butyl ester

The compound (250 mg) obtained in Reference Example 419 was treated by a method similar to that in Example 295 to give the title compound (256 mg).

MS (ESI) m/z; 581 [M+H] +

›Example 356

(R)-N-benzyl-1-[7-oxo-6-((S)-pyrrolidin-3-yl)-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (7.5 mL) of the compound (469 mg) obtained in Example 348 in methylene chloride was added trifluoroacetic acid (7.5 mL), and the reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated, aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted three times with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5), to the obtained product was added (hexane-ethyl acetate=1:1), and the solid was collected by filtration and dried to give the title compound (296 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 357

(R)-N-benzyl-1-[7-oxo-6-((R)-pyrrolidin-3-yl)-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (485 mg) obtained in Example 349 was treated is by a method similar to that in Example 356 to give the title compound (319 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 358

(R)-N-benzyl-1-{7-oxo-6-[(piperidin-4-yl)methyl]-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (2.20 g) obtained in Example 350 was treated by a method similar to that in Example 356 to give the title compound (1.75 g).

MS (ESI) m/z; 521 [M+H] +

›Example 359

(R)-N-benzyl-1-{7-oxo-6-[((RS)-pyrrolidin-3-yl)methyl]-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (950 mg) obtained in Example 351 was treated by a method similar to that in Example 356 to give the title compound (800 mg).

MS (ESI) m/z; 507 [M+H] +

›Example 360

(R)-N-benzyl-1-{7-oxo-6-[((S)-pyrrolidin-2-yl)methyl]-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (799 mg) obtained in Example 352 was treated by a method similar to that in Example 356 to give the title compound (625 mg).

MS (ESI) m/z; 507 [M+H] +

›Example 361

(R)-N-benzyl-1-{7-oxo-6-((R)-pyrrolidin-2-yl)methyl}-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (1.29 g) obtained in Example 353 was treated is by a method similar to that in Example 356 to give the title compound (653 mg).

MS (ESI) m/z; 507 [M+H] +

›Example 362

(R)-N-benzyl-2-[N′-methyl-N′-{7-oxo-6-[(piperidin-4-yl)methyl]-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}amino]propionamide

The compound (540 mg) obtained in Example 354 was treated by a method similar to that in Example 356 to give the title compound (340 mg).

MS (ESI) m/z; 509 [M+H] +

›Example 363

(R)-N-benzyl-1-[6-(2-methylaminoethyl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (256 mg) obtained in Example 355 was treated by a method similar to that in Example 356 to give the title compound (155 mg).

MS (ESI) m/z; 481 [M+H] +

›Example 364

(R)-N-benzyl-1-[6-((S)-1-methylpyrrolidin-3-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (7.0 mL) of the compound (247 mg) obtained in Example 356 in methylene chloride was added 35-38% aqueous formaldehyde solution (204 mg). The reaction mixture was stirred at room temperature for 1 hr, sodium triacetoxyborohydride (319 mg) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 17 hr. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-93/7), to the obtained product was added (hexane/ethyl acetate=1:1), and the solid was collected by filtration and dried to give the title compound (187 mg).

MS (ESI) m/z; 507 [M+H] +

›Example 365

(R)-N-benzyl-1-[6-((R)-1-methylpyrrolidin-3-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (174 mg) obtained in Example 357 was treated by a method similar to that in Example 364 to give the title compound (121 mg).

MS (ESI) m/z; 507 [M+H] +

›Example 366

(R)-N-benzyl-1-{6-[(1-methylpiperidin-4-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Example 358 was treated by a method similar to that in Example 364 to give the title compound (180 mg).

MS (ESI) m/z; 535 [M+H] +

›Example 367

(R)-N-benzyl-1-[7-oxo-6-{[1-(propan-2-yl)piperidin-4-yl]methyl}-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Example 358 was treated by a method similar to that in Example 364 to give the title compound (78.0 mg).

MS (ESI) m/z; 563 [M+H] +

›Example 368

(R)-N-benzyl-1-{6-[((RS)-1-methylpyrrolidin-3-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Example 359 was treated by a method similar to that in Example 364 to give the title compound (250 mg).

MS (ESI) m/z; 521 [M+H] +

›Example 369

(R)-N-benzyl-1-{6-[((S)-1-methylpyrrolidin-2-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (231 mg) obtained in Example 360 was treated by a method similar to that in Example 364 to give the title compound (202 mg).

MS (ESI) m/z; 521 [M+H] +

›Example 370

(R)-N-benzyl-1-{6-[((R)-1-methylpyrrolidin-2-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Example 361 was treated by a method similar to that in Example 364 to give the title compound (250 mg).

MS (ESI) m/z; 521 [M+H] +

›Example 371

(R)-N-benzyl-2-[N′-methyl-N′-{6-[(1-methylpiperidin-4-yl)methyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}amino]propionamide

The compound (270 mg) obtained in Example 362 was treated by a method similar to that in Example 364 to give the title compound (160 mg).

MS (ESI) m/z; 523 [M+H] +

›Example 372

(R)-N-benzyl-1-{6-[2-(N′,N′-dimethylamino)ethyl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (85.0 mg) obtained in Example 363 was treated by a method similar to that in Example 364 to give the title compound (75.0 mg).

MS (ESI) m/z; 495 [M+H] +

›Example 373

(R)-N-benzyl-1-[6-{2-[N′-methyl-N′-(2,2,2-trifluoroethyl)amino]ethyl}-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide hydrochloride

To a solution (6.0 mL) of the compound (300 mg) obtained in Example 363 in DMF were added N,N-diisopropylethylamine (240 mg) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (220 mg) under ice-cooling, and the reaction mixture was stirred at room temperature for 10 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=99/1-95/5). To a solution of the obtained crude product (300 mg) in acetone was added hydrogen chloride (4.0 mol/L ethyl acetate solution, 0.15 mL), and the mixture was stirred at room temperature for 10 min. The solvent was evaporated under reduced pressure, to the obtained product was added hexane, and the solid was collected by filtration and dried to give the title compound (130 mg).

MS (ESI) m/z; 563 [M+H] +

›Example 374

N-[(R)-1-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-5-yl}ethyl]-N-methylcarbamic acid tert-butyl ester

To a solution (2.8 mL) of the compound (162 mg) obtained in Reference Example 424 in DMF were added (D)-proline (72 mg) and potassium carbonate (116 mg), and the reaction mixture was heated at 80° C. for 2 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (494 μL). N,N-diisopropylethylamine (110 μL), benzylamine (92 μL), EDC hydrochloride (120 mg) and HOBt monohydrate (96 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (195 mg).

MS (ESI) m/z; 527 [M+H] +

›Example 375

N-[(S)-1-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-5-yl}ethyl]-N-methylcarbamic acid tert-butyl ester

The compound (191 mg) obtained in Reference Example 425 was treated by a method similar to that in Example 374 to give the title compound (180 mg).

MS (ESI) m/z; 527 [M+H] +

›Example 376

(R)-N-benzyl-1-{5-[(R)-1-(N′,N′-dimethylamino)ethyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (0.5 mL) of the compound (100 mg) obtained in Example 374 in methylene chloride was added trifluoroacetic acid (1 mL), and the reaction mixture was stirred at room temperature for 3 hr. The reaction mixture was concentrated, to a solution (1.6 mL) of the residue in methylene chloride were added 35-38% aqueous formaldehyde solution (65 μL) and sodium triacetoxyborohydride (101 mg), and the reaction mixture was stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted three times with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10), and the obtained crude product was purified by reversed-phase HPLC (Capcelpak C18; 0.05% trifluoroacetic acid-water/acetonitrile=55/45-45/55). To the obtained product was added diisopropyl ether, and the solid was collected by filtration to give the title compound (38 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 377

(R)-N-benzyl-1-{5-[(S)-1-(N′,N′-dimethylamino)ethyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (95 mg) obtained in Example 375 was treated by a method similar to that in Example 376 to give the title compound (54 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 378

N-[2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2,2-difluoroethyl]-N-methylcarbamic acid tert-butyl ester

To a solution (4.0 mL) of the compound (246 mg) obtained in Reference Example 427 in DMF were added (D)-proline (101 mg) and potassium carbonate (201 mg), and the reaction mixture was heated at 70° C. for 2 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (239 μL). N,N-diisopropylethylamine (202 μL), benzylamine (127 μL), EDC hydrochloride (222 mg) and HOBt monohydrate (178 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature for 8 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and is concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=20/30-0/100) to give the title compound (286 mg).

MS (ESI) m/z; 563 [M+H] +

›Example 379

(R)-N-benzyl-1-{5-[1,1-difluoro-2-(methylamino)ethyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (1.0 mL) of the compound (286 mg) obtained in Example 378 in methylene chloride was added trifluoroacetic acid (2 mL), and the reaction mixture was stirred at room temperature for 6 hr. The reaction mixture was concentrated, aqueous sodium carbonate solution was added, and the mixture was extracted three times with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10) to give the title compound (200 mg).

MS (ESI) m/z; 463 [M+H] +

›Example 380

(R)-N-benzyl-1-{5-[2-(N′,N′-dimethylamino)-1,1-difluoroethyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (1.8 mL) of the compound (100 mg) obtained in Example 379 in methylene chloride was added 35-38% aqueous formaldehyde solution (74 μL). The reaction mixture was stirred at room temperature for 1.5 hr, sodium triacetoxyborohydride (114 mg) was added to the reaction mixture, and the reaction mixture was stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10), to the obtained product was added diisopropyl ether, and the solid was collected by filtration to give the title compound (94 mg).

MS (ESI) m/z; 477 [M+H] +

›Example 381

(R)-N-benzyl-1-[6-((S)-1-hydroxypropan-2-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (4 mL) of the compound (260 mg) obtained in Reference Example 434 in DMF were added (D)-proline (132 mg) and potassium carbonate (211 mg), and the reaction mixture was heated at 80° C. for 2.5 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous sodium sulfate, and filtered. Chloroform was evaporated under reduced pressure from the filtrate, to the obtained mixture were added N,N-diisopropylethylamine (199 μL), benzylamine (125 μL), EDC hydrochloride (219 mg) and HOBt monohydrate (175 mg), and the reaction mixture was stirred at room temperature for 17 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10). To the obtained product was added ethyl acetate/hexane=3/1, and the solid was collected by filtration to give the title compound (218.8 mg).

MS (ESI) m/z; 482 [M+H] +

›Example 382

(R)-N-benzyl-1-[6-((R)-1-hydroxypropan-2-yl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (92 mg) obtained in Reference Example 435 was treated by a method similar to that in Example 381 to give the title compound (102 mg).

MS (ESI) m/z; 482 [M+H] +

›Example 383

(R)-N-benzyl-1-{6-[(S)-1-(N′,N′-dimethylamino)propan-2-yl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (8.0 mL) of the compound (215 mg) obtained in Example 381 and triethylamine (106 μL) in methylene chloride was added dropwise methanesulfonyl chloride (52 μL) under ice-cooling. After stirring at room temperature for 1.5 hr, the reaction mixture was concentrated. The obtained crude product was dissolved in acetonitrile (6.5 mL), and sodium iodide (134 mg) and dimethylamine (2.0 mol/L THF solution, 4.47 mL) were added. After stirring with heating at 65° C. for 2 hr, the reaction mixture was concentrated. To the residue was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted twice with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-93/7). To the obtained product was added ethyl acetate/hexane=1/1, and the solid was collected by filtration to give the title compound (123 mg).

MS (ESI) m/z; 509 [M+H] +

›Example 384

(R)-N-benzyl-1-{6-[(R)-1-(N′,N′-dimethylamino)propan-2-yl]-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide hydrochloride

To a solution (2.0 mL) of the compound (100 mg) obtained in Example 382 and triethylamine (76 μL) in methylene chloride was added dropwise methanesulfonyl chloride (38 μL) under ice-cooling. After stirring at room temperature for 2 hr, the reaction mixture was concentrated. The obtained crude product was dissolved in acetonitrile (3.0 mL), and sodium iodide (62 mg) and dimethylamine (2.0 mol/L THF solution, 2.08 mL) were added. After stirring with heating at 65° C. for 2 hr, the reaction mixture was concentrated. To the residue was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted twice with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-93/7). The obtained product was dissolved in ethyl acetate (2.0 mL), hydrogen chloride (4.0 mol/L ethyl acetate solution, 39 μL) was added, and the mixture was stirred for 30 min. The solvent was evaporated under reduced pressure, and the precipitated solid was collected by filtration to give the title compound (42 mg).

MS (ESI) m/z; 509 [M+H] +

›Example 385

(R)-N-benzyl-1-[5-(2-hydroxyethyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (18 mL) of the compound (750 mg) obtained in Reference Example 445 in DMF were added (D)-proline (480 mg) and potassium carbonate (760 mg), and the mixture was heated at 80° C. for 1 hr. After cooling to 0° C., concentrated hydrochloric acid (920 μL) was added and the mixture was neutralized. N,N-diisopropylethylamine (540 mg), benzylamine (600 mg), EDC hydrochloride (800 mg) and HOBt monohydrate (640 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10) to give the title compound (620 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 386

(R)-N-benzyl-1-[6-ethyl-5-(2-hydroxyethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (543 mg) obtained in Reference Example 446 was treated by a method similar to that in Example 385 to give the title compound (623 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 387

(R)-N-benzyl-1-[5-(2-hydroxyethyl)-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (446 mg) obtained in Reference Example 447 was treated by a method similar to that in Example 385 to give the title compound (577 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 388

(R)-N-benzyl-1-{5-[2-(N′,N′-dimethylamino)ethyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (8.0 mL) of the compound (480 mg) obtained in Example 385 and triethylamine (141 mg) in methylene chloride was added dropwise methanesulfonyl chloride (146 mg) under ice-cooling. Under ice-cooling, the reaction mixture was stirred for 1 hr. Chloroform was added to the reaction mixture, and the mixture was washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The obtained crude product was dissolved in acetonitrile (5.0 mL), and sodium iodide (90 mg) and dimethylamine (2.0 mol/L THF solution, 3.0 mL) were added. The reaction mixture was stirred with heating at 65° C. for 2 hr, and concentrated. To the residue was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10). To the obtained product were added ethyl acetate and hexane, and the solid was collected by filtration and dried to give the title compound (110 mg).

MS (ESI) m/z; 441 [M+H] +

›Example 389

(R)-N-benzyl-1-{6-methyl-7-oxo-5-[2-(2-piperidin-1-yl)ethyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (240 mg) obtained in Example 385 was treated by a method similar to that in Example 388 to give the title compound (105 mg).

MS (ESI) m/z; 481 [M+H] +

›Example 390

(R)-N-benzyl-1-{5-[2-(N′,N′-dimethylamino)ethyl]-6-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide hydrochloride

To a solution (1.0 mL) of the compound (60 mg) obtained in Example 386 and triethylamine (23 μL) in methylene chloride was added dropwise methanesulfonyl chloride (12 μL) under ice-cooling. Under ice-cooling, the mixture was stirred for 1.5 hr, diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The obtained crude product was dissolved in acetonitrile (1.0 mL), and sodium iodide (21 mg) and dimethylamine (2.0 mol/L THF solution, 700 μL) were added. After stirring with heating at 65° C. for 3 hr, the reaction mixture was concentrated. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10). The obtained product was dissolved in ethyl acetate (2.0 mL), and hydrogen chloride (4.0 mol/L ethyl acetate solution, 31 μL) was added. The precipitated solid was collected by filtration to give the title compound (43 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 391

(R)-N-benzyl-1-{5-[2-(N′,N′-dimethylamino)ethyl]-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide hydrochloride

The compound (100 mg) obtained in Example 387 was treated is by a method similar to that in Example 390 to give the title compound (73 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 392

(R)-N-benzyl-1-{5-[2-(methylamino)ethyl]-7-oxo-6-(propan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide hydrochloride

The compound (100 mg) obtained in Example 387 was treated by a method similar to that in Example 390 to give the title compound (37 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 393

(R)-N-benzyl-1-[6-ethyl-5-(3-hydroxypropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (10 mL) of the compound (476 mg) obtained in Reference Example 451 in DMF were added (D)-proline (273 mg) and potassium carbonate (437 mg), and the reaction mixture was heated at 80° C. for 1 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (527 μL). N,N-diisopropylethylamine (413 μL), benzylamine (345 μL), EDC hydrochloride (454 mg) and HOBt monohydrate (363 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5). To the obtained product was added diisopropyl ether, and the solid was collected by filtration to give the title compound (574 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 394

(R)-N-benzyl-1-{5-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propyl]-6-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution of the compound (50 mg) obtained in Example 393 in THF (1 mL) were added phthalimido (24 mg), triphenylphosphine (58 mg) and diisopropyl azodicarboxylate (1.9 mol/L toluene solution, 116 μL). The reaction mixture was stirred at room temperature for 1 hr, and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (57 mg).

MS (ESI) m/z; 571 [M+H] +

›Example 395

(R)-N-benzyl-1-{5-[3-(N′,N′-dimethylamino)propyl]-6-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution of the compound (57 mg) obtained in Example 394 in ethanol (1.0 mL) was added hydrazine monohydrate (49 μL), and the reaction mixture was stirred at room temperature for 6 hr. The reaction mixture was concentrated, to the residue was added methylene chloride, and the insoluble material was filtered off. The filtrate was concentrated, and the obtained crude product was dissolved in methylene chloride (1.5 mL). 35-38% Aqueous formaldehyde solution (86 μL) was added, and the reaction mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (106 mg) was added to the reaction mixture, and the reaction mixture was stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10). The obtained product was dissolved in ethyl acetate (1 mL), and hydrogen chloride (4.0 mol/L ethyl acetate solution, 30 μL) was added. The precipitated solid was collected by filtration to give the title compound (18 mg).

MS (ESI) m/z; 469 [M+H] +

›Example 396

(R)-N-benzyl-1-[6-(2-hydroxyethyl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (9 mL) of the compound (468 mg) obtained in Reference Example 453 in DMF were added (D)-proline (247 mg) and potassium carbonate (395 mg), and the reaction mixture was heated at 80° C. for 1 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted five times with chloroform. The organic layer was dried over anhydrous sodium sulfate, and filtered. Chloroform was evaporated under reduced pressure from the filtrate, to the obtained mixture were added N,N-diisopropylethylamine (374 μL), benzylamine (312 μL), EDC hydrochloride (412 mg) and HOBt monohydrate (329 mg), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted five times with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100) to give the title compound (479 mg).

MS (ESI) m/z; 468 [M+H] +

›Example 397

(R)-N-benzyl-1-[5-(1-hydroxy-2-methylpropan-2-yl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (3.0 mL) of the compound (156 mg) obtained in Reference Example 457 in DMF solution (3.0 mL) were added (D)-proline (79 mg) and potassium carbonate (126 mg), and the reaction mixture was heated at 70° C. for 3 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (150 μL). N,N-diisopropylethylamine (119 μL), benzylamine (100 μL), EDC hydrochloride (131 mg) and HOBt monohydrate (105 mg) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted twice with methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (189 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 398

(R)-N-benzyl-1-{5-[2-(hydroxymethyl)phenyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (5 mL) of the compound (340 mg) obtained in Reference Example 461 in DMF were added (D)-proline (181 mg) and potassium carbonate (580 mg), and the reaction mixture was heated at 80° C. for 1.5 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and filtered. Chloroform was evaporated under reduced pressure from the filtrate, to the obtained mixture were added N,N-diisopropylethylamine (295 μL), benzylamine (230 μL), EDC hydrochloride (403 mg) and HOBt monohydrate (322 mg), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-97/3) to give the title compound (375.2 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 399

(R)-N-benzyl-1-{5-[3-(hydroxymethyl)phenyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (192 mg) obtained in Reference Example 462 was treated by a method similar to that in Example 398 to give the title compound (142 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 400

(R)-N-benzyl-1-{5-[4-(hydroxymethyl)phenyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (136 mg) obtained in Reference Example 463 was treated by a method similar to that in Example 398 to give the title compound (155 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 401

(R)-N-benzyl-1-[5-{2-[(N′,N′-dimethylamino)methyl]phenyl}-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (3.0 mL) of the compound (150 mg) obtained in Example 398 and triethylamine (100 μL) in methylene chloride was added dropwise methanesulfonyl chloride (37 μL) under ice-cooling, and the reaction mixture was stirred under ice-cooling for 30 min. Dimethylamine (2.0 mol/L THF solution, 1.6 mL) was added, and the reaction mixture was stirred with heating at room temperature for 2 hr, and concentrated. To the residue was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-97/3) to give the title compound (154 mg).

MS (ESI) m/z; 503 [M+H] +

›Example 402

(R)-N-benzyl-1-[5-{3-[(N′,N′-dimethylamino)methyl]phenyl}-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (142 mg) obtained in Example 399 was treated by a method similar to that in Example 401 to give the title compound (60 mg).

MS (ESI) m/z; 503 [M+H] +

›Example 403

(R)-N-benzyl-1-[5-{4-[(N′,N′-dimethylamino)methyl]phenyl}-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (155 mg) obtained in Example 400 was treated by a method similar to that in Example 401 to give the title compound (74 mg).

MS (ESI) m/z; 503 [M+H] +

›Example 404

N-{[2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-5-yl}oxy]ethyl}-N-methylcarbamic acid tert-butyl ester

To a solution (9.5 mL) of the compound (1.61 g) obtained in Reference Example 465 in DMF were added (D)-proline (690 mg) and cesium carbonate (3.0 g), and the reaction mixture was heated at 70° C. for 2 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid. N,N-diisopropylethylamine (1.4 mL), benzylamine (880 μL), EDC hydrochloride (1.53 g) and HOBt monohydrate (1.23 g) were added to the reaction mixture at room temperature, and the reaction mixture was stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (542 mg).

MS (ESI) m/z; 543 [M+H] +

›Example 405

(R)-N-benzyl-1-[6-methyl-5-(2-methylaminoethoxy)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (2.0 mL) of the compound (200 mg) obtained in Example 404 in methylene chloride was added trifluoroacetic acid (2 mL), and the reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated, aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10) to give the title compound (75 mg).

MS (ESI) m/z; 443 [M+H] +

›Example 406

(R)-N-benzyl-1-{5-[2-(N′,N′-dimethylamino)ethoxy]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

To a solution (1.5 mL) of the compound (73 mg) obtained in Example 405 in methylene chloride was added 35-38% aqueous formaldehyde solution (57 μL). The reaction mixture was stirred at room temperature for 10 min, sodium triacetoxyborohydride (87 mg) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 2 hr. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted three times with methylene chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10) to give the title compound (45 mg).

MS (ESI) m/z; 457 [M+H] +

›Example 407

(R)-N-benzyl-1-[5-{2-[N-methyl-N-(propan-2-yl)amino]ethoxy}-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (47 mg) obtained in Example 405 and acetone (31 μL) were treated by a method similar to that in Example 406 to give the title compound (21 mg).

MS (ESI) m/z; 485 [M+H] +

›Example 408

(R)-N-benzyl-1-[5-((1RS)-1-hydroxyethyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (2 mL) of the compound (63 mg) obtained in Reference Example 477 in DMF were added (D)-proline (44 mg) and potassium carbonate (79 mg), and the reaction mixture was heated at 80° C. for 1 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, sodium chloride was added, and the mixture was extracted three times with chloroform. The organic layer was dried over magnesium sulfate, filtered and concentrated. The obtained residue was dissolved in DMF (2.0 mL), N,N-diisopropylethylamine (51 μL), benzylamine (31 μL), EDC hydrochloride (56 mg) and HOBt monohydrate (44 mg) were added, and the reaction mixture was stirred at room temperature for 2 hr. 0.5 mol/L Hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (46 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 409

(R)-N-benzyl-1-[5-(1-hydroxycyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (260 mg) obtained in Reference Example 478 was treated by a method similar to that in Example 408 to give the title compound (70 mg).

MS (ESI) m/z; 426 [M+H] +

›Example 410

(R)-N-benzyl-1-[5-(1-hydroxycyclobutyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (156 mg) obtained in Reference Example 479 was treated by a method similar to that in Example 408 to give the title compound (100 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 411

(R)-1-(5-acetyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-benzylpyrrolidine-2-carboxamide

To a solution (2 mL) of the compound (100 mg) obtained in Example 408 in chloroform was added manganese dioxide (210 mg), and the reaction mixture was stirred at 60° C. for 9 hr. Manganese dioxide (210 mg) was added, and the reaction mixture was heated at 60° C. for 4 hr. The reaction mixture was filtered through diatomaceous earth, the filtrate was concentrated, and the residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100). To the obtained product was added diisopropyl ether, and the solid was collected by filtration to give the title compound (78 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 412

(R)-N-benzyl-1-[5-(1-methoxycyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 482 was treated by a method similar to that in Example 408 to give the title compound (220 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 413

(R)-N-benzyl-1-[5-(1-methoxycyclobutyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (383 mg) obtained in Reference Example 483 was treated by a method similar to that in Example 408 to give the title compound (280 mg).

MS (ESI) m/z; 454 [M+H] +

›Example 414

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (10.0 mL) of the compound (400 mg) obtained in Reference Example 558 in DMF were added (D)-proline (162 mg) and cesium carbonate (704 mg), and the reaction mixture was stirred with heating at 70° C. for 1 hr. The reaction mixture was cooled to room temperature, and neutralized with 1.0 mol/L hydrochloric acid. To the obtained mixture were added N,N-diisopropylethylamine (0.327 mL), benzylamine (0.206 mL), EDC hydrochloride (360 mg) and HOBt monohydrate (288 mg), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted three times with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-20/80) to give the title compound (474 mg).

MS (ESI) m/z; 566 [M+H] +

›Example 415

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 558 was treated by a method similar to that in Example 178 to give the title compound (62 mg).

MS (ESI) m/z; 580 [M+H] +

›Example 416

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(propan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (500 mg) obtained in Reference Example 560 was treated by a method similar to that in Example 178 to give the title compound (500 mg).

MS (ESI) m/z; 534 [M+H] +

›Example 417

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(propan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (500 mg) obtained in Reference Example 560 was treated by a method similar to that in Example 178 to give the title compound (111 mg).

MS (ESI) m/z; 562 [M+H] +

›Example 418

(R)-N-benzyl-2-{N′-[6-(2,4-dimethoxybenzyl)-5-(propan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (500 mg) obtained in Reference Example 560 was treated by a method similar to that in Example 178 to give the title compound (352 mg).

MS (ESI) m/z; 536 [M+H] +

›Example 419

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (160 mg) obtained in Reference Example 562 was treated by a method similar to that in Example 178 to give the title compound (146 mg).

MS (ESI) m/z; 582 [M+H] +

›Example 420

(R)-1-[6-(2,4-dimethoxybenzyl)-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (160 mg) obtained in Reference Example 562 was treated by a method similar to that in Example 178 to give the title compound (144 mg).

MS (ESI) m/z; 596 [M+H] +

›Example 421

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-y]pyrrolidine-2-carboxamide

The compound (391 mg) obtained in Reference Example 563 was treated by a method similar to that in Example 178 to give the title compound (298 mg).

MS (ESI) m/z; 600 [M+H] +

›Example 422

(R)-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (391 mg) obtained in Reference Example 563 was treated by a method similar to that in Example 178 to give the title compound (348 mg).

MS (ESI) m/z; 614 [M+H] +

›Example 423

(R)-N-benzyl-1-[6-(2, 4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (570 mg) obtained in Reference Example 563 was treated by a method similar to that in Example 178 to give the title compound (45 mg).

MS (ESI) m/z; 586 [M+H] +

›Example 424

(R)-N-benzyl-1-[6-(2, 4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 563 was treated by a method similar to that in Example 178 to give the title compound (95 mg).

MS (ESI) m/z; 614 [M+H] +

›Example 425

(R)-N-benzyl-1-[5-(2-chlorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (274 mg) obtained in Reference Example 564 was treated by a method similar to that in Example 178 to give the title compound (200 mg).

MS (ESI) m/z; 616, 618 [M+H] +

›Example 426

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (159 mg) obtained in Reference Example 565 was treated by a method similar to that in Example 178 to give the title compound (100 mg).

MS (ESI) m/z; 612 [M+H] +

›Example 427

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (159 mg) obtained in Reference Example 565 was treated by a method similar to that in Example 178 to give the title compound (116 mg).

MS (ESI) m/z; 626 [M+H] +

›Example 428

(R)-N-benzyl-1-{6-(2,4-dimethoxybenzyl)-7-oxo-5-[2-(trifluoromethoxy)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (645 mg) obtained in Reference Example 566 was treated by a method similar to that in Example 178 to give the title compound (485 mg).

MS (ESI) m/z; 666 [M+H] +

›Example 429

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (652 mg) obtained in Reference Example 567 was treated by a method similar to that in Example 178 to give the title compound (507 mg).

MS (ESI) m/z; 596 [M+H] +

›Example 430

(R)-N-benzyl-1-[5-(2,4-difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (287 mg) obtained in Reference Example 568 was treated by a method similar to that in Example 178 to give the title compound (285 mg).

MS (ESI) m/z; 618 [M+H] +

›Example 431

(R)-1-[5-(2,4-difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (287 mg) obtained in Reference Example 568 was treated by a method similar to that in Example 178 to give the title compound (300 mg).

MS (ESI) m/z; 632 [M+H] +

›Example 432

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(5-methylthiophen-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (265 mg) obtained in Reference Example 577 was treated by a method similar to that in Example 178 to give the title compound (304 mg).

MS (ESI) m/z; 602 [M+H] +

›Example 433

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(3-fluoro-5-methylthiophen-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (408 mg) obtained in Reference Example 583 was treated by a method similar to that in Example 178 to give the title compound (442 mg).

MS (ESI) m/z; 620 [M+H] +

›Example 434

(R)-N-benzyl-1-[5-(3-benzenesulfonyl-1,1-difluoropropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (440 mg) obtained in Reference Example 585 was treated by a method similar to that in Example 178 to give the title compound (359 mg).

MS (ESI) m/z; 724 [M+H] +

›Example 435

(R)-N-benzyl-1-[5-(l-chlorocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (240 mg) obtained in Reference Example 586 was treated by a method similar to that in Example 178 to give the title compound (191 mg).

MS (ESI) m/z; 566 [M+H] +

›Example 436

(R)-N-benzyl-1-[5-(1-chlorocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 586 was treated by a method similar to that in Example 178 to give the title compound (171 mg).

MS (ESI) m/z; 594 [M+H] +

›Example 437

(R)-N-benzyl-1-[5-(3-fluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (165 mg) obtained in Reference Example 591 was treated by a method similar to that in Example 178 to give the title compound (129 mg).

MS (ESI) m/z; 570 [M+H] +

›Example 438

(R)-N-benzyl-1-[5-(4-fluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (101 mg) obtained in Reference Example 592 was treated by a method similar to that in Example 178 to give the title compound (63 mg).

MS (ESI) m/z; 570 [M+H] +

›Example 439

(R)-N-benzyl-1-[5-(2,5-difluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (284 mg) obtained in Reference Example 594 was treated by a method similar to that in Example 178 to give the title compound (294 mg).

MS (ESI) m/z; 588 [M+H] +

›Example 440

(R)-N-benzyl-1-[5-(3, 4-difluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Reference Example 595 was treated by a method similar to that in Example 178 to give the title compound (197 mg).

MS (ESI) m/z; 588 [M+H] +

›Example 441

(R)-N-benzyl-1-[5-(3, 5-difluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (225 mg) obtained in Reference Example 596 was treated by a method similar to that in Example 178 to give the title compound (143 mg).

MS (ESI) m/z; 588 [M+H] +

›Example 442

(R)-N-benzyl-1-[5-(4-fluoro-2-methoxyphenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (159 mg) obtained in Reference Example 597 was treated by a method similar to that in Example 178 to give the title compound (136 mg).

MS (ESI) m/z; 600 [M+H] +

›Example 443

(R)-N-benzyl-1-[5-(2-ethylphenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (238 mg) obtained in Reference Example 598 was treated by a method similar to that in Example 178 to give the title compound (254 mg).

MS (ESI) m/z; 580 [M+H] +

›Example 444

(R)-N-benzyl-1-{6-(4-methoxybenzyl)-7-oxo-5-[2-(trifluoromethyl)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (164 mg) obtained in Reference Example 599 was treated by a method similar to that in Example 178 to give the title compound (130 mg).

MS (ESI) m/z; 620 [M+H] +

›Example 445

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (341 mg) obtained in Reference Example 559 was treated by a method similar to that in Example 203 to give the title compound (418 mg).

MS (ESI) m/z; 534 [M+H] +

›Example 446

(R)-N-benzyl-1-[5-(5-chloro-2-fluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (511 mg) obtained in Reference Example 569 was treated by a method similar to that in Example 203 to give the title compound (515 mg).

MS (ESI) m/z; 634, 636 [M+H] +

›Example 447

(R)-N-benzyl-2-{N′-[6-(2,4-dimethoxybenzyl)-5-(1-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (300 mg) obtained in Reference Example 578 was treated by a method similar to that in Example 203 to give the title compound (259 mg).

MS (ESI) m/z; 564 [M+H] +

›Example 448

(R)-N-benzyl-1-{6-(2,4-dimethoxybenzyl)-5-[1-(fluoromethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (400 mg) obtained in Reference Example 579 was treated by a method similar to that in Example 203 to give the title compound (467 mg).

MS (ESI) m/z; 578 [M+H] +

›Example 449

(R)-N-benzyl-1-{6-(2,4-dimethoxybenzyl)-5-[1-(methoxymethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (400 mg) obtained in Reference Example 580 was treated by a method similar to that in Example 203 to give the title compound (480 mg).

MS (ESI) m/z; 590 [M+H] +

›Example 450

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluoro-5-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (525 mg) obtained in Reference Example 581 was treated by a method similar to that in Example 203 to give the title compound (542 mg).

MS (ESI) m/z; 614 [M+H] +

›Example 451

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(3-fluoropyridin-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (342 mg) obtained in Reference Example 582 was treated by a method similar to that in Example 203 to give the title compound (355 mg).

MS (ESI) m/z; 601 [M+H] +

›Example 452

(R)-N-benzyl-1-[5-(3-chloro-2-fluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (570 mg) obtained in Reference Example 587 was treated by a method similar to that in Example 203 to give the title compound (431 mg).

MS (ESI) m/z; 634, 636 [M+H] +

›Example 453

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (528 mg) obtained in Reference Example 588 was treated by a method similar to that in Example 203 to give the title compound (534 mg).

MS (ESI) m/z; 574 [M+H] +

›Example 454

(R)-1-[6-(2,4-dimethoxybenzyl)-7-oxo-5-trifluoromethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (415 mg) obtained in Reference Example 588 was treated by a method similar to that in Example 203 to give the title compound (455 mg).

MS (ESI) m/z; 588 [M+H] +

›Example 455

(R)-N-benzyl-1-[5-(2,3-difluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (187 mg) obtained in Reference Example 593 was treated by a method similar to that in Example 203 to give the title compound (220 mg).

MS (ESI) m/z; 588 [M+H] +

›Example 456

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-methoxymethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (282 mg) obtained in Reference Example 561 was treated by a method similar to that in Example 265 to give the title compound (219 mg).

MS (ESI) m/z; 550 [M+H] +

›Example 457

(R)-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Reference Example 558 was treated by a method similar to that in Example 265 to give the title compound (232 mg).

MS (ESI) m/z; 580 [M+H] +

›Example 458

(R)-N-benzyl-2-{N′-[6-(2,4-dimethoxybenzyl)-5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (300 mg) obtained in Reference Example 558 was treated by a method similar to that in Example 265 to give the title compound (271 mg).

MS (ESI) m/z; 554 [M+H] +

›Example 459

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (369 mg) obtained in Reference Example 570 was treated by a method similar to that in Example 265 to give the title compound (457 mg).

MS (ESI) m/z; 564 [M+H] +

›Example 460

(R)-1-[6-(2,4-dimethoxybenzyl)-5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (255 mg) obtained in Reference Example 570 was treated by a method similar to that in Example 265 to give the title compound (296 mg).

MS (ESI) m/z; 578 [M+H] +

›Example 461

(R)-N-benzyl-1-[5-(1-chlorocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (127 mg) obtained in Reference Example 586 was treated by a method similar to that in Example 265 to give the title compound (117 mg).

MS (ESI) m/z; 581 [M+H] +

›Example 462

(R)-1-[5-(1-chlorocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (88 mg) obtained in Reference Example 586 was treated by a method similar to that in Example 265 to give the title compound (76 mg).

MS (ESI) m/z; 595 [M+H] +

›Example 463

(R)-N-benzyl-1-[5-(1,1-difluoroethyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (528 mg) obtained in Reference Example 571 was treated by a method similar to that in Example 265 to give the title compound (498 mg).

MS (ESI) m/z; 570 [M+H] +

›Example 464

(R)-1-[5-(1,1-difluoroethyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (570 mg) obtained in Reference Example 571 was treated by a method similar to that in Example 265 to give the title compound (596 mg).

MS (ESI) m/z; 584 [M+H] +

›Example 465

(R)-N-benzyl-1-[5-(1,1-difluoro-2-methoxyethyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (1.05 g) obtained in Reference Example 572 was treated by a method similar to that in Example 265 to give the title compound (956 mg).

MS (ESI) m/z; 600 [M+H] +

›Example 466

(R)-1-[5-(1, l-difluoro-2-methoxyethyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (250 mg) obtained in Reference Example 572 was treated by a method similar to that in Example 265 to give the title compound (198 mg).

MS (ESI) m/z; 614 [M+H] +

›Example 467

(R)-N-benzyl-1-{6-(2,4-dimethoxybenzyl)-7-oxo-5-[1-(trifluoromethyl)cyclopropyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (600 mg) obtained in Reference Example 573 was treated by a method similar to that in Example 265 to give the title compound (636 mg).

MS (ESI) m/z; 614 [M+H] +

›Example 468

(R)-N-benzyl-2-[N′-{6-(2,4-dimethoxybenzyl)-7-oxo-5-[1-(trifluoromethyl)cyclopropyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}-N′-methylamino]propionamide

The compound (470 mg) obtained in Reference Example 573 was treated by a method similar to that in Example 265 to give the title compound (351 mg).

MS (ESI) m/z; 602 [M+H] +

›Example 469

(R)-N-benzyl-1-{5-[difluoro(phenyl)methyl]-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (187 mg) obtained in Reference Example 574 was treated by a method similar to that in Example 265 to give the title compound (190 mg).

MS (ESI) m/z; 632 [M+H] +

›Example 470

(R)-1-[5-(difluoro(phenyl)methyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (91 mg) obtained in Reference Example 574 was treated by a method similar to that in Example 265 to give the title compound (86 mg).

MS (ESI) m/z; 646 [M+H] +

›Example 471

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluoro-3-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (695 mg) obtained in Reference Example 575 was treated by a method similar to that in Example 265 to give the title compound (666 mg).

MS (ESI) m/z; 630 [M+H] +

›Example 472

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-5-(2-fluoro-3-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (607 mg) obtained in Reference Example 576 was treated by a method similar to that in Example 265 to give the title compound (642 mg).

MS (ESI) m/z; 614 [M+H] +

›Example 473

(R)-N-benzyl-1-[6-(2,4-dimethoxybenzyl)-7-oxo-5-pentafluoroethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (115 mg) obtained in Reference Example 584 was treated by a method similar to that in Example 265 to give the title compound (90 mg).

MS (ESI) m/z; 624 [M+H] +

›Example 474

(R)-1-[6-(2,4-dimethoxybenzyl)-7-oxo-5-pentafluoroethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (115 mg) obtained in Reference Example 584 was treated by a method similar to that in Example 265 to give the title compound (94 mg).

MS (ESI) m/z; 638 [M+H] +

›Example 475

(R)-N-benzyl-2-{N′-[6-(2,4-dimethoxybenzyl)-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (554 mg) obtained in Reference Example 562 was treated by a method similar to that in Example 265 to give the title compound (296 mg).

MS (ESI) m/z; 570 [M+H] +

›Example 476

(R)-N-benzyl-2-{N′-[6-(2,4-dimethoxybenzyl)-5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (850 mg) obtained in Reference Example 563 was treated by a method similar to that in Example 265 to give the title compound (550 mg).

MS (ESI) m/z; 588 [M+H] +

›Example 477

(R)-N-benzyl-2-{N′-[5-(1-chlorocyclopropyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (575 mg) obtained in Reference Example 586 was treated by a method similar to that in Example 265 to give the title compound (368 mg).

MS (ESI) m/z; 568 [M+H] +

›Example 478

(R)-N-benzyl-2-{N′-[6-(2,4-dimethoxybenzyl)-5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (770 mg) obtained in Reference Example 570 was treated by a method similar to that in Example 265 to give the title compound (699 mg).

MS (ESI) m/z; 552 [M+H] +

›Example 479

(R)-N-benzyl-1-[5-difluoromethyl-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (1.60 g) obtained in Reference Example 589 was treated by a method similar to that in Example 265 to give the title compound (1.75 g).

MS (ESI) m/z; 556 [M+H] +

›Example 480

(R)-1-[5-difluoromethyl-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (1.20 g) obtained in Reference Example 589 was treated by a method similar to that in Example 265 to give the title compound (1.37 g).

MS (ESI) m/z; 570 [M+H] +

›Example 481

(R)-1-[6-(4-methoxybenzyl)-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-[dideuterio(phenyl)methyl]pyrrolidine-2-carboxamide

The compound (350 mg) obtained in Reference Example 590 was treated by a method similar to that in Example 265 to give the title compound (410 mg).

MS (ESI) m/z; 554 [M+H] +

›Example 482

(R)-N-benzyl-1-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (460 mg) obtained in Example 414 was dissolved in a mixture (5.0 mL) of trifluoroacetic acid/water/triethylsilane=90/5/5 (v/v) under ice-cooling, and the mixture was stirred at room temperature for 2.5 hr. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10) to give the title compound (304 mg).

MS (ESI) m/z; 416 [M+H] +

›Example 483

(R)-N-benzyl-1-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (61 mg) obtained in Example 415 was treated by a method similar to that in Example 482 to give the title compound (14 mg).

MS (ESI) m/z; 430 [M+H] +

›Example 484

(R)-N-benzyl-1-[5-(propan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (450 mg) obtained in Example 416 was treated by a method similar to that in Example 482 to give the title compound (240 mg).

MS (ESI) m/z; 384 [M+H] +

›Example 485

(R)-N-benzyl-1-[5-(propan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (110 mg) obtained in Example 417 was treated by a method similar to that in Example 482 to give the title compound (39 mg).

MS (ESI) m/z; 412 [M+H] +

›Example 486

(R)-N-benzyl-2-{N′-[5-(propan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (350 mg) obtained in Example 418 was treated by a method similar to that in Example 482 to give the title compound (175 mg).

MS (ESI) m/z; 386 [M+H] +

›Example 487

(R)-N-benzyl-1-(7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (143 mg) obtained in Example 419 was treated by a method similar to that in Example 482 to give the title compound (98 mg).

MS (ESI) m/z; 432 [M+H] +

›Example 488

(R)-1-(7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (138 mg) obtained in Example 420 was treated by a method similar to that in Example 482 to give the title compound (84 mg).

MS (ESI) m/z; 446 [M+H] +

›Example 489

(R)-N-benzyl-1-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (19.9 g) obtained in Example 421 was treated by a method similar to that in Example 482 to give the title compound (13.9 g).

MS (ESI) m/z; 450 [M+H] +

›Example 490

(R)-1-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (339 mg) obtained in Example 422 was treated by a method similar to that in Example 482 to give the title compound (196 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 491

(R)-N-benzyl-1-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (44 mg) obtained in Example 423 was treated by a method similar to that in Example 482 to give the title compound (25 mg).

MS (ESI) m/z; 436 [M+H] +

›Example 492

(R)-N-benzyl-1-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (92 mg) obtained in Example 424 was treated by a method similar to that in Example 482 to give the title compound (34 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 493

(R)-N-benzyl-1-[5-(2-chlorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (197 mg) obtained in Example 425 was treated by a method similar to that in Example 482 to give the title compound (137 mg).

MS (ESI) m/z; 466, 468 [M+H] +

›Example 494

(R)-N-benzyl-1-[5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (93 mg) obtained in Example 426 was treated by a method similar to that in Example 482 to give the title compound (41 mg).

MS (ESI) m/z; 462 [M+H] +

›Example 495

(R)-1-[5-(2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (111 mg) obtained in Example 427 was treated by a method similar to that in Example 482 to give the title compound (63 mg).

MS (ESI) m/z; 476 [M+H] +

›Example 496

(R)-N-benzyl-1-{7-oxo-5-[2-(trifluoromethoxy)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (482 mg) obtained in Example 428 was treated by a method similar to that in Example 482 to give the title compound (285 mg).

MS (ESI) m/z; 516 [M+H] +

›Example 497

(R)-N-benzyl-1-[5-(2-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (498 mg) obtained in Example 429 was treated by a method similar to that in Example 482 to give the title compound (340 mg)

MS (ESI) m/z; 446 [M+H] +

›Example 498

(R)-N-benzyl-1-[5-(2,4-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (270 mg) obtained in Example 430 was treated by a method similar to that in Example 482 to give the title compound (195 mg).

MS (ESI) m/z; 468 [M+H] +

›Example 499

(R)-1-[5-(2,4-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (285 mg) obtained in Example 431 was treated by a method similar to that in Example 482 to give the title compound (179 mg).

MS (ESI) m/z; 482 [M+H] +

›Example 500

(R)-N-benzyl-1-[5-(5-methylthiophen-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (300 mg) obtained in Example 432 was treated by a method similar to that in Example 482 to give the title compound (218 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 501

(R)-N-benzyl-1-[5-(3-fluoro-5-methylthiophen-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (440 mg) obtained in Example 433 was treated by a method similar to that in Example 482 to give the title compound (319 mg).

MS (ESI) m/z; 470 [M+H] +

›Example 502

(R)-N-benzyl-1-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]azetidine-2-carboxamide

The compound (180 mg) obtained in Example 435 was treated by a method similar to that in Example 482 to give the title compound (104 mg).

MS (ESI) m/z; 416 [M+H] +

›Example 503

(R)-N-benzyl-1-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]piperidine-2-carboxamide

The compound (160 mg) obtained in Example 436 was treated by a method similar to that in Example 482 to give the title compound (50.0 mg).

MS (ESI) m/z; 444 [M+H] +

›Example 504

(R)-N-benzyl-1-(5-ethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (418 mg) obtained in Example 445 was treated by a method similar to that in Example 482 to give the title compound (220 mg).

MS (ESI) m/z; 384 [M+H] +

Example 505: (R)-N-benzyl-1-[5-(5-chloro-2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (515 mg) obtained in Example 446 was treated by a method similar to that in Example 482 to give the title compound (254 mg).

MS (ESI) m/z; 484, 486 [M+H] +

›Example 506

(R)-N-benzyl-2-{N′-[5-(1-methoxycyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (259 mg) obtained in Example 447 was treated by a method similar to that in Example 482 to give the title compound (100 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 507

(R)-N-benzyl-1-{5-[1-(fluoromethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (467 mg) obtained in Example 448 was treated by a method similar to that in Example 482 to give the title compound (230 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 508

(R)-N-benzyl-1-{5-[1-(methoxymethyl)cyclopropyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (480 mg) obtained in Example 449 was treated by a method similar to that in Example 482 to give the title compound (320 mg).

MS (ESI) m/z; 440 [M+H] +

›Example 509

(R)-N-benzyl-1-[5-(2-fluoro-5-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (541 mg) obtained in Example 450 was treated by a method similar to that in Example 482 to give the title compound (229 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 510

(R)-N-benzyl-1-[5-(3-fluoropyridin-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (344 mg) obtained in Example 451 was treated by a method similar to that in Example 482 to give the title compound (181 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 511

(R)-N-benzyl-1-(5-methoxymethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (180 mg) obtained in Example 456 was treated by a method similar to that in Example 482 to give the title compound (147 mg).

MS (ESI) m/z; 400 [M+H] +

›Example 512

(R)-1-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (220 mg) obtained in Example 457 was treated by a method similar to that in Example 482 to give the title compound (153 mg).

MS (ESI) m/z; 430 [M+H] +

›Example 513

(R)-N-benzyl-2-{N′-[5-(2-fluoropropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (259 mg) obtained in Example 458 was treated by a method similar to that in Example 482 to give the title compound (176 mg).

MS (ESI) m/z; 404 [M+H] +

›Example 514

(R)-N-benzyl-1-[5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (457 mg) obtained in Example 459 was treated by a method similar to that in Example 482 to give the title compound (260 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 515

(R)-1-[5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (296 mg) obtained in Example 460 was treated by a method similar to that in Example 482 to give the title compound (172 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 516

(R)-N-benzyl-1-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (117 mg) obtained in Example 461 was treated by a method similar to that in Example 482 to give the title compound (48 mg).

MS (ESI) m/z; 430 [M+H] +

›Example 517

(R)-1-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (76 mg) obtained in Example 462 was treated by a method similar to that in Example 482 to give the title compound (42 mg).

MS (ESI) m/z; 444 [M+H] +

›Example 518

(R)-N-benzyl-1-[5-(1,1-difluoroethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (478 mg) obtained in Example 463 was treated by a method similar to that in Example 482 to give the title compound (338 mg).

MS (ESI) m/z; 420 [M+H] +

›Example 519

(R)-1-[5-(1,1-difluoroethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (575 mg) obtained in Example 464 was treated by a method similar to that in Example 482 to give the title compound (381 mg).

MS (ESI) m/z; 434 [M+H] +

›Example 520

(R)-N-benzyl-1-[5-(1,1-difluoro-2-methoxyethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (955 mg) obtained in Example 465 was treated by a method similar to that in Example 482 to give the title compound (649 mg).

MS (ESI) m/z; 450 [M+H] +

›Example 521

(R)-1-[5-(1,1-difluoro-2-methoxyethyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (175 mg) obtained in Example 466 was treated by a method similar to that in Example 482 to give the title compound (130 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 522

(R)-N-benzyl-1-{7-oxo-5-[1-(trifluoromethyl)cyclopropyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (620 mg) obtained in Example 467 was treated by a method similar to that in Example 482 to give the title compound (427 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 523

(R)-N-benzyl-2-[N′-methyl-N′-{7-oxo-5-[1-(trifluoromethyl)cyclopropyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}amino]propionamide

The compound (233 mg) obtained in Example 468 was treated by a method similar to that in Example 482 to give the title compound (210 mg).

MS (ESI) m/z; 452 [M+H] +

›Example 524

(R)-N-benzyl-1-{5-[difluoro(phenyl)methyl]-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (190 mg) obtained in Example 469 was treated by a method similar to that in Example 482 to give the title compound (118 mg).

MS (ESI) m/z; 482 [M+H] +

›Example 525

(R)-1-[5-(difluoro(phenyl)methyl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (85 mg) obtained in Example 470 was treated by a method similar to that in Example 482 to give the title compound (51 mg).

MS (ESI) m/z; 496 [M+H] +

›Example 526

(R)-N-benzyl-1-[5-(2-fluoro-3-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (640 mg) obtained in Example 471 was treated by a method similar to that in Example 482 to give the title compound (409 mg).

MS (ESI) m/z; 480 [M+H] +

›Example 527

(R)-N-benzyl-1-[5-(2-fluoro-3-methylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (620 mg) obtained in Example 472 was treated by a method similar to that in Example 482 to give the title compound (419 mg).

MS (ESI) m/z; 464 [M+H] +

›Example 528

(R)-N-benzyl-1-[7-oxo-5-pentafluoroethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (89 mg) obtained in Example 473 was treated by a method similar to that in Example 482 to give the title compound (60 mg).

MS (ESI) m/z; 474 [M+H] +

›Example 529

(R)-1-(7-oxo-5-pentafluoroethyl-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (90 mg) obtained in Example 474 was treated by a method similar to that in Example 482 to give the title compound (54 mg).

MS (ESI) m/z; 488 [M+H] +

›Example 530

(R)-N-benzyl-1-[5-(3-benzenesulfonyl-1,1-difluoropropyl)-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (340 mg) obtained in Example 434 was treated by a method similar to that in Example 482 to give the title compound (248 mg).

MS (ESI) m/z; 574 [M+H] +

›Example 531

(R)-N-benzyl-2-[N′-methyl-N′-(7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)amino]propionamide

The compound (280 mg) obtained in Example 475 was treated by a method similar to that in Example 482 to give the title compound (150 mg).

MS (ESI) m/z; 420 [M+H] +

›Example 532

(R)-N-benzyl-2-{N′-[5-(2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (550 mg) obtained in Example 476 was treated by a method similar to that in Example 482 to give the title compound (318 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 533

(R)-N-benzyl-2-{N′-[5-(1-chlorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (350 mg) obtained in Example 477 was treated by a method similar to that in Example 482 to give the title compound (196 mg).

MS (ESI) m/z; 418 [M+H] +

›Example 534

(R)-N-benzyl-2-{N′-[5-(1-fluorocyclopropyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-N′-methylamino}propionamide

The compound (680 mg) obtained in Example 478 was treated by a method similar to that in Example 482 to give the title compound (410 mg).

MS (ESI) m/z; 402 [M+H] +

›Example 535

(R)-N-benzyl-1-[5-(3-chloro-2-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (431 mg) obtained in Example 452 was treated by a method similar to that in Example 482 to give the title compound (257 mg).

MS (ESI) m/z; 484, 486 [M+H] +

›Example 536

(R)-N-benzyl-1-(7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (534 mg) obtained in Example 453 was treated by a method similar to that in Example 482 to give the title compound (309 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 537

(R)-1-(7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (455 mg) obtained in Example 454 was treated by a method similar to that in Example 482 to give the title compound (253 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 538

(R)-1-(5-difluoromethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-N-((R)-1-phenylethyl)pyrrolidine-2-carboxamide

The compound (1.30 g) obtained in Example 480 was treated by a method similar to that in Example 482 to give the title compound (900 mg).

MS (ESI) m/z; 420 [M+H] +

›Example 539

(R)-N-benzyl-1-(5-difluoromethyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (1.70 g) obtained in Example 479 was treated by a method similar to that in Example 482 to give the title compound (1.29 g).

MS (ESI) m/z; 406 [M+H] +

›Example 540

(R)-N-benzyl-1-[5-(3-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (125 mg) obtained in Example 437 was treated by a method similar to that in Example 482 to give the title compound (96 mg).

MS (ESI) m/z; 450 [M+H] +

›Example 541

(R)-N-benzyl-1-[5-(4-fluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (56 mg) obtained in Example 438 was treated by a method similar to that in Example 482 to give the title compound (23 mg).

MS (ESI) m/z; 450 [M+H] +

›Example 542

(R)-N-benzyl-1-[5-(2,5-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (285 mg) obtained in Example 439 was treated by a method similar to that in Example 482 to give the title compound (160 mg).

MS (ESI) m/z; 468 [M+H] +

›Example 543

(R)-N-benzyl-1-[5-(3,4-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (194 mg) obtained in Example 440 was treated by a method similar to that in Example 482 to give the title compound (91 mg).

MS (ESI) m/z; 468 [M+H] +

›Example 544

(R)-N-benzyl-1-[5-(3,5-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (140 mg) obtained in Example 441 was treated by a method similar to that in Example 482 to give the title compound (62 mg).

MS (ESI) m/z; 468 [M+H] +

›Example 545

(R)-N-benzyl-1-[5-(4-fluoro-2-methoxyphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (118 mg) obtained in Example 442 was treated by a method similar to that in Example 482 to give the title compound (83 mg).

MS (ESI) m/z; 480 [M+H] +

›Example 546

(R)-N-benzyl-1-[5-(2-ethylphenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (248 mg) obtained in Example 443 was treated by a method similar to that in Example 482 to give the title compound (116 mg).

MS (ESI) m/z; 460 [M+H] +

›Example 547

(R)-N-benzyl-1-{7-oxo-5-[2-(trifluoromethyl)phenyl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (125 mg) obtained in Example 444 was treated by a method similar to that in Example 482 to give the title compound (70 mg).

MS (ESI) m/z; 500 [M+H] +

›Example 548

(R)-N-benzyl-1-[5-(2,3-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (219 mg) obtained in Example 455 was treated by a method similar to that in Example 482 to give the title compound (141 mg).

MS (ESI) m/z; 468 [M+H] +

›Example 549

(R)-N-[dideuterio(phenyl)methyl]-1-(7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (410 mg) obtained in Example 481 was treated by a method similar to that in Example 482 to give the title compound (305 mg).

MS (ESI) m/z; 434 [M+H] +

›Example 550

(R)-N-benzyl-1-{6-(4-methoxybenzyl)-7-oxo-5-[(R)-2-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (280 mg) obtained in Reference Example 602 was treated by a method similar to that in Example 178 to give the title compound (200 mg).

MS (ESI) m/z; 613 [M+H] +

›Example 551

(R)-N-benzyl-1-{6-(4-methoxybenzyl)-7-oxo-5-[(S)-2-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (360 mg) obtained in Reference Example 603 was treated by a method similar to that in Example 178 to give the title compound (220 mg).

MS (ESI) m/z; 613 [M+H] +

›Example 552

(R)-N-benzyl-1-{7-oxo-5-((R)-2-[(trifluoromethyl)pyrrolidin-1-yl]-6, 7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Example 550 was treated by a method similar to that in Example 482 to give the title compound (115 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 553

(R)-N-benzyl-1-{7-oxo-5-[(S)-2-(trifluoromethyl)pyrrolidin-1-yl]-6, 7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (220 mg) obtained in Example 551 was treated by a method similar to that in Example 482 to give the title compound (100 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 554

(R)-N-benzyl-1-[6-(4-methoxybenzyl)-7-oxo-5-(2,2,2-trifluoroethoxy)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (168 mg) obtained in Reference Example 605 was treated by a method similar to that in Example 178 to give the title compound (83 mg)

MS (ESI) m/z; 574 [M+H] +

›Example 555

(R)-N-benzyl-1-[7-oxo-5-(2,2,2-trifluoroethoxy)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (60 mg) obtained in Example 554 was treated by a method similar to that in Example 482 to give the title compound (31 mg).

MS (ESI) m/z; 454 [M+H] +

›Example 556

(R)-N-benzyl-1-[5-(1,1-difluoroethyl)-7-oxo-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (5 mL) of the compound (230 mg) obtained in Example 518 in DMF were successively added potassium carbonate (114 mg) and trideuteriomethyl iodide (77 μL) at room temperature, and the reaction mixture was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=60/40-20/80) to give the title compound (128 mg).

MS (ESI) m/z; 437 [M+H] +

›Example 557

(R)-N-benzyl-1-[5-difluoromethyl-7-oxo-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (110 mg) obtained in Example 539 was treated by a method similar to that in Example 556 to give the title compound (57 mg).

MS (ESI) m/z; 423 [M+H] +

›Example 558

(R)-N-benzyl-1-[5-(1,1-difluoro-2-methoxyethyl)-7-oxo-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (640 mg) obtained in Example 520 was treated by a method similar to that in Example 556 to give the title compound (227 mg).

MS (ESI) m/z; 467 [M+H] +

›Example 559

(R)-N-benzyl-1-[7-oxo-5-phenyl-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (294 mg) obtained in Example 487 was treated by a method similar to that in Example 556 to give the title compound (45 mg).

MS (ESI) m/z; 449 [M+H] +

›Example 560

N-[dideuterio(phenyl)methyl]-1-[7-oxo-5-phenyl-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (185 mg) obtained in Example 549 was treated by a method similar to that in Example 556 to give the title compound (26 mg).

MS (ESI) m/z; 451 [M+H] +

›Example 561

(R)-N-benzyl-1-[6-methyl-5-(5-methylthiophen-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (110 mg) obtained in Example 500 was treated by a method similar to that in Example 556 to give the title compound (42 mg).

MS (ESI) m/z; 466 [M+H] +

›Example 562

(R)-N-benzyl-1-[5-(3-fluoro-5-methylthiophen-2-yl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (159 mg) obtained in Example 501 was treated by a method similar to that in Example 556 to give the title compound (23 mg).

MS (ESI) m/z; 484 [M+H] +

›Example 563

(R)-N-benzyl-1-[5-(1-fluoromethylcyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (200 mg) obtained in Example 507 was treated by a method similar to that in Example 556 to give the title compound (130 mg).

MS (ESI) m/z; 442 [M+H] +

›Example 564

(R)-N-benzyl-1-{5-[1-(methoxymethyl)cyclopropyl]-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl}pyrrolidine-2-carboxamide

The compound (290 mg) obtained in Example 508 was treated by a method similar to that in Example 556 to give the title compound (110 mg).

MS (ESI) m/z; 454 [M+H] +

›Example 565

(R)-N-benzyl-1-[5-methoxymethyl-7-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (10 mL) of the compound (190 mg) obtained in Reference Example 610 in DMF were added (D)-proline (130 mg) and potassium carbonate (230 mg), and the reaction mixture was stirred with heating at 80° C. for 1.5 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted twice with chloroform. The organic layer was dried over magnesium sulfate, filtered and concentrated. To the obtained residue were added benzylamine (85 mg), EDC hydrochloride (150 mg), HOBt monohydrate (120 mg) and N,N-diisopropylethylamine (100 mg), and the reaction mixture was stirred at room temperature for 15 hr. 0.5 mol/L Hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (120 mg).

MS (ESI) m/z; 484 [M+H] +

›Example 566

(R)-N-benzyl-1-[6-methyl-7-oxo-5-(pyrazol-1-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (3 mL) of the compound (99 mg) obtained in Reference Example 613 in DMF were added (D)-proline (58 mg) and cesium carbonate (273 mg), and the reaction mixture was stirred with heating at 90° C. for 1 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted twice with chloroform. The organic layer was dried over magnesium sulfate, filtered and concentrated. To a solution of the obtained residue in DMF (2.0 mL) were added benzylamine (73 μL), EDC hydrochloride (128 mg), HOBt monohydrate (103 mg) and N,N-diisopropylethylamine (120 μL), and the reaction mixture was stirred at room temperature for 3 hr. 0.5 mol/L Hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (11.6 mg).

MS (ESI) m/z; 436 [M+H] +

›Example 567

[(3S,5R)-5-benzylcarbamoyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester

To a solution (3.4 mL) of the compound (200 mg) obtained in Reference Example 268 in DMF were added (2R,4S)-4-[(tert-butoxycarbonyl)amino]pyrrolidine-2-carboxylic acid (226 mg) and cesium carbonate (533 mg), and the reaction mixture was heated at 70° C. for 2.5 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted three times with chloroform. The organic layer was dried over magnesium sulfate, filtered and concentrated. To a solution of the obtained residue in DMF (2.0 mL) were added benzylamine (107 μL), EDC hydrochloride (188 mg), HOBt monohydrate (150 mg) and N,N-diisopropylethylamine (171 μL), and the reaction mixture was stirred at room temperature overnight. 1.0 mol/L Hydrochloric acid was added, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (237 mg).

MS (ESI) m/z; 561 [M+H] +

›Example 568

[(3R,5R)-5-benzylcarbamoyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-pyrrolidin-3-yl]carbamic acid tert-butyl ester

The compound (200 mg) and (2R,4R)-4-[(tert-butoxycarbonyl)amino]pyrrolidine-2-carboxylic acid (226 mg) obtained in Reference Example 268 was treated by a method similar to that in Example 567 to give the title compound (227 mg).

MS (ESI) m/z; 561 [M+H] +

›Example 569

(2R,4S)-4-amino-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide hydrochloride

To a solution (3.9 mL) of the compound (179 mg) obtained in Example 567 in methanol was added hydrogen chloride (4.0 mol/L ethyl acetate solution, 0.8 mL), and the reaction mixture was stirred at room temperature for 3 hr. The resultant solid was collected by filtration, and dried to give the title compound (151 mg).

MS (ESI) m/z; 461 [M+H] +

›Example 570

(2R,4R)-4-amino-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide hydrochloride

The compound (189 mg) obtained in Example 568 was treated by a method similar to that in Example 569 to give the title compound (178 mg)

MS (ESI) m/z; 461 [M+H] +

›Example 571

(R)-N-benzyl-1-(5-cyclopropyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-piperidine-2-carboxamide

To a solution (4 mL) of the compound (250 mg) obtained in Reference Example 617 in DMF were added (R)-piperidine-2-carboxylic acid (339 mg) and potassium carbonate (326 mg), and the reaction mixture was stirred with heating at 120° C. for 5 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted three times with chloroform. The organic layer was dried over sodium sulfate, filtered and concentrated. To the obtained residue were added N,N-diisopropylethylamine (228 μL), benzylamine (143 μL), EDC hydrochloride (251 mg) and HOBt monohydrate (201 mg), and the reaction mixture was stirred at room temperature overnight. Ethyl acetate was added to the reaction mixture, and the mixture was washed with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=70/30-0/100), and the obtained crude product was purified by reversed-phase HPLC (Capcelpak C18; 0.05% trifluoroacetic acid-water/acetonitrile=55/45-45/55). To the obtained product was added ethyl acetate/diethyl ether, and the solid was collected by filtration to give the title compound (213 mg).

MS (ESI) m/z; 424 [M+H] +

›Example 572

(R)-N-benzyl-1-(5-cyclopropyl-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-4,4-difluoropyrrolidine-2-carboxamide

A mixed solution of the compound (62 mg) obtained in Reference Example 617, the compound (121 mg) obtained in Reference Example 618 and N,N-diisopropylethylamine (2.0 mL) was stirred with heating at 120° C. for 12 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted with chloroform. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5), and the obtained crude product was purified by reversed-phase HPLC (Capcelpak C18; 0.05% trifluoroacetic acid-water/acetonitrile=55/45-45/55). To the obtained product was added diethyl ether, and the solid was collected by filtration and dried to give the title compound (15.5 mg).

MS (ESI) m/z; 446 [M+H] +

›Example 573

(R)-N-benzyl-1-[5-(1-cyanocyclopropyl)-6-methyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (1.8 mL) of the compound (84 mg) obtained in Reference Example 621 in methylene chloride were added trimethylsilyl trifluoromethanesulfonate (101 μL) and triethylamine (130 μL), and the reaction mixture was stirred at room temperature for 1 hr. Saturated aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10) to give the title compound (56.8 mg).

MS (ESI) m/z; 435 [M+H] +

›Example 574

6-methyl-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl]-5-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

To a solution (3 mL) of oxalyl chloride (63 μL) in methylene chloride was added dimethyl sulfoxide (100 μL) at −78° C., and the reaction mixture was stirred for 5 min. A solution (6.0 mL) of the compound (0.30 g) obtained in Reference Example 125 in methylene chloride and triethylamine (0.46 mL) were added at −78° C., and the reaction mixture was stirred for 1 hr, allowing the mixture to gradually warm to room temperature. Water was added, and the mixture was extracted once with ethyl acetate. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (0.19 g).

MS (ESI) m/z; 455 [M+H] +

›Example 575

5-ethyl-6-methyl-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl][1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

The compound (80 mg) obtained in Reference Example 126 was treated by a method similar to that in Example 574 to give the title compound (33 mg).

MS (ESI) m/z; 399 [M+H] +

›Example 576

5-methyl-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl]-6-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

The compound (170 mg) obtained in Reference Example 127 was treated by a method similar to that in Example 574 to give the title compound (110 mg).

MS (ESI) m/z; 455 [M+H] +

›Example 577

6-methyl-5-[(morpholin-4-yl)methyl]-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl][1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

The compound (127 mg) obtained in Reference Example 128 was treated by a method similar to that in Example 574 to give the title compound (42.0 mg).

MS (ESI) m/z; 470 [M+H] +

›Example 578

5-(3-methoxyazetidin-1-yl)-6-methyl-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl][1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

The compound (90 mg) obtained in Reference Example 129 was treated by a method similar to that in Example 574 to give the title compound (20 mg).

MS (ESI) m/z; 456 [M+H] +

›Example 579

5-ethyl-6-methyl-2-[(R)-2-(2-phenylaminoacetyl)pyrrolidin-1-yl][1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

is To a solution (2.0 mL) of oxalyl chloride (52 μL) in methylene chloride was added dimethyl sulfoxide (86 μL) at −78° C., and the reaction mixture was stirred for 10 min. A solution (4 mL) of the compound (200 mg) obtained in Reference Example 130 in methylene chloride and triethylamine (350 μL) were added at −78° C., and the reaction mixture was stirred for 1 hr, allowing the mixture to gradually warm to room temperature. Water was added, and the mixture was extracted once with ethyl acetate. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) to give the title compound (6.0 mg).

MS (ESI) m/z; 398 [M+H] +

›Example 580

6-(2,4-dimethoxybenzyl)-5-(2-fluorophenyl)-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl][1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

To a solution (4 mL) of oxalyl chloride (0.13 mL) in methylene chloride was added dimethyl sulfoxide (0.22 mL) at −78° C., and the reaction mixture was stirred for 5 min. A solution (8 mL) of the compound (0.43 g) obtained in Reference Example 131 in methylene chloride and triethylamine (1.0 mL) were added at −78° C., and the reaction mixture was stirred for 1 hr, allowing the mixture to gradually warm to room temperature. Water was added, and the mixture was extracted once with ethyl acetate. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (0.25 g).

MS (ESI) m/z; 601 [M+H] +

›Example 581

5-(2-fluorophenyl)-2-[(R)-2-(2-phenoxyacetyl)pyrrolidin-1-yl][1,3]thiazolo[5,4-d]pyrimidin-7(6H)-one

To a solution (5 mL) of the compound (0.25 g) obtained in Example 580 in methylene chloride were added water (0.5 mL) and trifluoroacetic acid (5.0 mL) at room temperature, and the reaction mixture was stirred for 1 hr. The reaction mixture was neutralized with saturated aqueous sodium hydrogen carbonate solution, and extracted once with chloroform. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5). Ethyl acetate was added to the obtained product, and the solid was collected by filtration to give the title compound (0.17 g).

MS (ESI) m/z; 451 [M+H] +

›Example 582

(R)-N-benzyl-1-[5-(2,6-difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (30.0 mL) of the compound (3.00 g) obtained in Reference Example 635 in N-methylpyrrolidone were added (D)-proline (1.45 g) and potassium carbonate (3.47 g), and the reaction mixture was stirred with heating at 80° C. for 1 hr. The reaction mixture was cooled to room temperature, and acidified with 1.0 mol/L hydrochloric acid. Sodium chloride was added, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and filtered. Chloroform was evaporated under reduced pressure from the filtrate, to the obtained mixture were added N,N-diisopropylethylamine (1.63 mL), benzylamine (981 mg), EDC hydrochloride (1.80 g) and HOBt monohydrate (1.50 g), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. To the residue was added diisopropyl ether, and the solid was collected by filtration and dried to give the title compound (3.80 g).

MS (ESI) m/z; 618 [M+H] +

›Example 583

(R)-N-benzyl-1-[5-(2,6-difluorophenyl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (3.78 g) obtained in Example 582 was treated by a method similar to that in Example 482 to give the title compound (2.52 g).

MS (ESI) m/z; 468 [M+H] +

›Example 584

(RS)-2-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-1-carboxylic acid benzyl ester

15s To a solution (5.00 mL) of the compound (0.47 g) obtained in Reference Example 66 in methylene chloride were added chlorotrimethylsilane (0.66 mL) and triethylamine (2.20 mL), and the reaction mixture was stirred at room temperature for 2 hr. Chlorotrimethylsilane (0.66 mL) and triethylamine (2.20 mL) were added, and the mixture was stirred for 3 days. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5) to give the title compound (0.31 g).

MS (ESI) m/z; 439 [M+H] +

›Example 585

(R)-N-benzyl-1-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (20 mL) of the compound (0.2 g) obtained in Reference Example 643 in methylene chloride was added mCPBA is (69-75%, 0.18 g) at 0° C., and the reaction mixture was stirred at room temperature for 1 hr. After confirmation of the completion of the reaction, water and aqueous sodium thiosulfate solution were added to the reaction mixture, and the mixture was extracted twice with chloroform. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was washed with ethyl acetate, filtered, and dried to give a white solid. To the obtained solid were added N,N-diisopropylethylamine (3.7 mL) and the compound (0.52 g) obtained in Reference Example 341, and the reaction mixture was stirred at 160° C. for 5 hr. After confirmation of the completion of the reaction, water and chloroform were added to the reaction mixture, and the mixture was neutralized with 1.0 mol/L hydrochloric acid and extracted twice with chloroform. The organic layer was washed once with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-90/10) to give the title compound (60 mg).

MS (ESI) m/z; 438 [M+H] +

›Example 586

(R)-N-benzyl-1-[7-oxo-5-(1,1,1-trifluoro-2-methylpropan-2-yl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

A mixture of the compound (180 mg) obtained in Reference Example 654 and the compound (2.8 mL) obtained in Reference Example 341 was stirred with heating at 150° C. for 4 hr. The compound (2.56 g) obtained in Reference Example 341 and N,N-diisopropylethylamine (1.4 mL) were added, and the reaction mixture was stirred with heating at 150° C. for 12 hr. The reaction mixture was cooled to room temperature, and ethyl acetate was added. The mixture was neutralized with 1.0 mol/L hydrochloric acid, and extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10). To the obtained product was added diisopropyl ether, and the solid was collected by filtration to give the title compound (50 mg).

MS (ESI) m/z; 466 [M+H] +

›Example 587

(R)-N-benzyl-1-(5-tert-butyl-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a mixture of the compound (150 mg) obtained in Reference Example 655 and potassium carbonate (144 mg) in DMF (4.3 mL) was added dropwise benzyl bromide (75 μL) at 0° C. The reaction mixture was stirred at room temperature overnight, and water (20 mL) was added at 0° C. The precipitated solid was collected by filtration, dissolved in chloroform/methanol (100/1), and the obtained solution was dried over anhydrous sodium sulfate, filtered and concentrated. To the residue was added hexane/diethyl ether=10/1, and the solid was collected by filtration. To a solution (2.5 mL) of the obtained solid in DMF were added (D)-proline (80 mg) and cesium carbonate (377 mg), and the reaction mixture was heated at 75° C. for 1 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted twice with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. To the obtained residue were added N,N-diisopropylethylamine (121 μL), benzylamine (76 μL), EDC hydrochloride (133 mg) and HOBt monohydrate (106 mg), and the reaction mixture was stirred at room temperature for 18 hr. 1.0 mol/L Hydrochloric acid was added and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; hexane/ethyl acetate=95/5-55/45). The obtained product was dissolved in a mixture (2.878 mL) of trifluoroacetic acid/water/triethylsilane=90/5/5 (v/v), and the reaction mixture was stirred at room temperature for 1 hr, and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-95/5) and purified by to reversed-phase HPLC (Capcelpak C18; 0.05% trifluoroacetic acid-water/acetonitrile=55/45-45/55). To the obtained product was added hexane-ethyl acetate mixed solvent (1:1), and the solid was collected by filtration to give the title compound (121 mg)

MS (ESI) m/z; 412 [M+H] +

›Example 588

2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidine-6-carboxylic acid tert-butyl ester

To a solution (22 mL) of the compound (1070 mg) obtained in Reference Example 661 in DMF were added (D)-proline (499 mg) and potassium carbonate (998 mg), and the reaction mixture was heated at 70° C. for 1.5 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (1.2 mL). N,N-diisopropylethylamine (1.01 mL), benzylamine (631 μL), EDC hydrochloride (1010 mg) and HOBt monohydrate (781 mg) were added at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10) to give the title compound (536.4 mg).

MS (ESI) m/z; 511 [M+H] +

›Example 589

(R)-N-benzyl-1-(10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (2.3 mL) of the compound (535 mg) obtained in Example 588 in methylene chloride was added trifluoroacetic acid (4.6 mL), and the reaction mixture was stirred at room temperature for 1.5 hr, and concentrated. The residue was diluted with water and chloroform, and the mixture was adjusted to pH 9 with 2 mol/L aqueous sodium carbonate solution, and the mixture was extracted twice with chloroform. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; chloroform/methanol=100/0-93/7) and silica gel column chromatography (solvent; chloroform/methanol=100/0-85/15), to the obtained product was added hexane/ethyl acetate=1/1, and the solid was collected by filtration to give the title compound (340.5 mg).

MS (ESI) m/z; 411 [M+H] +

›Example 590

(R)-N-benzyl-1-(6-methyl-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (1.5 mL) of the compound (80 mg) obtained in Example 589 in methylene chloride was added 35-38% aqueous formaldehyde solution (67 μL). The reaction mixture was stirred at room temperature for 1 hr, sodium triacetoxyborohydride (103 mg) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 1 hr. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted twice with methylene chloride. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-93/7), to the obtained product was added diethyl ether, and the solid was collected by filtration to give the title compound (76.6 mg).

MS (ESI) m/z; 425 [M+H] +

›Example 591

(R)-N-benzyl-1-[10-oxo-6-(propan-2-yl)-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (80 mg) and acetone (57 μL) obtained in Example 589 was treated by a method similar to that in Example 590 to give the title compound (67.7 mg).

MS (ESI) m/z; 453 [M+H] +

›Example 592

(R)-N-benzyl-1-[10-oxo-6-(2,2,2-trifluoroethyl)-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (1.5 mL) of the compound (85 mg) obtained in Example 589 in DMF were added N,N-diisopropylethylamine (108 μL) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (72 mg) under ice-cooling, and the reaction mixture was stirred at room temperature for 14 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=99/1-85/15), to the obtained product was added hexane/ethyl acetate=10/1, and the solid was collected by filtration to give the title compound (38.2 mg).

MS (ESI) m/z; 493 [M+H] +

›Example 593

(R)-N-benzyl-1-[6-(2,2-difluoroethyl)-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution of the compound (90 mg) obtained in Example 589 in dichloroethane-methylene chloride mixture (1.5 mL-1.0 mL) were added, under ice-cooling, N,N-diisopropylethylamine (76 μL) and difluoroethyl trifluoromethanesulfonate (56 mg), and the reaction mixture was stirred at room temperature for 24 hr. Water was added to the reaction mixture, and the mixture was extracted twice with chloroform. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=99/1-85/15), to the obtained product was added hexane/ethyl acetate=10/1, and the solid was collected by filtration to give the title compound (80.8 mg).

MS (ESI) m/z; 475 [M+H] +

›Example 594

[(S)-2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-5-hydroxymethyl-7-oxo-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}propyl]carbamic acid tert-butyl ester

To a solution (8 mL) of the compound (500 mg) obtained in Reference Example 670 in DMF were added (D)-proline (215 mg) and potassium carbonate (343 mg), and the reaction mixture was stirred with heating at 80° C. for 1.5 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (414 μL). N,N-diisopropylethylamine (325 μL), benzylamine (272 μL), EDC hydrochloride (357 mg) and HOBt monohydrate (252 mg) were added at room temperature, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, the precipitate was collected by filtration, and the filtrate was extracted once with ethyl acetate. The precipitate was dissolved in ethyl acetate, and the combined organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-94/6), to the obtained product was added hexane/ethyl acetate=1/1, and the solid was collected by filtration to give the title compound (275.3 mg).

MS (ESI) m/z; 543 [M+H] +

›Example 595

[(R)-2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-5-hydroxymethyl-7-oxo-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}propyl]carbamic acid tert-butyl ester

The compound (635 mg) obtained in Reference Example 671 was treated by a method similar to that in Example 594 to give the title compound (363.5 mg).

MS (ESI) m/z; 543 [M+H] +

›Example 596

[(S)-2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-5-[(methylsulfonyl)oxymethyl]-7-oxo-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}propyl]carbamic acid tert-butyl ester

To a solution (8 mL) of the compound (170 mg) obtained in Example 594 and triethylamine (48 μL) in methylene chloride was added dropwise methanesulfonyl chloride (26 μL) under ice-cooling, and the reaction mixture was stirred at room temperature for 1 hr. Triethylamine (48 μL) and methanesulfonyl chloride (26 μL) were added, and the reaction mixture was further stirred for 1 hr. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted twice with methylene chloride. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=95/5), to the obtained product was added diethyl ether, and the solid was collected by filtration to give the title compound (333.6 mg).

MS (ESI) m/z; 621 [M+H] +

›Example 597

[(R)-2-{2-[(R)-2-(benzylcarbamoyl)pyrrolidin-1-yl]-5-[(methylsulfonyl)oxymethyl]-7-oxo-7H-[1,3]thiazolo[5,4-d]pyrimidin-6-yl}propyl]carbamic acid tert-butyl ester

The compound (362 mg) obtained in Example 595 was treated by a method similar to that in Example 596 to give the title compound (390 mg).

MS (ESI) m/z; 621 [M+H] +

›Example 598

(R)-N-benzyl-1-[(S)-8-methyl-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (1 mL) of the compound (305 mg) obtained in Example 596 in methylene chloride was added dropwise trifluoroacetic acid (1 mL) under ice-cooling. The reaction mixture was stirred at room temperature for 1.5 hr, and concentrated under reduced pressure. The residue was diluted with water (3 mL) and THF (3 mL). Under ice-cooling, the reaction mixture was adjusted to pH 9-10 with saturated aqueous sodium hydrogen carbonate solution, stirred at room temperature for 2 hr, and extracted twice with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=98/2-88/12) to give the title compound (199 mg).

MS (ESI) m/z; 425 [M+H] +

›Example 599

(R)-N-benzyl-1-[(R)-8-methyl-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (390 mg) obtained in Example 597 was treated by a method similar to that in Example 598 to give the title compound (211 mg).

MS (ESI) m/z; 425 [M+H] +

›Example 600

(R)-N-benzyl-1-[(S)-6,8-dimethyl-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (2 mL) of the compound (85 mg) obtained in Example 598 in methylene chloride was added dropwise 35% aqueous formaldehyde solution (69 mg), and the reaction mixture was stirred at room temperature for 1 hr. Sodium triacetoxyborohydride (106 mg) was added, and the reaction mixture was stirred at room temperature for 1 hr. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted twice with methylene chloride. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; chloroform/methanol=100/0-92/8), to the obtained product was added hexane/diethyl ether (1/2), and the solid was collected by filtration to give the title compound (50 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 601

(R)-N-benzyl-1-[(R)-6,8-dimethyl-10-oxo-5,7,8,10-tetrahydro-6H-pyrazino[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

The compound (100 mg) obtained in Example 599 was treated by a method similar to that in Example 600 to give the title compound (39.4 mg).

MS (ESI) m/z; 439 [M+H] +

›Example 602

(R)-N-benzyl-1-(5-methyl-9-oxo-5,6,7,9-tetrahydroimidazo[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (11 mL) of the compound (305 mg) obtained in Reference Example 675 in N-methylpyrrolidone were added (D)-proline (390 mg) and potassium carbonate (624 mg), and the reaction mixture was stirred with heating at 130° C. for 2 hr. (D)-proline (260 mg) and potassium carbonate (468 mg) were added, and the reaction mixture was stirred with heating at 130° C. for 2 hr. The reaction mixture was cooled to 0° C., acidified with 1.0 mol/L hydrochloric acid, and extracted 4 times with chloroform and 2 times with chloroform/methanol (10/1). The organic layer was dried over magnesium sulfate, filtered and concentrated. To the obtained residue were added N,N-diisopropylethylamine (295 μL), benzylamine (185 μL), EDC hydrochloride (324 mg) and HOBt monohydrate (259 mg), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted 4 times with ethyl acetate and 2 times with ethyl acetate/methanol (10/1). The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by NH silica gel column chromatography (solvent; ethyl acetate/methanol=100/0-90/10). To the obtained product was added hexane/ethyl acetate (1/1), and the solid was collected by filtration to give the title compound (131.2 mg).

MS (ESI) m/z; 411 [M+H] +

›Example 603

(R)-N-benzyl-1-(5-methyl-9-oxo-5,9-dihydroimidazo[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (1.5 mL) of the compound (30 mg) obtained in Reference Example 678 in N-methylpyrrolidone were added (D)-proline (26 mg) and potassium carbonate (46 mg), and the reaction mixture was stirred with heating at 130° C. for 2 hr. The reaction mixture was cooled to 0° C., acidified with 1.0 mol/L hydrochloric acid, and extracted 2 times with chloroform and 3 times with chloroform/methanol (5/1). The organic layer was dried over magnesium sulfate, filtered and concentrated. To the obtained residue were added N,N-diisopropylethylamine (29 μL), benzylamine (18 μL), EDC hydrochloride (32 mg) and HOBt monohydrate (26 mg), and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted three times with ethyl acetate. To the aqueous layer was added sodium chloride, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/methanol=99/1-90/10). To the obtained product was added hexane/ethyl acetate (1/2), and the solid was collected by filtration to give the title compound (15.8 mg).

MS (ESI) m/z; 409 [M+H] +

›Example 604

(R)-N-benzyl-1-(5,5-difluoro-9-oxo-5,6,7,9-tetrahydropyrrolo[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (2.0 mL) of the compound (38 mg) obtained in Reference Example 683 in DMF were added (D)-proline (23 mg) and cesium carbonate (97 mg), and the reaction mixture was stirred with heating at 70° C. for 1 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (49 μL). N,N-diisopropylethylamine (45 μL), benzylamine (28 μL), EDC hydrochloride (50 mg) and HOBt monohydrate (40 mg) were successively added, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=40/60-0/100) to give the title compound (29.7 mg).

MS (ESI) m/z; 432 [M+H] +

›Example 605

(R)-N-benzyl-1-(5,5-difluoro-10-oxo-5,7,8,10-tetrahydro-6H-pyrido[1,2-a][1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (2.0 mL) of the compound (61 mg) obtained in Reference Example 689 in DMF were added (D)-proline (34 mg) and cesium carbonate (148 mg), and the reaction mixture was stirred with heating at 70° C. for 1 hr. The reaction mixture was cooled to 0° C., and neutralized with concentrated hydrochloric acid (74 μL). N,N-diisopropylethylamine (69 μL), benzylamine (43 μL), EDC hydrochloride (76 mg) and HOBt monohydrate (60 mg) were successively added, and the reaction mixture was stirred at room temperature for 5 hr. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=40/60-0/100) to give the title compound (56.9 mg).

MS (ESI) m/z; 446 [M+H] +

›Example 606

(R)-N-benzyl-1-[5-(2-hydroxypropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution of the compound (1000 mg) obtained in Example 482 in acetonitrile-water mixture (40 mL-40 mL) was added sodium hydrogen carbonate (2.10 g), and the reaction mixture was stirred with heating at 80° C. for 6 hr. The reaction mixture was allowed to cool to room temperature, 1.0 mol/L hydrochloric acid (25 mL) was added, and the mixture was extracted twice with chloroform. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5). Ethyl acetate was added to the obtained product, and the solid was collected by filtration and dried to give the title compound (660 mg).

MS (ESI) m/z; 414 [M+H] +

›Example 607

(R)-N-benzyl-1-[5-(2-methoxypropan-2-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

To a solution (30 mL) of the compound (600 mg) obtained in Example 482 in methanol was added potassium carbonate (4.00 g), and the reaction mixture was heated under reflux overnight. The reaction mixture was allowed to cool to room temperature, ethyl acetate and water were added, and the mixture was neutralized with 1.0 mol/L hydrochloric acid and extracted twice with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; ethyl acetate/hexane=50/50-100/0) to give the title compound (360 mg).

MS (ESI) m/z; 428 [M+H] +

›Example 608

[(2R,3S)-2-benzylcarbamoyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid benzyl ester

A mixture of the compound (250 mg) obtained in Reference Example 691, the compound (600 mg) obtained in Reference Example 696 and N,N-diisopropylethylamine (0.68 mL) in 1,4-dioxane (2.5 mL) was stirred with heating at 120° C. overnight. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=50/50-0/100) to give the title compound (320 mg).

MS (ESI) m/z; 595 [M+H] +

›Example 609

[(2R,3R)-2-benzylcarbamoyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid benzyl ester

The compound (0.25 g) obtained in Reference Example 691, the compound (440 mg) obtained in Reference Example 697 were treated by a method similar to that in Example 608 to give the title compound (0.36 g).

MS (ESI) m/z; 595 [M+H] +

›Example 610

(2R,3S)-3-amino-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

To a solution (3.0 mL) of the compound (300 mg) obtained in Example 608 in methylene chloride was added trimethylsilyl iodide (150 μL), and the reaction mixture was stirred at room temperature for 2 hr. To the reaction mixture were added water and ethyl acetate, and the mixture was extracted 3 times with 1.0 mol/L hydrochloric acid. The aqueous layer was neutralized with saturated aqueous sodium hydrogen carbonate solution, and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (solvent; chloroform/methanol=100/0-95/5). To the obtained product was added diisopropyl ether, the solid was collected by is filtration, and dried to give the title compound (95.0 mg).

MS (ESI) m/z; 461 [M+H] +

›Example 611

(2R,3R)-3-amino-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

The compound (320 mg) obtained in Example 609 was treated by a method similar to that in Example 610 to give the title compound (80.0 mg).

MS (ESI) m/z; 461 [M+H] +

›Example 612

(R)-N-benzyl-1-(5,7-diethyl-4-oxo-4,5-dihydro[1,3]thiazolo[4,5-d]pyridazin-2-yl)pyrrolidine-2-carboxamide

To a solution (13 mL) of the compound (300 mg) obtained in Reference Example 709 in N-methylpyrrolidone were added (D)-proline (240 mg) and potassium carbonate (440 mg), and the reaction mixture was stirred with heating at 70° C. for 2 hr. The reaction mixture was cooled to room temperature, acidified with 1.0 mol/L hydrochloric acid, and extracted twice with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. To a solution of the obtained residue in N-methylpyrrolidone were added N,N-diisopropylethylamine (210 mg), benzylamine (170 mg), EDC hydrochloride (300 mg) and HOBt monohydrate (240 mg), and the reaction mixt

›Tables in the description — 3

TABLE 1

test compound	KAT-II inhibitory test IC 50
(Example No.)	(μmol/L)
8	0.61
9	0.25
11	6.2
12	0.13
13	0.56
14	0.057
15	1.1
17	1.6
19	0.043
28	0.025
32	0.40
36	0.018
63	0.015
65	0.025
67	0.014
69	0.040
74	0.084
80	0.0086
85	0.17
94	0.0061
96	0.019
97	0.013
98	0.037
104	0.073
105	0.065
106	0.069
107	0.046
111	0.27
114	0.029
116	0.014
120	0.0047
131	0.11
132	0.051
133	0.15
134	0.23
135	0.023
137	0.069
138	0.39
140	0.077
142	0.98
143	2.2
144	0.72
145	1.5
146	0.14
148	0.23
149	0.16
153	0.048
155	0.32
157	0.47
158	0.17
160	5.2
166	0.19
167	0.090
168	0.41
170	0.88
171	1.8
172	0.84
175	3.7
176	0.52
178	0.012
183	0.032
190	0.026
191	0.031
194	0.076

TABLE 2

test compound	KAT-II inhibitory test IC 50
(Example No.)	(μmol/L)
203	0.014
204	0.0070
211	0.0073
213	0.016
221	0.0048
227	0.072
229	0.021
233	0.12
236	0.24
238	0.016
244	0.011
251	0.040
252	0.019
253	0.089
254	0.011
258	0.18
259	0.0043
264	0.16
265	0.0054
267	0.022
268	0.0088
273	0.0056
281	0.027
294	0.17
298	0.026
299	0.46
300	0.18
301	2.6
304	0.021
307	0.12
309	0.061
311	0.34
313	1.1
314	0.61
321	0.070
322	0.020
323	0.078
328	0.017
333	0.049
335	0.0056
337	0.0044
339	0.0079
341	0.011
345	0.0087
347	0.016
363	0.12
366	0.15
372	0.039
373	0.0080
376	0.014
396	0.076
406	0.37
411	0.015
414	0.043
482	0.0097
486	0.015
489	0.0060
499	0.0071
500	0.041
501	0.017
524	0.0040
530	0.019
532	0.017
536	0.0069
539	0.022
553	0.043

TABLE 3

test compound	KAT-II inhibitory test IC 50
(Example No.)	(μmol/L)
555	1.1
559	0.016
560	0.011
565	0.010
572	0.086
573	0.035
575	0.019
578	0.028
579	0.010
583	0.0090
585	0.012
590	0.28
593	0.051
601	0.14
602	0.031
603	0.0049
605	0.0082
606	0.0076
611	0.57
612	0.052
613	0.022
614	0.016
616	0.073
617	0.24
623	0.022
624	0.015
626	0.015
629	0.047
631	0.055
635	0.97
636	1.5
638	0.029
639	0.049
642	0.078
645	1.6
647	0.058
648	0.046
650	2.2
653	0.19
655	0.029
656	0.044
661	3.9
664	0.56
669	7.3
678	0.019
684	11
685	2.2
686	32
688	0.029
698	0.067
699	0.23
701	0.05
703	0.11
706	0.17
707	0.68
711	0.19
712	0.062
713	0.088
714	0.59
718	0.31
720	0.55
722	0.089
728	0.024
—	—

description truncated at 500,000 characters

Stored text is truncated at the source; the tail of the description is not held.

Claims as granted

31 claims

Classifications

6 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C07D513/04
C07D487/04
C07D471/04
C07D513/14
C07D519/00
C07B59/00

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

3.4 y

1,231 days filing → grant

Office actions

after a restriction

Responses

no RCE

Examiner

Erich A Leeser

art unit 1624 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 57 back · 6 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.